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Abstract 
The repeated emergence of drug resistance in Plasmodium falciparum underscores the 
importance of understanding the genetic architecture of current resistance pathways, as well as 
any associated fitness costs. Why resistance emerges in particular regions of the world has 
been linked to particular genetic backgrounds that better tolerate resistance-associated 
polymorphisms; this is likely to play a key role in driving the epidemiology of drug resistance, 
however is infrequently studied at a large scale in a laboratory setting. The first results chapter 
establishes a barcoding approach for P. falciparum with the aim of tracking parasite growth in 
vitro. The strategy used was adapted for P. falciparum by using a pseudogene (PfRh3) as a safe 
harbour to insert unique molecular barcodes. These libraries of barcoded P. falciparum vectors 
were also used as a readout of transfection efficiency. The second chapter establishes a proof 
of principle for phenotyping by barcode sequencing, using a panel of barcoded parasites 
generated in different genetic backgrounds that comprise sufficient genetic diversity to pilot 
the method. These were grown in the presence and absence of antimalarial compounds, and 
growth phenotypes were measured in parallel using BarSeq. The third results chapter studies 
the contribution of mutations in Pfkelch13, a molecular marker of artemisinin resistance, to 
parasite fitness. Combining CRISPR/Cas9-based genome editing and high throughput 
sequencing, the impact of Pfkelch13 alleles on fitness in the context of particular strain 
backgrounds is revealed. In particular, the impact of genetic background in the emergence and 
spread of drug-resistant lineages (referred to as KEL1) in Southeast Asia carrying a Y580 
Pfkelch13 allele. Overall, given the current pace of genome sequencing of pathogenic organisms 
such as P. falciparum, it will be important to increase the scale of experimental genetics, in 
order to tackle in real-time natural variation that might be under constant selection from drugs, 
thus anticipating the emergence of drug resistance in changing parasite populations. Through 
this work, tools were developed to facilitate parallel phenotyping by measuring in vitro growth 
using high-throughput sequencing. The work also develops novel approaches to address the 
importance of genetic background and a potential role for positive epistasis in a lineage 
responsible for the recent outbreak of drug-resistant malaria in Southeast Asia.   
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Chapter 1: Introduction 
1.1 Biology and epidemiology of malaria  
 1.1.1 The global burden of malaria 
Malaria is a vector-borne disease that has been an enormous burden on humanity for 
thousands of years (Harper and Armelagos 2010). It currently puts at risk 3.4 billion people in 
endemic countries; accounting for nearly half of the human population according to the World 
Health Organization (WHO) (World Health Organization 2016). Populations affected are mainly 
in low-income countries where control efforts remain challenging, and where burden persists 
given socioeconomic factors that have led to changes in surveillance and policies, and to an 
increase in prevalence (Pigott et al. 2012).  Historically malaria was even more widespread, and 
it has taken lives in many geographical locations and ecological conditions, ranging from the 
south of the United States to Southeast Asia, Southern Europe, Africa, Asia, and Central and 
South America. The outcomes of malaria varied widely between these various places, mainly 
because of differences in economic resources and implementation of control strategies, 
because global technologies for malaria control have not been efficiently utilised in all locations 
(Institute of Medicine, 1991).   
In the past decade, renewed efforts towards malaria elimination have been initiated, 
including the United Nations Millennium Development Goals of 2015, the Roll Back Malaria 
Strategy, or the Medicines for Malaria Ventures (MMV) initiatives all aiming to significantly 
reduce the burden of malaria  in endemic countries, and eventually to eliminate it (Hemingway 
et al. 2016; Van Voorhis et al. 2016). These efforts have clearly had an impact, with the World 
Health Organization estimating in 2015 that for the past 15 years global burden has decreased 
by 41%. All these world efforts have therefore drastically reduced mortality, primarily in Sub-
Saharan Africa. The reduction in mortality has been driven by improvements in prevention, 
including extensive use of insecticide-treated bed nets in houses, better diagnostic tools, 
improvement in policy for usage of particular antimalarials, and overall better health-care 
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policies worldwide (Moonen et al. 2010). Despite this generally positive trend, there were still 
214 million estimated cases and a total of 438,000 deaths in 2015 (World Health Organization 
2016). Even more troubling, according to the most recent report of the WHO, there has been 
little improvement over the past two years, with Africa having an unchanged number of deaths 
reported in 2015 and 2016 (World Health Organization 2017).   
Over this same time period, there has been a significant increase in our knowledge 
regarding the basic biology of the Plasmodium species that cause malaria. A notable example is 
the huge impact the completion of the reference genome of the human malaria parasite 
Plasmodium falciparum has had for the field (Gardner et al. 2002), which has led to significant 
contributions in the areas of drug and vaccine development (Le Roch, Chung, and Ponts 2012).  
Despite improvements in control and basic biology in the last decade, the global burden 
of malaria continues to be enormous. Currently, the population that is most affected by this 
parasitic disease is young children (0-10 years old), and it has had a dramatic impact on the 
development of many countries; from an economic and public health point of view. In addition, 
there are still challenges to the collective efforts towards elimination: the current lack of an 
efficient vaccine, the appearance of drug-resistant parasites to almost all antimalarial drugs 
that have been introduced into clinical practice, and the lack of effective prevention strategies 
that are spread worldwide rather than in individual countries. 
1.1.2 Plasmodium parasites 
To better understand the long-standing evolutionary arms race between Plasmodium 
parasites and their hosts it is important to do so in the context of its origin and natural history. 
Parasite species belonging to the Phylum Apicomplexa are unicellular eukaryotes that can infect 
various vertebrate hosts, ranging from reptiles to mammals and birds (Faust and Dobson 2015).  
In total there are six Plasmodium species that routinely infect humans; Plasmodium falciparum, 
Plasmodium vivax, Plasmodium malariae, Plasmodium knowlesi, Plasmodium ovale curtisi and 
Plasmodium ovale wallikeri. The two that cause the overwhelming majority of malaria mortality 
and complications are P. falciparum and P. vivax (Sutherland et al. 2010). Malaria symptoms for 
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both P. falciparum and P. vivax are very similar; both include high fever, chills, vomiting and 
headaches, usually accompanying the replicating asexual cycles of the parasite within the red 
blood cells of the host. After these symptoms start in a patient, it is essential to start treatment 
as soon as possible, as a delay can lead to potentially life-threatening consequences (Miller et 
al. 2002; Mackintosh, Beeson, and Marsh 2004). 
The full cycle of the malaria parasite will be discussed later in the chapter. However, it is 
important to note that different Plasmodium species have different lengths of asexual 
replication cycles, P. knowlesi, for example, has a 24-hour cycle, whereas P. falciparum, P. vivax 
and P. ovale have a 48-hour cycle. Finally, P. malariae has the longest asexual life cycle, lasting 
approximately 72 hours (Ott 1967). 
Plasmodium parasites infecting humans seem to have originated on multiple occasions, 
and as a consequence harbour large genetic diversity. Initially, P. falciparum was thought to be 
closely related to rodent and avian parasites. Waters et al. (1991) used small-subunit ribosomal 
RNA (SSU rRNA) to show the phylogenetic relationships between these parasites, and P. 
falciparum was forming a monophyletic clade with the avian malaria parasite P. gallinaceum. 
These findings suggested lateral transfer given the spread and adaptation of the vector with 
rapidly developing populations in the area (Waters, Higgins, and McCutchan 1991). A few years 
later, Escalante AA & Ayala FJ (1994) also utilised SSU rRNA of different species inside the genus 
Plasmodium to try to test the earlier hypothesis, however including other species such as 
Plasmodium reichenowi, which infects chimpanzees, showing that it was closer phylogenetically 
to P. falciparum than was previously thought. The latter was then positioned inside a clade of 
ape malaria, more distantly related to both avian parasites and other human-infecting parasites 
like P. vivax. This supported the hypothesis that the two species diverged when humans and 
chimpanzees diverged from their common ancestor 5 million years ago (Escalante and Ayala 
1994).  
Amongst those infecting humans - including the species accounting for the highest 
mortality, P. falciparum - there has been a debate over the highly similar morphological 
features with species infecting both chimpanzees (Pan troglodytes) and gorillas (Gorilla gorilla). 
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In 2010 it was shown that all of these parasites fall within the subgenus Laverania, and that the 
most closely related species to P. falciparum originated in a gorilla and was named Plasmodium 
praefalciparum (Sundararaman et al. 2016; Liu et al. 2010). 
P. vivax causes significantly less mortality than P. falciparum but has a much broader 
geographical distribution. It occurs at very low frequency in Africa, due to the high prevalence 
of the Duffy negative genetic trait in Sub-Saharan Africa. P. vivax relies on the Duffy antigen for 
the essential process of red-blood cell invasion. The widespread prevalence of this genetic trait 
in Africa means that the geographical distribution of P. vivax is almost sympatric to that of P. 
falciparum. P. vivax primarily occurs in temperate regions of Asia and the Americas, as opposed 
to P. falciparum that occurs predominantly in sub-Saharan Africa (Baird 2013), although the 
latter is also found throughout Asia and the Americas at low endemicity. 
Fig. 1.1 shows the distribution of P. falciparum, the species of study throughout this 
project. Distribution is measured by the prevalence of malaria caused by P. falciparum in 
children 2-10 years old, which includes those younger than five years old that are the most 









Figure 1.1 Map showing the spatial distribution of malaria caused by P. falciparum worldwide.  Prevalence 
of malaria in children between 2 and 10 years of age as a predictive of malaria prevalence. The lower end of 
the colour spectrum (white) indicates absent or very low risk of malaria, whereas prevalence is marked in 
orange and red. Map taken from the Malaria Atlas Project from the University of Oxford 
(https://map.ox.ac.uk/).  
1.1.3 The human malaria parasite Plasmodium falciparum 
Besides being the parasite species accounting for the highest mortality worldwide, P. 
falciparum has also been considered the most virulent, having evolved complex mechanisms to 
avoid being cleared by the immune system of the host, including the ability to cytoadhere to 
endothelial surfaces using the protein products of a variable gene family (Miller et al. 2002). As 
seen in Fig. 1.1, it is primarily present in sub-Saharan Africa but also has an important impact in 
South America and Southeast Asia. It is important to note that both the epidemiology and 
burden of disease in the different geographical locations vary greatly. Studying the population 
structure of parasites around the globe therefore would allow a more thorough understanding 
of the genetic architecture that makes specific parasite populations more successful under 
certain ecological conditions or selective pressures than others (Amato et al. 2018). This idea 
will be expanded in more detail in this same chapter. 
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The life cycle of P. falciparum, like that of other species in the genus, is complex, 
alternating between a human host and a mosquito vector (Bannister and Mitchell 2003). Fig. 
1.2 shows a representation of the life cycle of P. falciparum. 
The cycle starts with the infectious bite of a female Anopheles sp. mosquito, which as it 
feeds on a blood meal from the host will inject a variable amount (usually a median of 50-100) 
of the haploid, motile form called the sporozoite, which wait inside the salivary glands of the 
mosquito until blood feeding occurs (step 1) (Kebaier, Voza, and Vanderberg 2009). Sporozoites 
enter the skin and travel through the blood vessels until they reach the liver, where they invade 
liver cells (step 2-4). Once the liver cells (hepatocytes) are infected, parasites continue to 
replicate until becoming a multinucleated liver schizont that later ruptures releasing merozoites 
into the bloodstream, which subsequently infect erythrocytes (step 5) (Tavares et al. 2013; Aly, 
Vaughan, and Kappe 2009).  
Once parasites enter the red blood cells, they initiate the Intraerythrocytic 
Developmental Cycle (IDC), which is accompanied by the appearance of the typical 
physiological symptoms of malaria. In P. falciparum, the IDC usually takes 48 hours, although 
there is some evidence of subtle variations in the length in life cycle of different strains cultured 
in the laboratory (Rovira-Graells et al. 2016). During this stage of the life cycle, parasites, for the 
most part, undergo asexual replication, with systematic changes in different morphological and 
developmental stages shown in Fig. 1.2. This cycle initiates with a merozoite infecting a red 
blood cell (RBC), and shortly after entering a ring-like stage. This ring stage last for up to the 
first 24 hours, and is characterised by the development of membrane structures within the 
infected RBC. The parasites then enter the trophozoite stage, regarded as being a the most 
metabolically active developmental stage of the IDC (Bozdech et al. 2003). At this stage, the 
digestive vacuole (DV) appears and can be observed by light microscopy due to the formation 
of hemozoin crystals derived from hemoglobin digestion. Trophozoites take approximately 12 
hours to reach maturation, a process that ultimately leads to a transition from the G1/G0 cell 
cycle stage to the S phase, where a very fast DNA replication of the haploid genome starts to 
take place. The last stage in the asexual cycle, the schizont, can be easily distinguished as 
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multiple nuclei appear within the infected red blood cells. These nuclei are ultimately packaged 
into new daughter cells, called merozoites, and can number up to 36 depending on parasite 
strain. At maturity, the schizont ruptures and the merozoites are released into the 
bloodstream. Repeated rounds of this process leads to symptoms in malaria-infected patients 
such as high fevers and anaemia, peaking consistently with the length of the IDC (Lee et al. 
2014; Bousema et al. 2014). Fig. 1.3 shows in detail the different developmental stages that the 
parasite undergoes throughout the IDC. This is also the phase of the life cycle that is the easiest 
to maintain in vitro, and is the main part of the life cycle that will be discussed throughout this 












Figure 1.2 The life cycle of the human malaria parasite P. falciparum. It divides into three main 
developmental stages: the liver, intraerythrocytic and mosquito stages. Injected sporozoites migrate to the 
liver, where they generate liver-stage merozoites (A), a process which takes between 12-16 days. After this, 
parasites migrate into the bloodstream where most of the typical symptoms of malaria occur (B). Sexual 
differentiation takes place during the blood stages, with a later migration to the peripheral blood for uptake 
by a female Anopheles mosquito, within which fertilisation occurs thus completing the life cycle (C). Figure 








Figure 1.3 Intraerythrocytic Developmental Cycle.  A. Figure showing the Intraerythrocytic Developmental 
Cycle (IDC) of P. falciparum. Modified from (Bozdech et al. 2003). B. Development of sexual forms 
(gametocytes) into five distinct morphological stages. Only the last stage of differentiation of female and 
male gametocytes is transmissible to female Anopheles mosquitoes. Adapted from (Bousema et al. 2014). 
 
Once parasites are established in the bloodstream, they must enter a developmental 
stage capable of being transmitted to the mosquito host in order to continue their life cycle. 
Extensive evidence has been produced addressing the underlying molecular mechanisms of this 
developmental change, often referred to as “switching”, when a small fraction of the parasite 
population becomes a transmissible sexual form. Specific transcription factors of the ApiAP2 
family (De Silva et al. 2008) have a critical role in switching, with one member of the family, 
AP2-G, validated as essential for the primary developmental switch in both cultured P. 
falciparum parasites and the in vivo rodent malaria model Plasmodium berghei (Kafsack et al. 
2014; Sinha et al. 2014).   
Figure 1.3B shows the morphology of the two forms of P. falciparum gametocytes (7). Of 
note, parasites at the early stages of gametocyte development are very similar morphologically 
to asexual trophozoites entering the S phase; therefore, it is difficult to distinguish them by 
microscopy. Once gametocytes have finalised the five distinct stages of maturation shown in 
Fig. 1.3A, they go to the peripheral bloodstream where they can be taken up by a mosquito. 
Once they are taken up in a blood meal by the mosquito they develop either into the male 
microgamete (1n), which rapidly undergoes three rounds of DNA replication producing eight 
haploid genomes, or a female macrogamete (1n), leading to fertilisation (2n). Previous work by 
Billker et al. showed that the process of gamete activation is influenced by two main factors, 
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driven by a drastic change in the host environment. The considerable drop in temperature from 
37℃ to 18℃ following the transition between the mammalian and mosquito hosts, and the 
presence of xanthurenic acid, a molecule produced by the mosquito, are sufficient changes to 
trigger the differentiation of these two forms into gametes (Billker et al. 2004). Once this has 
taken place, the gametes mate inside the mosquito forming a zygote (2n), which later 
undergoes a round of replication followed by meiosis to form a tetraploid ookinete (Fig. 1.2, 
steps 9-10) (Bousema et al. 2014).  Ookinetes then cross the midgut epithelium of the mosquito 
to form oocysts. The latter undergo sporogony, within which several rounds of replication take 
place, resulting in haploid sporozoites that migrate to the salivary glands of the mosquito. By 
being injected into a new host, sporozoites re-start the life cycle of P. falciparum (11-12) 
(Bannister and Mitchell 2003). 
1.2 Next Generation Sequencing Technologies 
Until recently, DNA sequencing relied on capillary sequencing, a method developed by 
Fred Sanger in 1973 (Sanger et al. 1973). By using deoxynucleotides (ddNTPs) to prime the DNA 
polymerase, and by incorporating radioactive nucleotides, the order of bases in a sequence 
could be determined during the process of DNA replication (Bentley et al. 2008).  
More recently, there have been multiple platforms developed that fall into the category 
referred to as Next Generation Sequencing. These platforms have been developed in order to 
reach a higher number of more reliable sequence ‘reads’, and most importantly at a lower cost 
and considerably higher throughput than was previously accomplished with Sanger sequencing 
(Sanger et al. 1973). 
Next Generation Sequencing (NGS) has accelerated the field of genomics in various 
ways. Access to higher quality sequences has allowed expansion to other areas of genomics 
such as the accurate discovery of polymorphisms in DNA or transcriptomics, both of which have 
been shown to have important biological and clinical implications. The most well-known NGS 
platform comes from the biotechnology company Illumina, characterised by generating short-
reads from DNA sequencing. More recently, other companies such as Pacific Biosciences or 
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Oxford Nanopore have developed long-read sequencing, but will not be discussed here as all 
the next generation sequencing used in this study was performed using the Illumina platform. 
1.2.1 Illumina sequencing 
Illumina sequencing technology utilises a cycle of reversible termination chemistry, 
which was initially described by Bentley et al. 2008. It involves three major steps in sample 
preparation and processing: 1) library preparation, 2) generation of clusters, and 3) sequencing. 
Illumina sequencing libraries are generated by shearing DNA into short length fragments. There 
are different ways by which the shearing process can take place, including sonication (with a 
Covaris machine or equivalent) or by using enzymatic digestion. Fig. 1.4A shows the fragments 
generated after shearing, which are then end-repaired to make blunt ends. After this, adenine 
nucleotides (dAMP) are added to generate a dA-tail to the 3’ end of the blunt DNA fragments. 
The latter can be used as a template to ligate Illumina sequencing adaptors, which contain a 
thymine nucleotide overhang. Lastly, the reaction is catalysed using a T4 DNA ligase. Upon 
completion of the library, the fragments are washed to remove free adaptors. 
Appropriately sized fragments that contain the adaptors are then selected and bound 
into flow cells (Fig. 1.4B). The flow cell is a glass-based surface coated with oligonucleotides 
that are complementary to the sequencing adaptors attached to the DNA fragments (Bentley et 














    
    




Figure 1.4 Generation of a DNA sequencing library for the Illumina sequencing platform. DNA is sheared 
using sonication or enzymatic digestion.  A. Illumina sequencing adaptors are ligated to blunt-ended 
fragments. B. Sheared DNA fragments are immobilised after size quantification. C. Unlabeled nucleotides are 
incorporated for solid-phase bridge amplification. D-E. Paired-end reads are generated after synthesis of the 
complementary strand. F. Generation of clusters after single DNA molecules attached to the flow cell are 
clonally amplified.  
The flow cell contains complementary primers to the sequencing adaptors described 
previously, allowing single-stranded DNA molecules from the library to hybridise (Fig. 1.4B), 
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followed by a bridge amplification step in which the DNA molecules bound to the flow cell bind 
to another complementary oligonucleotide from the flow cell with its free adaptor (Fig. 1.4C). 
The generation of paired-end reads follows this process after acting as a template for synthesis 
of the complementary strand (Fig. 1.4D-E), which continues until clusters are generated that 
result from clonal amplification of single molecules of DNA, with thousands of templates per 
cluster being generated (Fig. 1.4F).      
    The next step in Illumina sequencing relies on the use of single modified nucleotides 
(dNTPs) that contain a terminator sequence that prevents incorporation of a subsequent 
nucleotide. These dNTPs are also fluorescently labelled, with a fluorophore that is specific to 
each DNA base; meaning that they can be excited in different channels by using a laser (Fig. 
1.5). Imaging allows the intensity of each fluorophore to be accurately measured, and the 
process of base determination takes place. After this process, the terminator moiety is removed 
to allow for another cycle to proceed. The base calling process for the Illumina platform uses a 







Figure 1.5 DNA sequence determination.  The addition of labelled reversible terminator nucleotides, primers 
and a polymerase to the flow cell allow for the initiation of the first chemistry cycle where the first base is 
identified after laser excitation and imaging. Multiple cycles take place and allow for determination of the 
sequence order of the bases identified in a particular DNA molecule. 
 Once the base calling has been performed, there are several bioinformatic tools in place 
to analyse short reads coming from the Illumina sequencing platform. Algorithms have been 
developed, such as the Burrows-Wheeler transform method (BWA) to allow for short reads to 
be efficiently aligned to a reference genome (Li and Durbin 2009).   
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1.3 Genetics and genomics of Plasmodium falciparum 
1.3.1 Efficient adaptation of P. falciparum to in vitro culture  
One of the major accomplishments of the last 50 years of malaria research was the 
successful adaptation of parasites to a stable in vitro culture system, thanks to the work of 
Trager and Jensen in 1976, who were able to successfully co-culture patient isolates with 
uninfected red blood cells (Trager and Jensen 1976). The use of supplemented media, the 
capacity to keep the culture at 37℃, and maintaining conditions similar to those in the 
bloodstream of a patient meant keeping the culture at elevated concentrations of carbon 
dioxide. Since this critical accomplishment, a large amount of research has come out from the 
establishment of the system, including one of the most significant achievements, the 
sequencing of the whole genome of P. falciparum. In their pioneering work, Gardner et al. 
assembled the first full genome, obtained from a clone named 3D7 of an adapted parasite 
strain NF54 that was isolated from a traveller that came back to the Netherlands (Gardner et al. 
2002). 
1.3.2 Sequencing and assembly of the whole genome of P. falciparum  
The genome of most Plasmodium spp. is composed of 14 chromosomes, and is around 
23 million bases which harbour approximately 5400 genes. One of the major findings of the 
grand effort to sequence the genome was the fact that P. falciparum had a surprisingly high 
adenine (A) and thymine (T) content (~80% A-T, and up to ~90% in intergenic regions of the 
genome). As well as being interesting evolutionarily, this is also one of the key reasons why 
validation of gene function in P. falciparum has been challenging. Even though the genome 
sequence revealed the sequence of many genes of interest, the high A-T content makes the 
generation of transfection constructs in E. coli challenging, as large P. falciparum DNA 
fragments are unstable in bacteria (Rug and Maier 2013).  
Analysis of the genes present in the P. falciparum genome revealed some surprises, 
including the lack of one of the two major DNA repair mechanisms. The absence of non-
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homologous end joining (NHEJ) was observed in various bioinformatics analyses performed 
since the assembly of its genome in 2002 by Gardner and collaborators (Gardner et al. 2002). 
Proteins such as Ku70, Ku80 and DNA ligase IV that act to repair stochastic double-strand 
breaks of DNA, and are key for NHEJ in other organisms are absent in P. falciparum (Lee et al., 
2014; Straimer, Lee, et al., 2012). This has significant implications for CRISPR/Cas9 genome 
editing, discussed further below. 
It took almost two decades after in vitro culture systems were developed to understand 
how to efficiently deliver DNA across the four membranes surrounding the nucleus of the 
parasite. Between 1995-96 the research groups of T.E. Wellems and A. Cowman published 
transfection by electroporation of P. falciparum ring stages (Wu, Kirkman, and Wellems 1996; 
Wu et al. 1995; Crabb et al. 1997). With this crucial event, molecular genetics in P. falciparum 
seemed possible. However, modification of the genome still required very long periods of time 
(up to six months of continuous culture) for homologous recombination to occur. Depending on 
the design of the constructs, transfections can either lead to stable maintenance of circularised 
plasmids (episomes), or chromosomal integration of the whole plasmid with single-crossover 
recombination driven by homologous recombination to repair a stochastic DNA damage event 
at the target locus (Duraisingh et al. 2002).  
1.3.3 Using genomic data to understand the diversity of P. falciparum 
populations worldwide 
Once a reference genome had been sequenced and assembled, understanding the 
genetic diversity of P. falciparum worldwide became a priority. Over the last decade, the next 
generation sequencing technologies described earlier were successfully adapted with the aim 
of performing large-scale genomic studies of parasites directly isolated from patients in 
malaria-endemic regions.  
As well as being of specific interest in understanding epidemiological features of 
malaria, genomics of P. falciparum also serves as a good system to study some of the general 
concepts in population genetics, for example how the effective population size (Ne) can 
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determine how specific variants spread in a given population. The latter can start from the 
notion that there have been evolutionary bottlenecks that have shaped genetic diversity of 
parasites in the different regions of the world, and that some variants that might be deleterious 
are more easily lost to natural selection in areas with a high Ne.  
An important study that utilised NGS methods was undertaken in 2012, in which a 
catalogue of single nucleotide polymorphisms (SNPs) was generated in order to characterise P. 
falciparum populations (Manske et al. 2012). The aim was to address how parasites are related 
across different regions of the world, and how this could be linked to ecological and 
epidemiological variables in the different regions. In this study, the global population structure 
of field parasites, and the extent to which these polymorphisms determined population 
structure was established for the first time. The result of the analysis of these polymorphisms 
by Principal Component Analysis (PCA) used the difference in the mean fixation index (FST) - a 
measurement typically used to differentiate populations - and a neighbour-joining phylogenetic 
tree to show a high degree of genetic structure in the global parasite populations. Clear 
differences between regions were also identified, with, for example, Thailand and Cambodia in 
Southeast Asia forming distinct clusters (green and blue respectively in Fig. 1.6), whereas Mali 
and Burkina Faso in West Africa (yellow and brown, respectively) showed a higher level of 
admixture. The latter is a feature generally consistent with more stable transmission, which is 
the case for West Africa, as opposed to low or unconstant transmission commonly observed in 
Southeast Asia. This finding can also be explained by the high levels of inbreeding observed in 


















Figure 1.6 Genomic diversity of P. falciparum isolates. Neighbor-joining tree of 227 world samples included 
in this study showing high degree of population structure in Southeast Asia as opposed to West Africa 
(Burkina Faso and Mali). Lines indicate an individual sample and the length of the branches refers to the 
genetic distance between samples, showing highly structured populations in SEA. Modified from (Manske et 
al. 2012). 
The findings from this study are relevant for our understanding of antimalarial drug 
resistance, as overall for populations with low genetic diversity and high levels of inbreeding 
(e.g. Southeast Asia or South America), mutations that appear to be beneficial under a certain 
selective pressure might increase in frequency; an example that has been seen with 
antimalarials such as chloroquine and more recently artemisinin (Payne 1987; Ashley et al. 
2014). This would be consistent with differences in Ne, and will be addressed later in the 
dissertation from the perspective of some of the variants involved in antimalarial drug 
resistance.   
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1.4 Antimalarial drug resistance 
1.4.1 A history of antimalarial drug resistance 
The constant process of adaptation between pathogens and hosts has been extensively 
studied and is often referred to by Leigh Van Valen’s New Evolutionary Law (“Red Queen 
Hypothesis”) (Valen, 1973). The latter usually implies that this co-adaptation between 
pathogens and hosts occurs in cycles, indicating that fitness lost through adaptive compromise 
is then restored via compensatory mechanisms. Some of these fluctuations can come not from 
host immunity, but rather from externally applied selective pressures such as, in the case of 
Plasmodium parasites, an antimalarial compound, and ultimately how the process of 
adaptation takes places will depend on the population and evolutionary history of the parasite 
and host. Given this, understanding the emergence and spread of antimalarial drug resistance 
not only has to be understood in the context of the history of different compounds being 
utilised and approved for the clinic, but also in the context of the various drug policies that exist 
worldwide, with all their socioeconomic implications for public health. 
The mechanisms by which resistance mutations emerge, persist and spread within 
parasite populations depends heavily on biological fitness, or the ability of a parasite to persist 
in a given population, which is in turn shaped by external factors such as host or local 
environment, meaning that resistance-conferring alleles can be passed to the next generation 
at different rates (Moura de Sousa et al. 2017).  
Generally, parasites have evolved mechanisms which allow them to optimize 
biochemical processes in order to cope with such selective pressures, which might incur an 
associated fitness cost. An example of drugs impacting negatively fitness are mutations 
in cytochrome b that result in decreased susceptibility to the antimalarial atovaquone but 
negatively impact fitness (Peters et al. 2002), or copy number amplifications in the multidrug 
resistance gene pfmdr1 leading to increased survival upon exposure to the antimalarial drug 
mefloquine but reduced fitness (Preechapornkul et al. 2009). Another line of evidence that can 
be extrapolated from the field is the reversal of resistance to chloroquine in Malawi after the 
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drug was removed from use, supporting the idea that mutations in the chloroquine resistance 
gene pfcrt had a fitness cost in these African parasites (Kublin et al. 2003). Although fitness 
landscapes are shaped by various ecological and evolutionary forces, measuring parasite fitness 
in laboratory settings has proven to be useful in order to study the impact of drug resistance on 
parasite fitness, specifically determined by the in vitro growth of individual parasite strains over 
time. However, due to the limitations in transfection efficiency for P. falciparum, a general 
feature of most assays that are aimed at measuring parasite fitness is that they rely on head-to-
head competition comparing at most two lines, and have not involved parallel phenotyping at a 
large scale, limiting the understanding of the in vitro fitness of cultures P. falciparum strains. 
Identifying markers of drug resistance allows accurate tracking of the origin and spread 
of resistance mutations, and interrogation of their fitness effects. Some regions in the world are 
clearly more prone to the emergence of resistance alleles. Specifically, Southeast Asia has 
historically been a “hot-spot” of drug resistance as will be described with some examples later 
in this chapter. Some of the explanations for this very localised epidemiology of resistance have 
a lot to do with both environmental factors and natural history, an example being the study of 
the worldwide genetic diversity of Plasmodium falciparum populations performed by Manske et 
al. 2012 (Manske et al. 2012).  
Various studies have shown that Southeast Asia has overall low mosquito transmission 
rates as compared to West Africa (Dalrymple, Mappin, and Gething 2015). Infections in a low 
transmission setting are usually characterised by a high proportion of patients carrying 
symptomatic infections; this is thought to result in high drug treatment rates and low levels of 
immunity, in contrast to areas of high transmission, which have a high prevalence of 
asymptomatic infections due to the more routine development of effective clinical immunity. 
As such, the epidemiology of drug resistance in Southeast Asia is potentially driven in part by 
widespread drug exposure of largely monoclonal parasite infections (Blasco et al. 2017).     
Today the current pipeline of drugs for treatment is being compromised as it relies on a 
limited number of compounds to which resistance is becoming widespread (Flannery et al. 
2013). Table 1.1 shows the major antimalarial compounds that have been introduced into the 
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clinic, the year in which they were introduced, the year when resistance was first reported and 
some references to potential mechanisms of action (Paloque et al. 2016). 
Table 1.1 Summary of main antimalarials that have been introduced into the field and for which resistance 









Reference to main resistance mechanisms 
Quinine 1632 1910 Disruption of drug accumulation inside the food vacuole by 
reduced propensity of the drug transporter PfMDR1 to transport 
the anti-malarial (Sanchez et al. 2010; Koenderink et al. 2010). 
Chloroquine 1945 1957 Drug extrusion from the digestive vacuole by mutated drug 
transporter Pfcrt due to negativity of the transporter allowing 
efflux of protonated chloroquine (Ibraheem et al. 2014; 
Summers, Nash, and Martin 2012; Setthaudom et al. 2011).  
Proguanil 1948 1949  
Modification of the drug target: reduced inhibition of enzymatic 




Mefloquine 1977 1982 Reduction of parasite susceptibility to mefloquine by 
amplification of pfmdr1 copy number (Sidhu et al. 2006). 
Atovaquone 1996 1996 Modification of the drug target by inhibition of the ubiquinol 
oxidation pocket of cytochrome bc1 complex (Kessl, Meshnick, 
and Trumpower 2007). 
Artemisinins 1980s 2006 Delayed progression of ring stages, up-regulation of unfolded 
protein response, quiescence (Witkowski et al. 2010; Ariey et al. 
2014; Mok et al. 2015).   
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1.4.2 Antimalarials and their mechanisms of action 
1.4.2.1 The Digestive Vacuole 
 
There have been many compounds derived or synthesized that have antimalarial 
properties and for which the mechanism of action seems to be associated with the blockage of 
the heme detoxification pathway undertaken by the parasite inside the DV.  
The DV is a highly specialized organelle that is formed by endocytosis of RBC cytosol at 
structures known as cytostomes, which are formed by invagation of the parasite plasma 
membrane and parasitophorous vacuolar membrane (Dluzewski et al. 2008; Aikawa et al. 
1966). Abu Bakar et al. 2010 used live imaging to further characterize the formation of this 
organelle, using fluorescence dextran probes to demonstrate a change in the acidity of the 
compartment after its formation (Bakar et al. 2010). As a result, the mature DV of Plasmodium 
parasites is highly acidic (pH 5.2-5.5) and is maintained by a proton gradient through an ATPase 
pump (Klonis et al. 2007; Dhingra et al. 2017). During most of the intraerythrocytic 
developmental cycle this compartment plays an essential role in the process of degradation of 
host hemoglobin (Hb), primarily carried out by aspartic and cysteine proteases including 
plasmepsins 2 and 3 (PM2 and PM3) and falcipains. The breakdown products include short 
peptides and amino acids, as well as heme that is ultimately detoxified into inert hemozoin 
crystals (Hz) (Chugh et al. 2013). It has been found that antimalarials belonging to the quinoline 
class interfere with the heme detoxification process. In Fig. 1.7 some of the quinolines are 
labelled as QN (Quinine), CQ (Chloroquine), Amodiaquine (AQ), and Piperaquine (PPQ) (Blasco 

















Figure 1.7 Diagram of the digestive vacuole of P. falciparum and various antimalarials with their suggested 
mechanism of action. The blue oval corresponds to the DV of the parasite where multiple antimalarials have 
been shown to act. In particular, 4-aminoquinolines have an ability to interfere with the process of 
detoxification of heme coming from hemeoglobin degradation (quinine (QN), chloroquine (CQ), piperaquine 
(PPQ), amodiaquine (AQ), mefloquine (MFQ) and lumefantrine (LMF)). Additional known and validated 
pathways being targeted by other antimalarials are related to the pyrimidine biosynthesis (sulfadoxine (SDX) 
inhibiting dihydro dihydropteroate synthase (DHPS) and pyrimethamine (PYR)/cycloguanil (CYC) inhibiting 
dihydrofolate reductase (DHFR). Electron transport chain in the mitochondria (atovaquone (ATQ) inhibiting 
cytochrome B (CYTb) and dihydroorotate dehydrogenase (DHODH). Protein translation in the apicoplast 
(clindamycin (CLD) and doxycycline (DOX)), and artemisinin (ART), for which variant forms of Pfkelch13 (K13) 
increase survival measured by RSA(0-3h). Figure taken from (Blasco et al. 2017). 
1.4.2.2 Quinolines  
Resistance to quinolines is generally thought to be related to processes undertaken in 
and involving the DV. In particular, it has been associated with specific polymorphisms in two 
main genes; the chloroquine resistance transporter gene (Pfcrt) and the multidrug resistance 1 
gene (Pfmdr1) (Fidock et al. 2000). Historically, some quinolines have been used as a 
monotherapy, however with the emergence and spread of drug resistance, they are mostly 
now being used in combination with the frontline antimalarial artemisinin, which will be 
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described further on this chapter. An exception to this is quinine, which has been recently used 
as monotherapy for the treatment of severe malaria, however there has been some contesting 
evidence against it, showing that artesunate as a monotherapy might be safer for this purpose 
(Noubiap 2014). Some of the quinolines that have been used in the field include quinine, 
chloroquine, mefloquine, piperaquine, primaquine, and lumefantrine, shown inside the DV in 
Fig. 1.7. Quinine was the first compound to be utilised in a widespread manner for the 
treatment of malaria, and it dates to the beginning of the 17th century. It was isolated from the 
bark of the “quina-quina” tree, native to South America. Although there are some legends that 
indicate that it had been used by the indigenous populations for the treatment of fevers, the 
evidence is not very strong, at least as it is written in the post-colonial history of the Americas. 
The trigger for widespread use is alleged to be when a Spanish countess was cured by 
indigenous people in Peru with the bark of this tree, resulting in the transport of the plant to 
Europe in 1638 (Achan et al. 2011).   
Although quinine has been in use for a very long time (Table 1), issues related to toxicity 
and adverse side effects were always present (Goldenberg and Wexler 1988), emphasising the 
case for a search for a safer and effective substitute.  Although there have been some reports of 
quinine treatment failure thought to be related to resistance, primarily in South America in the 
1960s, other hypothesis as to why it may not be fully effective are related to its 
pharmacological properties, including poor tolerability by the different age groups treated, 
however full-scale resistance to quinine is not thought to be present today (Achan et al. 2011).  
1.4.2.3 Chloroquine 
As an alternative to quinine, chloroquine (CQ) was synthesized in the 1940s and its main 
purpose was to treat malaria. CQ, another 4-aminoquinoline compound, is a weak base that 
accumulates in the DV because it becomes protonated there due to the low pH environment. 
Once accumulated in the DV, CQ can block the heme detoxification process, leading to toxicity 
to the parasite (Lewis et al. 2014).  
Chloroquine was extensively used after its introduction, as it was highly efficacious and 
also had pharmacological properties that made it suitable for patients of all ages. It was central 
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to the WHO global malaria eradication campaign in the mid 1950s, which combined extensive 
administration of chloroquine with vector control strategies (primarily through DDT), leading to 
some lower transmission geographical regions being cleared of malaria (Wellems and Plowe 
2001). However, its use came with the almost unavoidable consequence of drug resistance, and 
its success was compromised when there started to be reports of independent emergence of 
resistant parasites in Southeast Asia and South America. After 20 years, CQ resistance spread to 
Sub-Saharan Africa, with devastating effects in morbidity and mortality, mostly in paediatric 
populations (Fidock et al. 2000). Figure 1.8 shows the likely trajectory taken by chloroquine-
resistant parasites emerging in Southeast Asia, entering Africa through Zanzibar (Schwartz et al. 
1983).  
Figure 1.8 World map showing the emergence of chloroquine resistance. Resistant parasites emerged in the 
late 1950s in Southeast Asia (marked with a red circle) and South America and subsequently spread 20 years 
later to areas with high endemicity in Africa. Map adapted from the Malaria Atlas Project from the University 
of Oxford. The first major study that aimed to understand the mechanism of resistance to 
chloroquine was published by Wellems et al. in 1990. The aim of this study came from the 
observation that in resistant parasites, chloroquine was being expelled from the DV, therefore 
limiting efficacy. However, these strains could become sensitive again by the addition of a 
compound called veramapil (VP), which counteracted the resistance mechanism (Martiney et 
al. 1995). In mammalian tumour cells, the reversal of resistance by VP had been observed in a 
similar manner, and was mediated by a multidrug resistance gene (mdr), an ATP-driven P-
glycoprotein transporter. Given the ability to reverse the effect in other biological systems, the 
study aimed at understanding whether MDR proteins in P. falciparum would also be involved in 
a mechanism of resistance to chloroquine. To isolate the resistance determinants, the authors 
performed a genetic cross in a chimpanzee between the chloroquine-sensitive P. falciparum 
strain HB3 (CQS) - originally isolated from Honduras - and the chloroquine resistant strain Dd2 
(CQR), originating from Laos. The purpose of the cross would be to dissect the genetic basis of 
the phenotype by studying the segregation of that trait in the progeny. After completing the 
cross and obtaining the progeny, the two candidate multidrug resistance genes (Pfmdr1 and 
Pfmdr2) did not seem to be involved in resistance, suggesting the phenotype was linked to 
different genetic loci. Notably, the progeny of the cross was split into two clear groups: 
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sensitive and resistant, with no intermediate phenotypes (Wellems et al. 1990). Restriction 
Fragment Length Polymorphisms (RFLPs) were used on all the progeny to study the inheritance 
of all 14 chromosomes, finding a 400 kb region on chromosome 7 to be linked to modulating 
chloroquine resistance (Wellems, Walker-Jonah, and Panton 1991). This region was later 
narrowed down to 36 kb by Su et al. in 1997 (Su et al. 1997). 
Later in 2000, Fidock et al. looked for transcripts arising from this 36 kb region on 
chromosome 7, and found previously uncharacterised transcripts coming from a gene they 
named Pfcrt, which was defined as the Chloroquine Resistance Transporter. One finding from 
these studies was the observation that the resistance phenotype was associated with the 
presence of at least four independent mutations in the Pfcrt gene: K76T, A220S, N326D and 
I356L.  The chloroquine resistant strain Dd2 also had an additional four mutations, which were 
speculated to compensate for any loss of fitness caused by the resistance mutations, a 
mechanism that often occurs in pathogens during their process of co-evolving within hosts 
(Fidock et al. 2000). The importance of these mutations has also been supported by genome 
editing studies that will be described further (Straimer, Lee, et al. 2012). 
1.4.3 Artemisinin: The current frontline antimalarial 
Artemisinin is currently the frontline antimalarial in use. It, or one of its derivatives, has 
been used as monotherapy or more recently in combination with other antimalarials as 
Artemisinin Combination Therapies (or ACTs), and has contributed significantly to the recent  
reductions in the global burden of malaria (World Health Organization 2016).  
The origin of the use of artemisinin dates to the year 340 AD. This record comes from a 
book published in this year by Ge Hong called “Handbook of prescriptions for emergencies”. In 
the text, a plant called Artemisia annua L. (“qinghaosu” in Chinese), commonly referred to as 
‘wormwood’ (shown in Figure 1.9A), was extracted in water in order to treat symptoms that are  
characteristic of a person infected with malaria (Guo 2016).  
This plant was rediscovered after the emergence of resistance to chloroquine in the 
1950s. With the concern of not having an effective treatment for malaria, a call was made 
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among research groups in China to examine their traditional medicines for antimalarial 
properties. With this effort, the creation of Project 523 took place under the leadership of 
Youyou Tu, who later received the Nobel Prize for Physiology and Medicine in 2015. The project 
aimed at isolating possible components from all the available collections of herbal materials in 
order to identify extracts with possible pharmacological properties against Plasmodium 
parasites. Extracts of Artemisia annua L. (Figure 1.9B shows the structure of the active extract) 
showed outstanding properties against different Plasmodium species, and this led researchers 
to extend their work to clinical trials in order to treat P. falciparum, the species that at the time 
was becoming resistant to all other antimalarials introduced in the region (Tu 2011; Schlitzer 
2007). 
A                                      B  
Figure 1.9 Artemisia annua.   
A. Picture taken from (Nosten 2010). B. Structure of 
artemisinin taken from (Shandilya et al. 2013) 
 
By 2001, the WHO was recommending every country to implement in their malaria 
healthcare policies a combination of the extract from Artemisia annua L. together with another 
antimalarial (partner drug) (Price and Douglas 2009). The reasoning behind the decision to 
include a partner drug was that despite the rapid effect of artemisinin on parasite clearance, 
the drug also has a very short half-life in the plasma. Thus the longer lasting partner drug would 
act to eliminate any parasites remaining after artemisinin has disappeared from circulation 
(Eastman and Fidock 2009). Additionally, the principle of using a combination therapy approach 
for any pathogenic disease is based on the fact that there is a theoretically lower probability of 
acquiring resistance mutations to multiple, unrelated compounds, than to a single compound, 
therefore reducing the risk of treatment failure (Rybak and McGrath 1996).  
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1.4.4 Artemisinin resistance 
The WHO recommendation of 2001 regarding use of artemisinin combination therapies 
(ACTs) was widely taken up and proved effective, but only seven years later Noedl and 
collaborators showed in clinical trials that P. falciparum parasites in Cambodia displayed some 
level  of resistance to artemisinin (Noedl et al. 2008). 
The study by Noedl et al. used monotherapy to investigate the presence of resistance to 
artemisinin, even though artemisinin was not meant to be used alone for treatment in endemic 
countries. In their study in Western Cambodia, they enrolled volunteers that were infected with 
P. falciparum but without significant complications. They treated groups of patients with either 
artemisinin (artesunate) or with quinine and tetracycline (previously described). Artemisinin-
resistance was defined by using molecular, in vivo, in vitro, and pharmacokinetic criteria to 
distinguish delayed parasite clearance from those patients that cleared parasites at the 
effective rate. To be defined as failing treatment, patients had to have parasites for more than 
seven days after the start of the treatment or experienced reemergence of parasites within 28 
days of the start of treatment. From the patients included in the study, four out of the 60 
patients had reemergence of parasites, and were classified as treatment failure, although two 
of these were due to drug inefficacy, and only two due to drug resistance (Figure 1.10A). 
Clinical artemisinin resistance was subsequently defined as the time it would take the drug to 
clear half of the total parasitaemia in the circulating blood, measured by thick blood smear, 
combined with a higher IC50 to the compound. Figure 1.10B provides additional evidence to 
their statement by showing a higher inhibitory concentration (IC50) for dihydroartemisinin from 
the two slow-clearing patients, distinguishing them with the other two patients that had 











Figure 1.10 Resistance to artemisinin monotherapy. A. Curves showing the reduction of parasitaemia over 
time for the 60 patients involved in the study by Noedl et al. 2008. B. Inhibitory concentrations for all 
patients involved in the study with those circled in red showing patients that had slow-clearance because of 
resistance and those circled in blue having slow-clearance because of treatment failure. Reproduced from 
(Noedl et al. 2008). 
1.4.5 Genetics and epidemiology of artemisinin resistance 
1.4.5.1 Population genetics of artemisinin resistance  
 
Following additional studies showing that there was indeed evidence of resistance to 
artemisinin, various research groups started to analyse whole genomes of parasites isolated 
from distinct geographical regions to unravel the genetic architecture of what seemed to be an 
alarming phenotype (Straimer et al. 2015). 
In 2013, Miotto and collaborators aimed to address the population structure of drug-
resistant P. falciparum and - given it was a phenotype so far only seen within Southeast Asia - 
tried to tackle the question of how resistance emerged within these populations and whether it 
could also emerge in areas of high mortality such as West Africa. 
Consistent with the results by Manske et al. (Manske et al. 2012), analysing the genome 
sequences of 290 global samples by Principal Component Analysis identified clear population 
structure within Southeast Asia. This finding was consistent with the presence of low levels of 
genetic diversity in the area as a consequence of the low transmission rates. Figure 1.11A 
shows a neighbour-joining tree of all the samples included in the study, showing evidence that 
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there is a surprising level of structure in Southeast Asia even within geographically close 
locations. Samples from within Cambodia were analysed to identify their ancestry, with the 
finding that some parasites (genotype group KH1 comprising Northeastern Cambodia, Thailand 
and Vietnam) were all more closely related amongst them. However, three other groups of 
samples were genetically more distant than samples from the region (genotypes KH2, KH3, KH4 
from Western Cambodia), and an additional set of examples that accounted for the population 
with the highest level of admixture (genotype KHA) (Figure 1.11B) (Miotto et al. 2013). 
 
Figure 1.11 Population structure of P. falciparum. A. Neighbour-joining tree consisting of 825 samples 
isolated from malaria patients based on a pairwise distance matrix. The distance between samples 
represented by mismatches is defined by the length of the branches shows two highly differentiated set of 
samples corresponding to West Africa and Southeast Asia. A high degree of structure is observed within 
Southeast Asian samples explained by the distinct clusters in the tree, whereas a less structured population 
was observed for West Africa. B. A principal component analysis showing PC2 and PC3 for the Southeast 
Asian samples only, showing population structure within samples from Cambodia. Reproduced from (Miotto 
et al. 2013). 
This analysis raised the clear question whether these high levels of population structure 
had anything to do with the different phenotypes seen in the region, in particular, slower 
parasite clearance after treatment with artemisinin. To answer this question, Miotto et al. 
correlated the values that were available for clearance time of parasitaemia between the 
different genotype groups (KH1, KH2, KH3, KH4 and KHA). With this analysis, they found that in 
particular, KH2 had a much higher clearance time than KH1, which they characterised as having 
a “wild-type” phenotype to artemisinin tolerance. Interestingly, KHA showed a very variable 
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phenotype, suggesting that this was an admixed population and that perhaps those genomic 
regions which were responsible for the higher tolerance to artemisinin had been ancestrally 
acquired. 
Amongst the most interesting aspects that were discussed by the authors is the 
possibility that some of the genotypes (e.g. KH2) had accumulated a particular set of mutations 
that allowed them to be resistant but also to compensate for a potential loss of fitness as a 
consequence of drug pressure. These genotypes seemed to be spreading in the area and had a 
slower clearance rate when treated with artemisinin. If this was the case, there was an urgent 
need to understand whether specific genetic backgrounds exposed to the same selective 
pressure could harbour additional mutations leading to the phenotypes observed in the field, 
and ultimately to lead to a spread of resistance to artemisinins (Miotto et al. 2013). 
This study led other groups to try to identify genetic markers of artemisinin resistance, 
and with access to whole genome sequences of the parasite sub-populations identified by 
Miotto and collaborators, some of these were also experimentally validated. 
1.4.5.2 A search for molecular markers of artemisinin resistance 
The previous findings were worrying as at the time the whole world was relying on 
artemisinin for the treatment of malaria. With the improvement of sequencing technologies 
and genome analysis tools, researchers around the globe attempted to characterise the genetic 
basis and epidemiology of resistance, now threatening the lives of millions of people. In 2014, a 
research study used an in vitro drug sensitivity assay that correlates well with the clinical 
measurement of artemisinin resistance, described earlier. The latter defines the time it takes 
the drug to clear 50% of the circulating parasites in a patient. Together with genomic data, the 
aim of the study was to identify a molecular marker of artemisinin resistance (Ariey et al. 2014). 
The same group had previously published the Ring Stage Survival Assay (0-3h), or RSA(0-3h). It 
consists of treating early (0 to 3 hour) ring stages with a concentration that correlates with the 
concentration used to treat malaria in patients: 700nM of the primary metabolite from 
artemisinin, dihydroartemisinin (DHA). The usefulness of this protocol was primarily because in 
artemisinin-resistant isolates from patients in a region in Cambodia, the early rings stages were 
 30 
resilient to the treatment, resulting in the reemergence of parasites as a consequence of a 
delayed developmental stage that could be coming from quiescence, or dormancy (Witkowski 
et al. 2010).  
In the study of 2014, Ariey et al. used a lab-adapted, artemisinin-sensitive strain isolated 
from Tanzania (F32-TEM) and cultured it with increasing concentrations of artemisinin for five 
consecutive years. In parallel, a clone was cultured for the same amount of time in the absence 
of artemisinin pressure as a control. Whole genome sequencing of the two clones was 
performed before and after the phenotype of the selected line (F32-ART5) reached a 10% 
increase in the clearance half-life as measured by the RSA(0-3h). The acquisition of mutations in 
seven genes at around 40 cycles after drug selection was consistent with an increase in 
resistance measured by RSA of 8-10%. Among the mutations acquired in this period, only those 
that were present in the drug-selected clone and not in the untreated or in 3D7 were used for 
phenotype validation. With this, the authors validated their importance in the resistance 
phenotype of parasites isolated from patients in the field, primarily in regions of the world in 
which at the time treatment failure was occurring at an increasing rate. Given all the 49 
sequenced parasite strains had been culture adapted, they performed in vitro RSA(0-3h) on all of 
them, finding that some of the candidate genes that were observed in their 125-cycle selection 
as being important for acquisition of resistance also contained polymorphisms in these 
parasites isolated from patients. In particular, various mutations in PF3D7_1343700 (Pfkelch13) 
were associated with a high-resistance phenotype measured with RSA(0-3h), as seen in Figure 
1.12 (Ariey et al. 2014). Notably, some mutations had a higher frequency and a slightly lower 
RSA(0-3h) (e.g. C580Y); whereas others had a higher RSA but their global prevalence was lower 
(e.g. I543T), at least within the strains that were included in this study, using the wild type 












Figure 1.12 A molecular marker of artemisinin resistance. Ring-Stage Survival assay (RSA) performed on 0-3 
hour ring stages of culture-adapted strains that had reported a delayed parasite clearance phenotype in vivo, 
and contained mutations in Pfkelch13. Reproduced from (Ariey et al. 2014). 
Overall, the authors confirmed that Pfkelch13 is an essential molecular marker of 
artemisinin resistance, and established the phenotype obtained after a long selection 
experiment with samples isolated from the field. Additionally, the authors showed that the 
mutation C580Y is the most prevalent. However, there was one Pfkelch13 mutation from the 
selection experiment that conferred a higher level of resistance, but is not common as C580Y, 
arguing that perhaps these mutations were associated with a higher fitness cost, leading to 
their lower prevalence. 
1.4.5.3 Pfkelch13 and different artemisinin resistant populations 
With access to whole genome sequences from many regions of the world, and with the 
recent establishment of Pfkelch13 as a molecular marker of artemisinin resistance (Ariey et al. 
2014), Miotto et al. published a study in 2014 aimed at understanding which other genes were 
involved in resistance pathways in those genotypes that were spreading in Southeast Asia. 
Partly the importance of this study was to understand the reason behind some mutations in 
Pfkelch13 being absent from regions of high transmission intensity such as West Africa. The 
authors performed a Genome-Wide Association Study (GWAS) in which they examined 1612 
samples with phenotypic data (ex vivo and in vitro RSA(0-3h)) coming from Cambodia, Thailand, 
Myanmar, Laos and Bangladesh. Similar to the results from Ariey et al. 2014, they found that 
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the only mutation in the propeller domain of Pfkelch13 that had a strong association with the 
observed phenotype was C580Y, and in regions with some level of resistance, it had almost 
reached levels of genetic fixation (Fst of 1). Interestingly, they were able to identify phenotypic 
boundaries between subpopulations with different levels of resistance (low vs. high), all of 
which contained C580Y, and used these subpopulations to dissect some of the components of 
the genetic background important in the differentiation between medium and high levels of 
artemisinin resistance, as measured by parasite clearance half-life and RSA(0-3h). The principle of 
compensatory mechanisms, or stepwise acquisition of resistance-associated polymorphisms 
has been studied for other candidate molecular markers such as Pfcrt (Gabryszewski et al. 
2016) or Pfdhfr (Lozovsky et al. 2009). 
1.4.5.4 Link of Pfkelch13 to artemisinin resistance 
It is still not clear how mutations in the kelch propeller domain encoded by Pfkelch13 
confer artemisinin resistance. Some studies have linked these polymorphisms to an increase in 
the levels of the phosphatidylinositol-3-phosphate kinase (PfPI3K), and its lipid product PI3P in 
ring stages, increasing tolerance to artemisinin (Kahrstrom 2015; Mbengue et al. 2015), but 
studies of populations of resistant parasites suggest that the mechanism of resistance is more 
complex.  
In mammalian cells, kelch proteins have the capacity of acting as cytosolic adaptors of 
substrates targeted to the ubiquitination pathways as a response to oxidative stress. Keap1 - a 
kelch-like protein in humans - has been shown to bind to Nrf2 (nuclear factor erythroid 2-
related factor 2), which acts as a repressor of Keap1 leading it to the ubiquitination pathway 
and subsequent degradation by the proteasome. When a cell is in normal homeostatic 
conditions, Nrf2 is continuously being ubiquitinated, however under stress conditions such as 
oxidative stress, some residues of the kelch-like protein Keap1 have been seen to be modified 
by ubiquitin leading to a decline in the activity of one of the ligase subunits which form part of 
the ubiquitination process, in turn leading to an accumulation of Nrf2 (McMahon et al. 2003). 
This has been shown to have some level of effect on transcription as it would control the 
 33 
expression of genes related to cell stress response, specifically related to ubiquitination and 
degradation of proteins by the proteasome (Taguchi et al. 2011). 
The link between mutations in Pfkelch13 and resistance to artemisinin has also been 
studied in the context of how these kelch-like proteins act and affect transcriptional response in 
human cells. A study published in 2015 by Mok et al. showed strong differences in the 
transcriptional response of artemisinin tolerant and sensitive parasites. In particular, they 
observed the activation of the unfolded protein response in the resistant backgrounds, 
potentially related to the decline in activity of the ubiquitin-proteasome system given the 
mutations present in Pfkelch13, similar to what had been observed for kelch proteins in 
mammalian cells (Mok et al. 2015).  
There have been other studies aimed at studying artemisinin response in both sensitive 
and resistant parasites isolated in the field and adapted to culture. A study by Dogovski et al. 
2015 showed that when wild-type parasites were treated with artemisinin, there was an 
accumulation of ubiquitinated proteins, again linking the mechanisms of action of this drug to 
cell-stress response mechanisms. When the authors made the same approach to study the 
response of resistant parasites to artemisinin they observed that the accumulation of 
ubiquitination declined, potentially a mechanism that would allow a delayed cell death; an 
observation that had been described before. To validate their approach, they included in their 
study a compound that was known to inhibit the proteasome. Interestingly what they saw was 
that this compound would synergise the effect of artemisinin, suggesting that the mechanism 
of action of artemisinin directly interferes with the cell stress response pathways and those 
resistant parasites seem to have enhanced proteostasis mechanisms (Dogovski et al. 2015).  
Although these studies do not definitively establish how the resistance phenotypes 
correlate with mutations in Pfkelch13, they provide some critical knowledge on the relevance of 
this protein and the necessity to perform more thorough studies on other candidates on the 
genetic background of drug-resistant parasites. To understand what these mechanisms might 
be, some of the available information on similar proteins in human cells and their effect in 
regulating transcription of genes involved in cell-stress response mechanisms such as the 
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ubiquitin-proteasome can be studied in various ways. An example can be the work by Miotto et 
al. (O. Miotto et al. 2015) which can be a starting point at trying to understand these different 
mechanisms.   
Overall, studying the effect of these haplotypes seen in the field and their effect on 
parasite fitness, understanding the genetic architecture of drug resistance, and identifying new 
antimalarial compounds that avoid current resistance pathways are all urgent priorities for the 
field. 
1.4.5.5 Biological fitness and antimalarial drug resistance 
The underlying genetic architecture and epidemiological features that explain why 
resistance emerges in some areas of the world and not in others has been studied through 
various approaches. Whether mutations in Pfkelch13 had a direct impact on resistance was 
experimentally validated by Straimer et al. and by Ghorbal et al., using genome editing 
technologies to introduce polymorphisms previously reported by Ariey et al., and observed in 
parasite populations in the field. Some of the lines included by Straimer et al. would contain 
some of these polymorphisms in K13 previously shown to be associated with the high tolerance 
phenotype after artemisinin pressure. Figure 1.12 shows the different Pfkelch13 mutations that 
gave high RSA(0-3h) values such as I543T, Y493H and R539T: all of these have a lower prevalence 
when compared to C580Y, which is widespread throughout Southeast Asia. To study the 
contribution of each one of these haplotypes, the mutations were removed from parasite 
isolates from Cambodia which were artemisinin-tolerant. These mutations were also 
introduced into standard laboratory strains and artemisinin-sensitive field isolates. Fig. 1.13 
shows the different backgrounds in which mutations in Pfkelch13 were introduced. Fig. 1.13A 
shows the effect of mutations observed in the field on parasite survival using the RSA method. 
It was clear from this experiment that mutations that had the highest RSA values were present 
at very low frequencies in the field, as opposed to the most common mutation C580Y. Figure 
1.13B shows a different experiment aimed at understanding the contribution of genetic 
background to resistance phenotypes. Because of its high prevalence, mutation C580Y was 
introduced into different genetic backgrounds, and RSA(0-3h) values were obtained. Remarkably, 
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when this mutation was introduced in Cambodian isolates Cam2, Cam3.II and CamWT, and 
even a lab-adapted strain originally from Laos, Dd2, the survival rate was significantly higher 







Figure 1.13 ZFN-based editing of Pfkelch13. ZFN-based genome editing to address epidemiologically relevant 
SNPs and their effect on artemisinin resistance. A. Pfkelch13 mutations seen in the field and their effect on 
artemisinin tolerance in the lab adapted strain Dd2, measured by RSA(0-3h). B. The most prevalent mutation 
seen in the field for Pfkelch13, C580Y introduced into different genetic backgrounds and the effect on 
artemisinin tolerance measured by RSA(0-3h). Reproduced from (Straimer et al. 2015). 
Evidence from this work supports the idea that the genetic background has an 
important effect on artemisinin resistance. Understanding the different levels by which 
mutations in Pfkelch13 impact the biological fitness of parasite isolates is therefore key to 
improve surveillance strategies.  
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1.4.5.6 Mode of action of artemisinin  
The mechanism of action of artemisinin is still not fully understood, and is likely to be 
more complicated than it was previously thought.  
Artemisinin is a sesquiterpene lactone with an endoperoxide bridge (Figure 1.9B). There 
have been studies in the past showing that the breakage of the endoperoxide bridge leads to 
the release of free radicals which were in part responsible for its antimalarial properties. In 
1991, Meshnick and collaborators suggested that artemisinin would get activated into toxic free 
radicals for the parasite by entering into contact with the heme inside the parasite, which is 
produced as a result of the digestion of haemoglobin inside red blood cells (Meshnick 2002). 
This leads to a mechanism of action whereby release of free radicals interferes with the heme 
detoxification performed by the parasite inside its DV, leading to membrane destabilisation 
(Antoine et al. 2014). Other studies have shown slightly contradictory results, as there were 
observations of artemisinin accumulating in the parasite membrane rather than the DV, and 
explicitly showing artemisinins could kill early ring stages which lack heme, therefore in 
principle the compound could not be activated by the iron present in the process of 
haemoglobin degradation leading to the production of toxic free radicals. In 2004, Eckstein-
Ludwig et al. suggested that artemisinins acted by inhibiting the sarco-endoplasmic reticulum 
Ca2+-ATPase (SERCA) ortholog in Plasmodium falciparum, PfATP6 (Eckstein-Ludwig et al. 2003). 
Additionally, other studies have suggested artemisinins are activated by the electron 
transport chain in the mitochondria, leading to its membrane being depolarised and ultimately 
damaged as a consequence of the toxic free radicals being released upon artemisinin activation 
(W. Li et al. 2005). 
Another mechanism that has been described for the mode of action of artemisinin 
comes from the observation that a small proportion of parasites would enter a state of 
dormancy, resuming the infection by having a recrudescence after completion of the 
treatment. Less evidence exists as to how artemisinin enhances this biological state, however, 
this putative mechanism provides yet another reason why artemisinin should be used in 
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combination with compounds for which no phenotype of quiescence has been observed 
(Witkowski et al. 2010).  
Overall, the mechanism of action of artemisinin is complex, and different studies have 
shown evidence of it having a pleiotropic effect on the cell, targeting multiple proteins. Given 
the challenges in validating some of these targets, it is essential to direct efforts towards 
policies for the use of combination therapies and to invest in large-scale screening of 
compound libraries to identify new candidates to either use with it, or to replace it.        
1.4.6 Artemisinin combination therapies (ACTs) 
Artemisinin combination therapies (ACTs) have been used, ever since resistance to 
artesunate monotherapy became a threat, as the front-line antimalarial. According to the 
World Health Organisation, it has been one of the significant contributors to the reduction in 
malaria mortality in areas of high endemicity, attributed primarily to low ACT failure rates (less 
than 10%) (World Health Organization 2016). Table 1.2 shows the different ACTs that have been 
used thus far to treat malaria in different regions of the world. Ideally, countries should have 
availability of as many combinations as possible, given that there have been reports of 
resistance to the partner drugs currently available, therefore having a more extensive chemical 
space would be advantageous for any health care policy. Unfortunately, this is not the case, and 
neighbouring countries have different health care policies and surveillance strategies, which 















1.4.6.1 Resistance to ACTs 
Ever since the different partner-drug combinations with artemisinin have been adopted to the 
different countries, there have also been various reports showing some level of resistance to 
the partner drug, specifically in the context of artemisinin-resistant parasites from Southeast 
Asia (Amaratunga et al. 2016; Amato et al. 2017). 
The first combination to be introduced into clinical practice was artesunate and mefloquine in 
the mid-1990s; resistance to the latter had already been reported in the past, thought to be 
associated with amplification of a multidrug resistance locus (Pfmdr1) (Price et al. 2004). 
Previous studies had seen an increase in mefloquine resistance when used as a monotherapy or 
in combination with sulfadoxine-pyrimethamine, leading to high treatment failure in Thailand 
and Cambodia. When mefloquine was used in combination with artesunate, however, a 
decrease of treatment failure was observed after application of a 3-day dose of artesunate was 
performed. As a consequence of the effectiveness of the new treatment regime with 
artesunate, which would be enough for two parasite life cycles, the rate of resistance to 
mefloquine decreased, meaning that sensitivity of parasites to the drug as measured by the 
inhibitory concentration (IC50) had increased (Nosten et al. 2000; Woodrow and White 2016). 
Similar strategies were then used to treat P. falciparum malaria worldwide.  More recently, 
there have been reports of treatment failure to one of the most widely used ACTs in the 
Greater Mekong Subregion (Western Cambodia): dihydroartemisinin-piperaquine. In 2017, 
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there were two independent studies published which showed an association of specific genetic 
markers and the treatment failure to this combination therapy. What both studies found after 
performing a Genome-Wide Association Study (GWAS) was that there was an amplification of 
the aspartic proteases plasmepsin 2 and 3, localised in chromosome 14 in piperaquine 
resistance lines. Interestingly, they also found that an amplification in Pfmdr1 that had been 
observed and possibly attributed to mefloquine pressure in the past was absent from samples 
having the plasmepsin 2 and 3 amplification, suggesting that perhaps they represent opposing 
mechanisms of resistance. The latter is currently being explored in the region and use of triple 
combination therapies is being encouraged in areas of high resistance (Witkowski et al. 2017; 
Amato et al. 2017).  
In another study, Dhingra et al. had showed the results on a line originating from Indochina 
(Dd2) which had been selected in their earlier work (Eastman et al. 2011) using continuous 
piperaquine pressure. Comparative studies using Whole Genome Sequencing revealed a novel 
haplotype in Dd2 for the chloroquine resistance transporter PfCRT, carrying the mutation C101F 
with a possible association to the phenotype, and a de-amplification of Pfmdr1 (previously 
associated with both mefloquine and chloroquine resistance). With this finding, the authors 
were able to use genome editing tools to validate the resistance phenotype observed. Among 
their findings, was the fact that if the mutation was inserted into a Dd2 background, it led to 
both a decrease in susceptibility to piperaquine and a decrease in replication rates, possibly 
because of a fitness cost associated with that particular haplotype. Additionally, they found that 
Pfmdr1 had no impact on piperaquine susceptibility as it has been previously reported, but 
rather that the de-amplification observed in the field was a result of the removal of mefloquine 
from use and an expansion of a piperaquine resistance-conferring haplotype occurring in the 
same genetic background (single copy of Pfmdr1) (Dhingra et al. 2017). 
Given these findings, it is essential to understand the waves of drug resistance that have taken 
place worldwide by employing large-scale population studies. However, it is equally important 
to perform validation of polymorphisms identified in the field, specifically in the context of 
fitness in different genetic backgrounds. Different genome editing tools have been used for this 
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purpose. This will help to accumulate knowledge into the different pathways and mechanisms 
that P. falciparum uses in the process of acquiring resistance, and the implications for its 
biological fitness. 
1.5 Genome engineering 
For many pathogenic organisms, genome engineering has been crucial for 
understanding mechanisms of drug resistance, identifying essential targets for drug discovery, 
validation of potential molecular markers of resistance observed in field studies, among other 
applications. Together with the recent advancements in Next-Generation Sequencing 
technologies, the field of genome editing has also been growing rapidly, leading for example to 
genetic screens at the whole-genome level being carried out, and to the generation of large 
numbers of genetically modified pathogens. These extensive collections have led to subsequent 
validation of gene essentiality, leading to the identification of many exciting targets. Some 
recent studies exploring at the genome-scale level the function of genes in Plasmodium spp. 
and Toxoplasma gondii have both shed light into the biology of these parasites and also 
discovered their high degree of essentiality as a potential tool for vaccine development or drug 
discovery (Sidik et al. 2016; Bushell et al. 2017; Zhang et al. 2018). The case of P. falciparum has 
perhaps benefited most from these technologies, even though still many gene functions remain 
unknown given the challenges of genetic modification specific to this species.   
1.5.1 DNA double-strand breaks and different repair mechanisms 
The principle for all genome engineering approaches is to take advantage of the DNA 
repair pathways of cells that are brought into action as a consequence of double-strand breaks 
in the DNA.  Figure 1.14 shows the two main DNA repair pathways that are activated upon DNA 










Figure 1.14  Main DNA-repair mechanisms. Two main DNA repair mechanisms that can be undertaken by the 
cell after a nuclease-induced double strand break. Homology-directed repair (HDR) requires a sequence of 
homology to be provided (donor sequence) for introducing modifications into the genome. The NHEJ 
pathway has been referred to as the “error-prone” pathway as it can generate disruptions to the genomic 
sequence by introducing insertions or deletions as errors generated by the repair machinery. In Plasmodium 
sp., the NHEJ pathway is likely to be absent based on various bioinformatic analysis (Kirkman et al. 2014).  
Double strand breaks can be extremely damaging for cells and it is therefore essential 
that cells have mechanisms in place to repair them, in order to allow the cell to copy their 
genome during DNA replication in an accurate matter. The latter has been shown to include 
chromatin modifications that allow for enzymes involved in the repair process to access the 
DNA after the damage has occurred (Dinant et al. 2008; Gupta et al. 2016). In eukaryotes, 
Double Strand Breaks (DSB) can be repaired typically by two main DNA repair pathways. The 
first one is considered as being “error-free” homologous recombination (homology-directed 
repair or HDR). The other “error-prone” mechanism of repair is by end joining (Non-
homologous end joining or NHEJ) (Krogh and Symington 2004).  
The HDR DNA repair pathway relies on having a template to repair a DSB in an “error-
free” manner. This template can come from a sister chromatid, a segment of exogenous DNA 
such as a donor plasmid, or another homologous chromosome for the case of diploid organisms 
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(Davis and Maizels 2014). In 1981, Orr-Weaver and collaborators published a study in the 
budding yeast Saccharomyces cerevisiae, which showed that inducing double-strand breaks in 
DNA increases the rate of repair by initiating the homologous recombination DNA repair 
pathway. This study showed that plasmid DNA could be integrated into chromosomal DNA of 
yeast via this mechanism (Orr-Weaver et al. 1981). This finding would later on apply to many 
eukaryotic organisms, including P. falciparum, and HDR has formed the basis of all genetic 
modification approaches in this organism.     
By contrast, the canonical NHEJ pathway has been referred to as “error-prone” as it 
introduces mutations in the genetic code, thereby promoting genetic variability. NHEJ depends 
on the presence of the proteins Ku70/Ku80 and the DNA ligase IV, in a process which joins the 
two ends of a DSB together, often introducing or removing small numbers of bases as it does so 
(Pinder et al. 2015). It is important to note that one of the features that became apparent with 
the sequencing of the P. falciparum genome was that it lacked one of the two major DNA repair 
mechanisms. Several bioinformatic analyses performed during its assembly in 2002 by Gardner 
et al. (Gardner et al. 2002) showed that such proteins (Ku70, Ku80 and DNA ligase IV) that act 
to repair stochastic double-strand breaks of DNA, and are key for NHEJ in other organisms, 
were absent in P. falciparum (Straimer, Lee et al. 2012; Lee et al. 2014). There are, however, 
other apicomplexan parasites such as Toxoplasma gondii that do have NHEJ, indicating that 
Plasmodium parasites have lost the machinery at some stage during their evolution (Kirkman et 
al. 2014). 
The way cells sense a DBS and initiate the repair mechanisms is quite complex and Fig. 
1.15 shows the multiple steps undertaken by the machinery of the cell, which has been 
extensively studied in the budding yeast model. The first steps are of sensing the double strand 
break and the two fragments are tethered together with the MRX-Sae2 complex (Gnügge and 
Symington 2017). Once the two ends are close there are two proteins involved in resectioning 
the 5’ to 3’ strands. These form part of the STR-Dna2 complex which commits the cell to repair 
via homologous recombination and essentially protects the cell from the “error-prone” repair 
pathway. Tails of single-strand DNA (ssDNA) are generated on the 5’-3’ direction on both 
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strands after exonucleolytic processing (by Exo 1). Rad51 is a nucleoprotein that protect the 
ssDNA tails generated during the process of resectioning described, leading to a loop formation 
necessary for the process of strand invasion once it recognises the complementary strand; in 
haploid organisms this is primarily the sister chromatid generated during DNA replication. The 
process of D-loop formation and strand invasion can take place as a single cross-over, double-
crossover or by break-induced replication which is the result of the distal chromosome arm 
being lost and the rest of the strand being synthesized by the replication machinery (Lee et al. 







 Figure 1.15 DNA repair by homology-directed repair. A. The first step when there is a chromosomal double-
strand break, in a typical diploid organism in which the other chromosome is used as a template for repair.  B. 
Representation of the sensing step performed by the MRX-Sae2 complex, holding together the two 
fragments of DNA. C. Resectioning of the strands is carried out by Exo1 and the STR complex. The latter step 
exposes the 3’ end and allows for binding of RPA. D. RPA is replaced by the Rad51 protein which enables the 
formation of a nucleoprotein filament (in grey), allowing for the formation of the D-loop and strand invasion 
to take place (D-E).  Adapted from Lee et al. 2014). 
In P. falciparum there are not many studies showing the overall mechanisms used for 
repairing double-strand breaks; rather most studies have focused towards the understanding of 
the expansion of antigenic variation, acquisition of drug-resistant alleles and overall genetic 
diversity and evolution. P. falciparum chromosomes are arranged by having genes relevant for 
cell-cycle progression and DNA replication in the centre (core genome), whereas genes 
important for antigenic variation (clonally variant gene families), which in P. falciparum include 
var, rifin and stevor gene families, are located in the sub-telomeric regions. The latter has been 
extensively studied given that a large proportion of malaria-associated virulence factors, which 
allow the parasite to evade the host’s adaptive immune system and lead to chronic infections, 
are due to these gene families. The fact that this chromosomal organisation is maintained 
despite P. falciparum lacking major DNA repair pathways remains puzzling, specifically given the 
mechanisms by which these antigenic gene families get propagated through recombination 
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(Claessens et al. 2014), and the highly repetitive nature and extremely high AT content of the 
genome overall. DSBs in the sub-telomeric regions of P. falciparum may be repaired through 
the process of extending telomeres by a telomerase (referred to as “telomere healing”) 
(Calhoun et al. 2017), but other questions about genome integrity remain.  
Another important aspect that has been widely studied in the context of P. falciparum 
DNA repair is related to the evolution of drug resistance. As mentioned earlier, it has been 
shown that certain parasite genotypes are more prone to become resistant to antimalarials, 
whereas others take a longer time to become resistant (e.g. to chloroquine), potentially 
because of a fitness cost in particular environmental conditions and given their natural history. 
One hypothesis that has been explored, given the fact that at some point all the resistance 
phenotypes have been linked in some way to DNA polymorphisms, is that some genotypes are 
more capable of mutating their DNA (referred to as Accelerated Resistance to Multiple Drugs, 
ARMD) (Hegreness et al. 2008). It has been proposed that these parasites might both become 
resistant faster and alleviate any fitness cost linked with resistance-conferring polymorphisms. 
ARMD has been studied in detail in other biological systems such as yeast and mammalian 
systems, where they seem to be associated with defects in the DNA repair machinery, leading 
to a higher mutation rate and the likelihood of resistance-associated mutations to propagate 
more rapidly (Rathod et al. 1997).  
ARMD was studied in the context of P. falciparum in 2016. The transcriptional response 
after different DNA damaging agents were applied to cultured parasites leading to the 
observation that when one of these damaging agents such as methyl methanesulphonate 
(MMS) was applied, the transcriptional response would vary between strains that had been 
reported to have ARMD  (Dd2 and W2) in an earlier study by Rathod et al. 1997 (Rathod et al. 
1997). The ARMD strains were proposed to contain the genetic background to tolerate de novo 
mutations associated with drug resistance in higher frequencies than the two non-ARMD 
strains included in the study, 3D7 and D6, which can remain susceptible to compounds for 
longer periods of time.  What the authors found was that ARMD strains had a failure in 
response to DNA damaging agents such as MMS, as they were not upregulating genes involved 
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in repair pathways that were seen in the non-ARMD, as confirmed by transcriptomics analysis 
using microarray technologies. The authors collected genomic DNA at the same time points as 
they isolated RNA, and after performing Whole Genome Sequencing they found that 18 genes 
involved in DNA repair had non-synonymous mutations. This helped to confirm the idea that 
parasites becoming resistant to antimalarials can harbour polymorphisms in genes involved in 
DNA repair mechanisms, increasing the likelihood of de novo mutations to emerge and be 
maintained given specific genetic backgrounds, as in the case of the multidrug-resistant W2 and 
Dd2 (Gupta et al. 2016).  
Even though this and other studies provided some evidence of higher mutation rates in 
certain P. falciparum backgrounds, it does not exactly extrapolate to parasites directly isolated 
from the field and therefore it does not necessarily explain how resistant parasites emerge and 
spread globally. 
1.5.2 Genome editing technologies 
Understanding of the function of genes crucial for essential biological functions can be 
achieved by both forward and reverse genetics. In addition to this, introducing single 
polymorphisms identified from large-scale genomics studies as potentially having an important 
role in a specific biological function is an important tool. Editing technologies are also powerful 
as they allow the study of genes known to be essential - as it has been shown that in many 
cases polymorphisms might be enough to explain a phenotype, without inactivating the genes 
(Winzeler et al. 1999).  
Forward genetics is when a phenotype of interest is chosen, and the genetic 
underpinning of that phenotype is explored. The use of genetic crosses in P. falciparum, used as 
described above to uncover the genetic basis of chloroquine resistance, is one example of 
forward genetics. Another is the use of random mutagenesis, which has been carried out in P. 
falciparum by using transposable elements. Zhang et al. 2018 took the approach of using the 
transposable element piggyBac, that inserts at the nucleotide target site TTAA, which, taking 
into account the high AT content of P. falciparum, allows the theoretical possibility of multiple 
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insertions into every gene in the genome. Many mutants were generated. These approaches 
end up being highly useful, especially in an organism that is not very genetically tractable such 
as P. falciparum (Zhang et al. 2018).     
Reverse genetics takes the opposite approach by studying the function of specific genes 
in order to identify the possible phenotypes that might occur after these genes are disrupted. 
Generally, it requires prior knowledge of the genomic sequence of the organism of interest to 
design specific targeting vectors with sufficient homology to the target of interest. For this 
reason, the field of reverse genetics has been growing exponentially since access to sequencing 
technology has become more affordable and ubiquitous in many research environments 
around the world. As discussed earlier, in Plasmodium parasites there have been challenges 
that have made the technologies lag behind other organisms, even when compared to other 
Apicomplexan parasites such as Toxoplasma gondii (Sidik et al. 2016). Stable transfection 
technologies were developed in the 1990s, and the genome was sequenced in the early 2000s, 
but the functions of the majority of P. falciparum genes remain unknown. The discovery of gene 
functions by reverse genetics has been slow, with less than 10% of the total genes examined 
(Sanderson et al. 2017), and a generally slow trajectory of new genes investigated every year, 
with the only exceptions being two significant spikes in reported phenotypes in 2008 when a 
knockout screen was performed on exported proteins in the asexual cycle (A. G. Maier et al. 
2008), and a knockout screen of the P. falciparum kinome in 2011 (Solyakov et al. 2011). 
1.5.2.1 The Plasmodium Modification Project (PlasmoGEM) 
Plasmodium berghei has been a more genetically tractable organism than the human 
malaria parasites largely because it has a much higher transfection efficiency than P. 
falciparum, and as a consequence of this more gene functions have been studied in this species. 
A significant contribution has come as a result of the establishment of the Plasmodium 
Modification Project (PlasmoGEM), which has attempted to overcome the limitations of 
transfections for scalable approaches to reverse genetics.  
The PlasmoGEM resource is comprised of a library of targeting vectors available for use 
for reverse genetics screens in P. berghei. They were generated by using the low copy linearised 
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plasmid pJAZZ-OK from (Godiska et al. 2010) to insert P. berghei genomic DNA libraries. After 
end-sequencing to identify the fragments contained within any given clone, recombineering 
technology from bacteriophage N15 was used to convert these pJAZZ-OK clones into targeting 
vectors. The significant advantage of these vectors is the fact that they exist inside E.coli as a 
low-copy linear prophage with covalently closed hairpin ends, which allows large DNA 
fragments, including higher % A+T sequences and repetitive sequences, to be maintained inside 
the bacterial cell (Ooi et al. 2008).  
Generating vectors compatible with Plasmodium was performed initially in three steps. 
The first step was to generate the size-selected gDNA library in pJAZZ-OK linear vectors derived 
from bacteriophage N15, with an average insert size of 9kb, and covering almost the full 
genome of P. berghei. This library was then used for generation of knock-out vectors using 
homologous recombination in E. coli, expressing the temperature-sensitive plasmid 
pSC101gbaA-tet: encoding the bacteriophage lambda Red-ET. The first step was to replace a 
sequence of interest by the positive/negative selectable cassette zeo-pheS using short 
homology arms as overhangs in the primers used to amplify the target of interest, and flanked 
by gateway sites. This is used as an intermediate vector for the gateway reaction for generating 
the final vector containing the positive/negative selectable markers hDHFR/yFCU, shown to 
work for Plasmodium parasites (Pfander et al. 2011). Using this efficient recombineering 
technology, Gomes et al. 2015 published a study in which an 11bp-long unique barcode was 
introduced to the final vector to track individually mutated parasite clones over time using 
whole genome sequencing approaches (Gomes et al. 2015). Figure 1.16 shows the generation 
of the knockout targeting vectors.  The initial linear vector from genomic DNA library previously 
described, flanked by NotI restriction sites, was replaced with zeo-pheS cassette flanked by 
sites attR2 and attR1 for gateway recombineering. Finally, a unique barcode was used for the 
second step in a gateway reaction to introduce the positive and negative selectable marker for 









Figure 1.16 PlasmoGEM vector construction from gDNA library. Schematic representation of the different 
steps in the generation of the final knockout vector. The gDNA library contains a region of homology to gene 
of interest flanked by NotI sites. Intermediate vector contains the zeo-pheS cassette flanked by attR1/attR2 
for gateway recombineering. The final vector contains two homology arms to gene of interest for 
replacement with positive/negative selection cassettes, a unique barcode and constant primer binding sites 
arg444/arg445 flanking amplicon for NGS. Reproduced from (Gomes et al. 2015). 
1.5.2.2 Barcode sequencing 
The use of barcodes in these P. berghei modification vectors is linked to the 
development of a new reverse genetics approach referred to as Barcode Analysis by 
Sequencing (BarSeq). This technique was originally developed for the study of gene function in 
yeast. In this work, the authors selected mutants for two well-characterised drug targets to 
grow each strain in a pool under drug pressure. As each strain was individually barcoded, they 
were able to amplify the 20-mer barcode with primers containing the required sequence for 
Illumina NGS, and fitness of particular mutants was confirmed, outperforming their previous 
method using barcode microarray assay, for this specific drug target (Giaever and Nislow 2014; 
Smith et al. 2009).  
The PlasmoGEM team adapted BarSeq technology to establish a scalable pipeline for 
doing experimental genetics in P. berghei. PlasmoGEM vectors carry a unique 11bp barcode 
which does not exist anywhere else in the genome, next to annealing sites for oligonucleotides 
containing standard Illumina sequences for BarSeq. These unique barcodes allow multiple 
barcoded mutants to be generated as pools in a single transfection, with BarSeq being used to 
track the relative growth rate of each mutant within the pool.  As a proof of principle, protein 
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kinases were studied and those that had been previously shown to be essential were confirmed 
by this approach (Tewari et al. 2010; Gomes et al. 2015). 
The application of BarSeq in P. berghei was extended to half the genes in the genome in 
2017 by Bushell and collaborators. In this pioneering study, barcode sequencing was used to 
determine growth of 2578 individual mutants. This study found that in this parasite species, the 
proportion of essential genes was surprisingly high, as compared to other members across the 
evolutionary tree of Apicomplexan parasites, and the evolution of parasitism. Additionally, it 
shed light on a number of potential antimalarial drug targets, given their high degree of 
essentiality (Bushell et al. 2017). This study showed the power of these kinds of approaches for 
studying gene functions, and the value of using genetic modification in a large-scale matter. 
1.5.2.3 Nuclease-mediated genome editing 
 So far, large-scale reverse genetics screens in P. falciparum have not been performed. It 
is not clear why there exists such a big difference in transfection efficiency across Plasmodium 
species, with P. berghei having a much high efficiency than P. falciparum, leading to 
considerably fewer genes being targeted and phenotypes studied in the human parasite 
(Bushell et al. 2017). 
Technologies such as nuclease-mediated genome editing have accelerated genome 
modification in many organisms and have helped in the identification of functions of genes that 
were previously unknown. These site-specific nucleases work by inducing a DNA double-strand 
break at a target locus and thus engaging the DNA repair machinery, as discussed previously. 
Different site-specific nucleases have been identified such as Zinc Finger Nucleases 
(ZFNs), TALENs and more recently CRISPR-Cas. Both ZFN and CRISPR-Cas have been used in P. 
falciparum and are illustrated in Fig. 1.17, together with the conventional allelic exchange 
which was introduced in the 1990’s and has been used most extensively (Crabb et al. 1997; Wu 










Figure 1.17 Genome editing in P. falciparum. Schematic representation of some of the different strategies 
that have been used to modify the genome of P. falciparum. A. Conventional approach that was used since 
the 1990s, which would likely be triggered by a stochastic DNA break near the site of interest (marked with 
an asterisk), thus forcing the repair machinery to use a homology-directed repair. Plasmid integration was 
stimulated by  providing a sequence of homology on the plasmid. Given the stochasticity of the process, it 
could take up to six months of continuous culture under drug selection to recover mutant parasites. B-C. Two 
different approaches of genome editing by using directed site-specific nucleases to target a locus of interest 
for subsequent double-strand break and repair. As in 1.17A, a construct with homology to the target is 
provided. Zinc Finger Nuclease-based genome editing relies on the heterodimerization of two zinc finger 
proteins (ZFN-L and ZFN-R) fused to the FokI restriction enzyme (shown in red), whereas the CRISPR-Cas 
system consists of the nuclease Cas9 bound to a single gRNA that has homology to a region of the genome 
thus forming an RNA-DNA structure for double strand break. Reproduced from (Lee and Fidock 2014). 
ZFNs consist of binding domains from transcription factors and a FokI restriction enzyme 
with nuclease activity. The binding domains provide a unique specificity to a DNA sequence, 
generating a heterodimer, and then inducing a double-strand break through the FokI activity 
(Urnov et al. 2010). By providing a donor sequence with enough homology, homologous 
recombination takes place at the site of the ZFN induced DSB, leading to gene editing or 
disruption. While ZFNs can be very efficient, the design of the constructs is challenging, and the 
costs are high as a unique ZFN needs to be designed for every gene. This limits the potential of 
ZFNs to become scalable to a genome-wide approach (Porteus and Carroll 2005).  
ZFNs have been used in P. falciparum to validate candidate markers associated with 
drug resistance. To date, multiple loci have been targeted using this technology, including 
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relevant genes involved in mechanisms of drug resistance, including Pfcrt (Straimer, Lee, et al. 
2012), phosphatidylinositol-4-OH kinase (McNamara et al. 2013), and more recently a molecular 
marker associated with increased tolerance to artemisinin, Pfkelch13 (Straimer et al. 2015). 
Despite being a useful technology for the implementation of nuclease-driven homologous 
recombination, the rate of successful recombination relies on the cleavage activity of ZFNs, the 
distance to the site where the polymorphism is being incorporated, and the length of the 
homology of the donor sequence. From the previous studies by using different nuclease-
induced strategies, it has been established that longer arms of homology correlate with the 
efficiency of recombination, and given the difficulty of successful cloning of long stretches of an 
AT-rich genome such as Plasmodium, into E. coli, this becomes challenging.  
Like ZFNs, Tal effector-like nucleases (TALENs) have also been shown to be a powerful 
tool for genome editing in many organisms. TALEN design is more straightforward than ZFNs 
and could potentially increase throughput, however perhaps because it contains a highly 
repetitive binding domain of 34-amino acids, and the large size of the nuclease, there is no 
published evidence of this method being used for P. falciparum (Lee and Fidock 2014).  
    
1.5.2.4 CRISPR/Cas9-based genome editing  
Recently CRISPR/Cas9 has emerged as an easily programmable and affordable genetic 
modification tool for many organisms, and is now by far the most widespread genome editing 
tool in general use (Cong and Zhang 2015). In the last few years, it has also been shown to work 
in P. falciparum, which is very promising as reverse genetics now seems feasible and scalable 
for tackling different biological questions (Ghorbal et al. 2014; Wagner et al. 2014).  
This platform is based on a bacterial CRISPR (Clustered regularly-interspaced short 
palindromic repeats) and an associated protein Cas9 (Figure 1.18). As part of the immune 
mechanisms used by many bacterial species to protect themselves from foreign DNA, they 
incorporate foreign nucleic acids between CRISPR arrays within their genome, containing a 
unique sequence for recognition by the gRNA-Cas9 complex. The subsequently transcribed 
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CRISPR RNAs will contain “protospacers” that are complementary to the foreign sequences. 
This transcript will then couple with a second RNA (transactivating RNA), and after processing 
by an RNase, will form a complex with the nuclease (Cas9). The Cas9 nuclease will target and 
cleave the foreign DNA, upstream of a Protospacer Adjacent Motif (PAM) (of variable sequence 
depending on the CRISPR system). The way this natural mechanism has been adapted to 
genome editing in other organisms is by using a fusion of the CRISPR transcript with the 
protospacer or sequence of homology to the genome, coupled with part of the transactivating 
RNA. The resulting complex comprises a 20-nucleotide single guide RNA (gRNA), which directs 
the nuclease to the target gene (Sander and Joung 2014).  
Figure 1.18 Cas9/gRNA-binding.  
Figure illustrating the binding of the gRNA/Cas9 
complex, upstream of the recognition motif (PAM). 
The first 20 nt of the gRNA is complementary to the 
target DNA sequence (in red), directing the Cas9 
nuclease to the target site and after unwinding of 
the target and the formation of a gRNA-DNA hybrid, 
leading finally to a double strand break. 
Reproduced from (Sander and Joung 2014). 
 
This technology has now been adapted to P. falciparum with various approaches, the 
general method being to provide the parasite with plasmids bearing the Cas9 and gRNA under 
the control of specific promoters. Two different RNA polymerase III-based promoters have been 
used to transcribe gRNAs, which rely on a defined transcription start site to produce an 
accurate gRNA. In the study by Ghorbal et. al 2014, a U6 upstream region was used, whereas T7 
RNA polymerase, derived from bacteriophage T7, was adapted in a study by Wagner et al. in 
the same year (Wagner et al. 2014).  
Ghorbal et al. used an approach in which two plasmids were co-transfected. The first 
plasmid carried the Cas9 along with the selectable marker yDHODH, and the second plasmid 
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carried the gRNA and the donor sequence of homology to the target site for repair by 
homologous recombination. The U6 small nuclear RNA (snRNA) requires the RNA polymerase III 
in order to get transcribed, initiating with a guanosine nucleotide as was established in the 
original CRISPR-Cas9 paper by Ran et al. (Ran et al. 2013). However, Ghorbal et al. were able to 
achieve expression of the gRNA without the initial G, which for the genome of P. falciparum 
would be advantageous given the low G-C content (less than ~20% in the genome), and the fact 
that the Streptococcus pyogenes Cas9 has an NGG PAM requirement. Fig. 1.19 shows the 
plasmid design used by Ghorbal et al. which consisted of the pUF1 plasmid driving the 
expression of Cas9, flanked by two nuclear localization signals (NLS), by Plasmodium-specific 
promoters and with the drug-selectable marker ydhodh. The second plasmid contains the 
sgRNA expression cassette and the donor sequence for generating a knockout, with homology 
arms flanking the positive drug-selectable cassette hdhfr. This vector also contains the negative 
selectable marker yFCU. In the same study, the strategy was used to generate single mutations 
in the genome by providing a region of homology that contains the mutations of interest, and in 
this particular case the system was used to validate the importance of the Pfkelch13 mutation 


















Figure 1.19 Two plasmid CRISPR/Cas9 approach for P. falciparum. A. Schematic representation of the Cas9-
expressing plasmid, flanked by nuclear-localisation signals and a 5’ hsp promoter and 3’ Pbdhfr terminator 
sequence. A positive selectable marker yDHODH is also present in this plasmid. B. Plasmid containing the 
sgRNA expression cassette using the U6 promoter for RNA Polymerase III. Homology regions shown are 
flanking a positive selection cassette hDHFR for generating gene knockouts and also a negative selectable 
marker yFCU is present. Reproduced from (Ghorbal et al. 2014). 
Overall, recent advances in genome sequencing technologies and the implementation of 
genome editing technologies in disease-causing pathogens such as P. falciparum have added 
new layers to the study of infectious diseases. There is now the need to use these tools at scale 
and understand, almost at real time, what the changes in the genome of this parasite mean and 
what the implications are for surveillance and for containment of alleles that might be 
modulating drug resistance to current or future antimalarial compounds, and what their 






1.6 Project Aims 
My project will entail developing a method to perform parallel phenotyping in P. 
falciparum using BarSeq and Next Generation Sequencing in order to explore epidemiologically 
relevant resistance associated alleles and their effects on parasite fitness. For this, the following 
specific aims were established, which are organised into three independent chapters:  
1. The first chapter will aim at establishing a barcode sequencing approach for P. 
falciparum in order to track parasite growth in vitro, as previously developed for P. berghei.  In 
addition to this, transfection efficiency will be quantified with BarSeq by using pools of 
barcoded vectors, with the limitations for P. falciparum being discussed in the context of a 
growing field of genome-scale CRISPR/Cas9 screens.    
i. First, a complex pool of 96 uniquely barcoded vectors will be generated aimed at 
performing experimental genetics at scale in P. falciparum 
ii. Pools of vectors will be used as readout of transfection efficiency in P. falciparum 
by comparing the barcode complexity in the input pool and output post-
transfection 
iii. A constant genomic region (PfRh3) will be evaluated as a safe harbor for barcode 
insertion by using CRISPR/Cas9-based genome editing 
 2. The second results chapter aims at adapting BarSeq to P. falciparum to study both 
the inherent fitness and drug response of different antimalarial compounds of a panel of strains 
harbouring sufficient genetic diversity and drug-resistance profiles.   
i. Libraries of uniquely barcoded parasites will be generated using the pools 
described in chapter 3 
ii. Different genetic backgrounds will be used in order to cover sufficient genetic 
and phenotypic diversity for developing a proof-of-principle of BarSeq in P. 
falciparum 
iii. Both inherent fitness and drug response of the various strains will be measured 
and compared with standard inhibitory concentration assays  
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3. The last results chapter will be centered around the contribution of specific Pfkelch13 
alleles generated with CRISPR/Cas9 have to parasite fitness and artemisinin resistance. In this 
chapter, similar approaches as in other results chapters will be used for measuring competitive 
parasite growth in vitro, and the epidemiological relevance of these results will be discussed.  
i. First, CRISPR/Cas9 editing vectors will be built in order to efficiently edit Pfkelch13 in 
a representative strain belonging to the KEL1 recently described in Amato et al. 
2018. Additional lab-adapted strain 3D7 will be used as a non-KEL1 strain. 
ii. Edited lines will be used to perform competition assays to measure the impact of 
variant C580Y in Pfkelch13 has on parasite fitness measured as in vitro growth.  
iii. CRISPR/Cas9 approaches will be used to mimic a double strand break at position 580 
in Pfkelch13, and by providing a pool for homologous-directed repair containing a 
donor sequence with homology to the locus and at position 580 any codon to 
change to, the experimental outcome of which codons were tolerated will be 











Chapter 2: General Methods 
2.1 In vitro cultures of Plasmodium falciparum 
2.1.1 Parasite culture maintenance and synchronization 
For routine culture of parasites adapted to culture, various parasite strains were used 
(Table 2.1), and the protocol established by Trager and Jensen in 1976 was followed  (Trager 
and Jensen 1976). The different parasite strains were routinely cultured in O+ RBCs provided by 
anonymous healthy donors from the National Health Services (NHS), and kept in incubators at 
37°C and routinely gassed with a mix with concentrations of 1% O2, 3% CO2 and 96% N2. The 
blood was previously depleted of leucocytes, washed twice in Roswell Park Memorial Institute 
Media (RPMI), and resuspended at 50% haematocrit in a medium provided by Sigma-Aldrich 
containing RPMI-1640 supplied with HEPES, Albumax II, gentamicin, glutamax and 
supplementation with 20mM HEPES. Unless otherwise stated, this was the method for media 
preparation. Certain strains required a modification to the culturing protocol and the medium 
was supplemented with human serum, or certain drugs were added for various purposes, 
mainly for selecting transfections or performing drug assays. The routine measurements 
relevant for the maintenance of the cultures were parasitaemia and haematocrit which are 
described below. 
 
Parasitaemia refers to the number of parasite-infected Red Blood Cells (iRBC) with 
respect to the total parasite population. The total parasite count can be from a blood smear 
taken from a malaria-infected patient (Warhurst and Williams 1996), or it can be from a routine 
laboratory in vitro culture. For the experiments throughout this work, counts for culture 
maintenance were performed in at least five different fields and the parasitaemia obtained by 
dividing the number of iRBCs over the total count of uninfected Red Blood Cells (uRBC).  
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Haemeatocrit refers to the percentage of red blood cells that are in the total volume of 
culture. haematocrits can vary but normally they are in the range of 1-5% for standard in vitro 
cultures. 
2.1.1.1 Culture maintenance  
In order to maintain viable and healthy parasite cultures, parasitaemia was maintained 
at less than 5% and hematocrit throughout all the experiments performed was kept between 3-
5%.  The latter is a standard parasite culture media that has not been overly modified since first 
described by Trager and Jensen (Trager and Jensen 1976). Depending on the parasite strain 
(which will be specified accordingly), cultures were diluted when the parasitaemia would reach 
these percentages. For field isolates the range of parasitaemia was between 1 and 5% in order 
to avoid parasites under high stress which has been shown to lead to an abnormal production 
of gametocytes (Carter et al. 2013). Other parasite strains that have been long-adapted to 
laboratory conditions were kept at parasitaemia below or above the mentioned range used for 
field isolates.  
Parasitaemia was measured by resuspending parasite cultures at ~50% haematocrit for 
homogenization and to avoid aggregation of cells. A drop of the suspension of approximately 
2uL was used to perform the blood smear that was later stained with 10% Giemsa solution 
(Sigma-Aldrich) for 10 minutes and observation at 100X magnification with a light microscope 
was performed. For a more precise measurement of parasitaemia, flow cytometry was used as 
in section 2.4.2.1. 
2.1.1.2 Parasite synchronization 
Parasite synchronization is needed in order to overcome the challenges of the 
asynchrony reached by parasites in culture, in which only a few life cycles are required before 
losing synchrony, as reported by Trager and Jensen (Radfar et al. 2009; Trager and Jensen 
1976). Several methods have been described that allow parasite synchronization.  
Sorbitol at 5% in water and sterile filtered was used mainly for enriching for ring stages 
and reducing the time window of parasites in the culture. According to a modified version of 
the standard protocol developed by Lambros and Vanderberg in 1979 (Lambros and 
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Vanderberg 1979). Parasites are centrifuged at 1100g for 5 minutes on either 15 or 50mL Falcon 
tubes in order to remove the media. The remaining parasite pellets were resuspended in 7 
volumes of 5% sorbitol and left at 37°C inside the incubator for 5 minutes. After incubating the 
falcon tubes were centrifuged at a lower speed (800g for 5 minutes), sorbitol was removed with 
a vacuum aspirator and a washing step was performed with complete media. The washed pellet 
was then resuspended at the appropriate haemeatocrit.  
A different synchronization protocol was performed by using a Percoll gradient, 
attempting to isolate both late stages, segmenting schizonts or rings whilst avoiding cellular 
stress from sorbitol treatment. This was particularly relevant for highly sensitive strains such as 
recently adapted field isolates to enrich for later stages, usually late trophozoites or schizonts 
(Saliba and Jacobs-Lorena 2013), and for narrowing the stage window required for particular 
experiments. Percoll purification used throughout this work was a 63% solution prepared in 10X 
PBS and homogenized with RPMI-1640 as previously described in (Blackman et al. 1990). 
Parasite pellet was corresponding to a 50mL culture flask at 3% haematocrit was resuspended 
in a maximum volume of 5mL of complete media and loaded above the percoll solution, 
avoiding mixing of the two phases created with the loading. The percoll gradient at this stage 
was centrifuged 1300g for 11 minutes with no brake in order to get the gradient and isolate the 
required stages. Figure 2.1 shows the graphical representation of the gradient described, and 






















Figure 2.1 Density gradient using a 63% v/v of Percoll solution.  Used for separation of late stages of P. 
falciparum based on density. Uninfected red blood cells (uRBCs) will settle at the bottom of the 15mL falcon 
tube, layered on top the percoll solution and the media from the culture. In between these two phases, a thin 
layer (brown) will contain the late stages. 
            
Additional synchronization steps were performed using a magnetic cell separation 
(MACS). The latter was useful for enrichment of late stages (mid-trophozoites and schizonts). 
Cultures were centrifuged for 5 minutes at 1100g and resuspended in complete media before 
loading them through the magnetic columns from Miltenyi Biotec. After cultures have passed 
through the column, the late stages were retained with the magnet and the uninfected red 
blood cells went through together with the rings. Once this was completed, the column was 
removed from the magnet and the parasites captured on the matrix of the column based on 
their hemozoin content can be diluted with standard RPMI 1640.    
2.1.2 Thawing and freezing parasites 
 Table 2.1 shows all the parasite strains used throughout this dissertation. Frozen 
parasite stocks were kept in vials either in a -80 freezer or in liquid nitrogen. The vials were 
thawed at room temperature and transferred to a 50mL falcon tube. 1/10th of 12% NaCl 
(prepared from stock from Sigma-Aldrich) per volume of pellet was added to the thawed cells 
while shaking the falcon tube gently. After adding this solution, the parasite pellet was left at 
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room temperature for two minutes. Ten times the pellet volume of 1.6% NaCl was added slowly 
to the cells while agitating them slowly as with the previous solution. Once this solution has 
been added, the falcon tubes were centrifuged at 800g for 5 minutes and the supernatant was 
removed using a vacuum or a strip pipette. After removing the media, the parasites were 
resuspended dropwise in the third solution which was 1.2% NaCl and 2% glucose, also by 
agitating slowly the tubes. Another step of centrifugation with the previous settings was 
conducted and a posterior washing step using standard culture media were performed before 
finally resuspending the pellet in 10mL of culture media and adding 50% RBCs to reach a final 
haematocrit of 3%. All solutions used for the thawing process were pre-warmed inside one of 
the 37°C incubator and at the point of preparation they were sterile filtered using a 0.22 uM 
membrane filters.  
 Ideally, parasites were frozen down once a 2% parasitaemia was reached and the 
majority of the parasite population was at the ring stage. For freezing down cultured parasites, 
a glycerolyte solution was used using 28% glycerol, 3% sorbitol, 0.65% NaCl and was sterile 
filtered through a 0.22uM membrane filter. Parasite cultures were centrifuged at 1100g for 5 
minutes and pellet was resuspended in 2 times their volume of the glycerolyte solution 
described. This protocol was modified from an original described by Radfar et al. 2009 (Radfar 
et al. 2009). 
 
Table 2.1 Parasite strains used, origin and year when they were adapted into culture. Table includes the 
references to the strain in the fourth column (Walliker et al. 1987; Udeinya et al. 1983; Guinet et al. 1996; 








2.1.3 Cloning of parasites by limiting dilution 
In order to generate isogenic parasite lines either from culture strains or from 
transfections for various experimental procedures, parasites were cloned using a limiting 
dilution protocol. The method was modified from an already described protocol (Rosario 1981) 
that uses a 96-well plate in which parasites are diluted at 0.5-0.8 parasites per well at 1.8% 
haematocrit. The expectation was to obtain approximately 50% of clonal parasites distributed 
across the plate. For more recently adapted field strains the protocol used was slightly modified 
in order to allow parasites to grow better. Calculations for the later were performed for 1 
parasite per well rather than less than that. The times taken for parasites to become visible via 
microscopy ranged from 17 to 21 days in well adapted strains and more than 25 days for the 
recently adapted field isolates. Detection of positive wells was first performed using DNA stain 
Sybr Green as in (Lyko et al. 2012) in order to have an estimate of the amount of DNA present 
in each well and discard either empty well defined by an absorbance and emission equal to the 
negative control wells, or much higher than the average wells indicating possibly more than one 
parasite per well. Positive wells were later validated using light microscopy. 
 
2.2 Transfection of Plasmodium falciparum 
Genetic manipulation of P. falciparum was performed via standard transfections 
previously described (Deitsch, Driskill, and Wellems 2001; Wu et al. 1995). For all the 
electroporation methods used in this project, cells were monitored for different time ranges 
until parasites were visible via light microscopy. Times for this observation varied from 14 days 
in a very efficient transfection to 40 days in the most inefficient ones. Monitoring was 
performed by smearing and staining with 10% Giemsa for 100x magnification over weeks at 
least twice a week as described earlier. Drug selections were performed from day 1 post 
transfection and for a course of six days for CRISPR/Cas9 and for the whole time for episomal 
transfections, in order to select for parasites stably replicating episomes. During the project 
different drug selectable markers were used. Following these regimes, the most common 
plasmid that was used encoded the human dihydrofolate reductase gene (hdhfr), and parasites 
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were selected 24 hours after transfection with WR99210 compound, and for a total of six days 
for integration or until parasites were recovered for episomal transfections. The other drug 
selectable marker that was used throughout this project was the yeast dihydroorotate 
dehydrogenase (yDHODH), for DSM1 selection. 
The different methods for transfection used over the course of this project are 
described below. Parasites ready for transfection were resuspended in cytomix for washing 
(120mM KCl, 0.15 mM CaCl2, 2mM EGTA, 5mM MgCl2, 10mM K2HPO4, 25mM HEPES, pH 7.6) 
and either cytomix or Primary Cell Solution (P3) solution from Amaxa for resuspension of DNA: 
2.2.1 Direct electroporation of infected red blood cells (iRBCs)  
2.2.1.1 Lonza 4D Nucleofactor  
Cultured parasites with a hematocrit of 3% were split and centrifuged at 1100g in order 
to obtain a final pellet volume of 100uL, at a parasitemia close to 5%, with a high prevalence of 
early rings. The pellet was washed in cold complete cytomix with recipe described earlier. After 
washing the parasites were resuspended in 100uL of solution P3 containing 50-100ug of 
plasmid DNA and were loaded to an Amaxa cuvette. The program utilised for transfection of 
infected erythrocytes was the equivalent for the cell solution used to dissolve the plasmid DNA. 
The electroporated cells were rapidly resuspended in warm complete parasite culture medium 
and left to recover from one to two hours before posterior centrifugation. The pellets were 
then resuspended at the desired hematocrit in a 5mL culture well of a 6-well plate. 
2.2.1.2 BioRad Gene Pulser Xcell Electroporator 
Conditions of cultures and parasitaemia to use for transfection remain mostly 
unchanged for this electroporation method, except more RBCs are loaded. BioRad cuvettes can 
harbour a larger volume and are considerably more affordable than the Lonza cuvettes, yielding 
similar transfection efficiencies, therefore they were the electroporator of choice for most 
experiments during the course of this project. For the 0.2-cm cuvettes, 150uL of packed iRBCs 
at >5% parasitaemia were homogenised with 300uL of of plasmid DNA (between 50 and 100ug) 
previously resuspended in complete cytomix. The cuvettes were then electroporated using the 
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following settings:  950 microfarad (μF) at a voltage of 0.31 kilovolts (Kv) as in Deitsch et al.  
(Deitsch et al. 2001).   
2.2.1.3 Electroporation of uRBCs preloaded with DNA 
Preloading of RBCs was performed following the protocol developed by Deitsch et al. 
(Deitsch et al. 2001) in 2001. For this approach, 300uL of RBCs were homogenized with a lower 
concentration of plasmid DNA resuspended in cytomix. Concentrations varied from 10-50ug 
throughout the course of this project. Once the RBCs were electroporated, they were mixed 
with parasites in culture, allowing for reinvasion to occur and providing other preloaded cells to 
increase the efficiency of parasites taking up the plasmid. Unless otherwise specified, settings 
remained the same as previously described. For the case of the field isolates used in this study, 
this method was particularly helpful and some specific optimizations to the protocol were 
performed to increase the efficiency.  
 
2.3 Molecular cloning  
2.3.1 Saponin lysis and genomic DNA extraction from parasite cultures 
Preparation of genomic DNA (gDNA) was performed from culture volumes of not less 
than 5mL at 3% haematocrit and more than 2% parasitaemia to assure sufficient yield for 
molecular experiments. Parasite cultures was centrifuged and pellet resuspended in 0.15% 
Saponin in PBS and left at room temperature for five minutes in order for cellular lysis to take 
place. Saponin-lysed pellets were then washed twice with PBS to remove all remains of blood 
and media. Pellets were then directly used for gDNA extraction. Briefly, extraction of genomic 
DNA was performed using the DNeasy Blood Tissue Kit from Qiagen, using 20uL of Proteinase K. 
For lysis, 200uL of lysis buffer (AL) were added and the samples were incubated at 56°C for 10-
15 minutes and precipitated using 200uL of 100% Ethanol. The samples were then eluted in 
Elution Buffer (Qiagen) at a final volume of 60uL and concentration was measured using a 
either a Qubit or a Nanodrop, depending on experiment. Extracted DNA was kept at -20C and 
used for different experiments, ranging from PCR for to whole genome amplification.   
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2.3.2 Molecular cloning  
2.3.2.1 Oligonucleoetide design   
 All the primers that were used throughout this study were generated using software 
LaserGene from DNA Star or with the free online platform Benchling (https://benchling.com/).  
For the first approach, secondary structures and melting temperatures were validated using 
Olicocalc (http://biotools.nubic.northwestern.edu/OligoCalc.html). Once the sequence was 
obtained and validated it was ordered through the Agresso purchasing system from the 
Wellcome Sanger Institute, using mainly Sigma-Aldrich or IDB providers. A full list of primers is 
provided in the appendix.  
 DNA synthesis was performed for certain sequences in order to facilitate the cloning 
process. The design was performed using the software specified and the synthetic DNA was 
ordered using gBlocks from  IDT (https://sg.idtdna.com/site/order/gblockentry), or alternatively 
if the construct was challenging to synthetize, GeneArt from Thermo Fisher was used 
(https://www.thermofisher.com/th/en/home/life-science/cloning/gene-synthesis/geneart-
gene-synthesis.html).           
2.3.2.2 Polymerase Chain Reaction (PCR) 
Polymerase Chain Reaction or PCR is normally used to increase the number of copies of 
a particular DNA sequence, which can be later confirmed by methods such as capillary 
sequencing or Next Generation Sequencing. The way the reaction works is by cycling through 
different temperatures using a thermostable polymerase. The latter can either be a 
proofreading enzyme to avoid random incorporation of nucleotides, or non-proofreading used 
primarily to confirm by agarose gel rather than sequencing (KAPA from KAPA biosystems or 
GoTaq from Promega, respectively). Reactions for the thermocycler depended on the 
manufacturer instructions of the thermostable polymerases used, but generally it started with 
DNA denaturation at 95°C, followed by a drop-in temperature dependent on the melting 
temperature of the primer and thus an accurate annealing temperature. For all the 
oligonucleotides designed throughout this project, the temperature was adjusted in ordered to 
improve annealing of primer and DNA template, usually ranging between 50°C and 60°C. After 
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denaturation at 95°C, given the high AT content of the genome of P. falciparum, the extension 
temperature required was reduced from 72°C to 62°C in most reactions performed, unless 
specified otherwise. The extension time would also depend on the length of the fragment being 
amplified. The reaction was followed by multiple cycles of denaturation-annealing-elongation, 
varying from 5 to 35 cycles, depending on experimental setup and whether it was a nested PCR 
reaction, adjusted to increase specificity in a secondary reaction.   
BarSeq-specific reactions for library amplification for NGS required a 2-step nested PCR 
reaction. For library amplification from a plasmid pool, DpnI treatment was used to remove any 
remaining vector template. For this, a final reaction volume of 25uL was used with a total of 
80ng of plasmid DNA (PCR 1). Alternative, a PCR product from endogenous genes was used as 
template to amplify integrated barcodes. For measuring integrated barcodes, specific 
requirements and further reactions are listed in section 2.5. 
2.3.2.3 PCR for bacterial colonies  
PCR was also performed as a screening strategy for bacterial colonies of the plasmids 
transformed throughout this project. For these reactions, GoTaq enzyme was used according to 
manufacturer’s settings and was performed directly from the agar plate. The reaction volume 
was of 10uL for this reaction, and the conditions for PCR slightly varied for screening colonies.  
2.3.2.4 Confirmation of PCR products and purification 
In order to confirm the correct size of the PCR reactions performed during these studies, 
or to confirm plasmids after performing restriction digestions, agarose gels were made at a 
concentration of 0.8% agarose in tris-acetate-ethylenademiaminetetraacetic acid (EDTA), TAE. 
After agarose was completely dissolved in TAE, either ethidium bromide (Sigma) or Sybr Safe at 
a final concentration of 0.5ug/ml were used to visualise DNA bands. Agarose solution was let at 
room temperature in the tray until solid and the DNA samples were loaded with 1X of loading 
buffer.  5uL of DNA ladder (Hyperladder from Bioline) were added to one well of the gel in 
order to define the fragment size accurately. PCR bands were observed using UV light and were 
excised, and a QIAgen kit was used to purify the PCR products from the gel band, following 
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manufacturer’s instructions. The latter was only performed for certain reactions, specifically for 
Gibson assemblies. Otherwise, a PCR purification was performed and is described later.  
 For purifying PCR products, a Macherey and Nagel PCR purification kit was used 
following the instructions of the manufacturer. 
2.3.2.5 Restriction digestions, annealing of oligonucleotides and DNA ligation  
 All the conditions required for the restriction endonucleases used in this study were 
established using the New England Biolabs (NEB) website for optimization of digestion 
(https://www.neb.com/tools-and-resources/usage-guidelines/optimizing-restriction-
endonuclease-reactions). Most reactions were performed at an incubation temperature of 
37°C, unless specified otherwise for using particular enzymes. The volume for a restriction 
digestion was of 10uL and consisted of 1uL of each enzyme, 2uL of CutSmart buffer also from 
Promega (unless specified otherwise), plasmid (0.5-1ug total), and nuclease free water. 
 Annealing of oligonucleotides was performed by adding equimolar amounts of 
complementary primers (at 100uM concentration), followed by Buffer number 2 from New 
England Biolabs, for a total volume of 10uL. The thermocycling program for annealing (5-minute 
incubation at 95°C and gradual reduction until room temperature was achieved), was 
performed on the PCR tubes, and the annealed oligonucleotides were diluted 1:100 in 5mM Tris 
(pH 8.0) for following T4 ligation.  
For vector cloning, after plasmid digestion was performed, DNA fragments were ligated 
using the standard T4 DNA ligase from Promega in a total volume of 10uL. The proportion of 
plasmid to insert used was following the manufacturer instructions, and the reaction was 
incubated at 16°C for 1-4 hours or at room temperature overnight, a modification of the 
protocol of the manufacturer (New England Biolabs).      
2.3.2.6 Gibson Assemblies         
Gibson cloning was used to amplify homology regions from P. falciparum from different 
genes for the various experiments performed. PCR products of the homology regions would 
have a sequence of overlap to one of the vectors used defined by the oligonucleotides used. A 
2x master mix of Gibson Assembly Master Mix from New England Biolabs (NEB) was used, and a 
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ratio of insert (region of homology or two homology arms) to cut the vector as described earlier 
of 2:1 was used for a two or three-fragment assembly at 50°C for 25 minutes. Colonies were 
screened for integration of the homology region and grown in LB medium with 1:1000 dilution 
of 100mg/mL of ampicillin, as all vector backbones contain this a cassette for ampicillin 
resistance.  
2.3.2.7 Bacterial transformation 
The ligated plasmids were transformed into chemically ultracompetent cells XL-10 
(Agilent Technologies). For all the transformations, cells in a total volume of 30-50uL were 
defrosted on ice for 30 minutes before adding the DNA. The total amount of DNA transformed 
ranged between 0.1-50ng following manufacturer’s instructions, and was gently added directly 
to the tube containing the cells. After adding them they were incubated on ice for another 30 
minutes. The cell suspension was heat shocked for 30 seconds and rapidly moved to ice for two 
minutes, following addition of 900uL SOC recovery medium. The suspension was incubated in a 
shaking heat block pre-warmed at 37°C for one hour and then plated into Luria-Bertani (LB) 
agar plates, supplemented with 100ug/uL of ampicillin (Sigma-Aldrich), and incubated overnight 
at 37°C. Colonies were grown in mini preps from Macherey and Nagel and stocks were made at 
a final concentration of 25% glycerol for storing at -80°C.  
 
2.4 Parasite phenotypic assay 
2.4.1 Drug sensitivity assays 
 Standard drug sensitivity assays were performed following the protocol by Smilkstein et 
al. 2004 (Smilkstein et al. 2004) which was modified slightly to accommodate the availability of 
equipment in the laboratory. The principle of the protocol is to take advantage of the absence 
of DNA in enucleated Red Blood Cells in order to stain with SYBR Green I only DNA coming from 
parasitised RBCs, therefore measuring growth by the amount of DNA present in a given well, in 
presence of a particular compound.  
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Serial dilutions of the compound of interest were performed in duplicate as shown in Fig 
2.2, obtaining a final volume of media in all the wells of 100uL. The last two columns were left 
as a control (no drug was added to those wells), and were used for the calculations of parasite 
growth and inhibitory concentration. A total of 100uL of parasitized culture, ideally at the ring 
stages were added to all the wells. The final parasitaemia would be between 0.5 and 1%, 
depending on growth rates of particular strains, and a final haematocrit of 1.8%. A total of 
200uL of culture and drug suspension were incubated at the optimal gas concentrations 
described earlier for a total of 72 hours.  
After the 72-hour incubation, a final concentration of 3X of SYBR Green I (stock at 
10,000x) was diluted in lysis buffer (20mM Tris pH 7.5, 5mM EDTA, 0.008% saponin, 0.08% 
Triton X-100). From the lysis solution, 15uL of the solution were loaded onto a 96 well plate. 
The incubated parasites were resuspended with a multichannel pipette and 30uL were taken to 
load on top of the SYBR Green solution. The plate was covered in foil and left at 37°C for 30 
minutes and then loaded on a FLUOstar Omega Microplate reader. All the results obtained from 
the plate reader were interpreted as parasite growth and the half inhibitory concentration 
(IC50). Compounds used throughout the project are listed in table 2.2, and the analysis and 
statistical tests was performed using an R script using the package drc (for generating dose-
response curves) (Ritz et al. 2015). The latter takes into account different parameters for 
analysis: the lower limit or parasite activity in the absence of drug, the upper limit or 
concentration value at which parasites reach 100% inhibition, the slope of the curve that 
indicates the kinetics of the reaction and the shift when the different strains reach 50% 








Table 2.2 List of compounds used for inhibitory concentration assays and the range of concentrations used 
for setting up the serial dilution plates for BarSeq experiments. The concentration for chloroquine was overall 
higher for all given the high IC50 of some of the strains used such as V1/S and CAM. 
 
 
       
 













Figure 2.2 Plate layout for inhibitory concentration assays. Each sample is loaded in duplicate (e.g. rows A 
and B for sample 1). The selected drug is loaded at the maximum concentration on column 1 and a serial 
dilution of 1:2 per column is performed until column 10. Columns 11-12 are the negative controls which are 
used for the analysis of the dose response curve.    
2.4.2 Ring-stage Survival Assay (RSA) 
2.4.2.1 RSA measured by thin smear and light microscopy: 
 A modified version of the protocol by (Witkowski et al. 2013) was used for pulsing early 
ring stages with dihydroartemisinin (DHA). Briefly, late-stage parasites (schizonts) were purified 
using the 63% percoll solution described earlier in section 2.1.1.2. The layer with the schizonts 
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was carefully removed and washed in 50mL of warm complete medium. Pellet was 
resuspended in ⅕ of the original volume of the culture: for a 50mL original culture, the late 
stages were transferred after purification to a 10mL flask for posterior re-invasion.  The later 
would take place within three hours to make sure parasites were in the 0-3-hour window 
required for the assay. A final concentration of 700nM DHA (unless otherwise specified for 
specific experiments) was added to the exposed (treated) parasites. The assay was performed 
in triplicate and a control well using the same concentration of DMSO present in the DHA stock 
was used in order to measure final survival of treated parasites by comparing to the final 
parasitaemia of the untreated. After the six-hour treatment, the media with the drug was 
washed twice with 15mL of complete medium, and the parasites were left to recover until they 
reached 72 hours since start of treatment. In order to measure the percentage survival, the 
following formula was used: 
 
Growth rate = NE/INI 
% Survival = (DHA/NE)*100 
 
* NE=non-exposed, INI=initial parasitaemia and DHA=exposed. 
 
The variables used for the measurement were calculated from thin blood smears and observed 
under the light microscope. A total of 10,000 red blood cells were counted in order to have an 
accurate measurement of survival.  
2.4.2.2 Two-color flow cytometry approach to measure labelled parasite populations and for 
performing RSA(0-3h)  
The steps for parasite preparation were the same as with the thin blood smear 
approach described above, however after 72 hours a specific treatment for measuring parasite 
survival using flow cytometry was used.  
A two-color flow cytometric approach was also used in order to measure survival of 
parasites treated with DHA in vitro. The protocol used for this approach was adapted and 
slightly modified from Amaratunga et al. 2014 in (Amaratunga, et al. 2014). The two dyes used 
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for this assay were SYBR Green I Nucleic Acid Stain (Sigma-Aldrich) and MitoTracker Deep Red 
(Thermo Fisher), with 497/520 nm and 644/665 Excitation/Emission, respectively. The 
concentrations were modified as it was easier to perform the gating than with the 
concentrations published. A total concentration of 2xSYBR-green, 160 nM mitotracker deep red 
in complete media were used for the staining. Briefly, 100uL of culture were loaded into a 96-
well plate, washed once with PBS and resuspended in 100uL of the two-dye mix. The parasites 
were left at 37°C inside the incubator for 30 minutes, covered. After staining, the plates were 
centrifuged and two washes with PBS were performed before resuspending in a total volume of 
200uL of PBS. This was then diluted 1 in 10 for loading to a benchtop Cytoflex Flow Cytometer 
from Beckman Coulter. The gating strategies were performed following the published protocol 
and are shown as follows, after being exported from the flow cytometer and loaded for 










































Figure 2.3 Gating for two-color flow cytometry approach. Two left panels represents the total population of 
cells in the control wells. Top right panel represent the live cells in the non-exposed parasites (NE). The 
bottom right panel are the exposed parasites (DHA). For both gating panels, the right gate (Q2) represents 
the mitotracker positive (staining only mitochondria thus only live parasites will be on this gate) and SYBR 
green positive cells which are the surviving cells after the assay. The top left gate (Q1) includes both live cells 
but mitotracker negative and dead cells as SYBR green is a DNA dye. Measurement of survival will be by using 
the formula described for the microcopy approach. Modified from (Amaratunga, et al. 2014). 
     
2.5 Barcode Sequencing 
2.5.1 Competition assays using Next Generation Sequencing (NGS) 
 For measuring the relative growth of individual parasites in a pool, parasites were 
carefully quantified in order to achieve a 1:1 ratio of each strain measured in the competition. 
Depending on the experimental designed, gDNA was collected and extracted following the 
protocols described earlier in this chapter.  Each experiment was performed in duplicate or 
triplicate, which will be specified accordingly in the following chapters. 
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2.5.1.1 Library preparation and Illumina sequencing (BarSeq) 
Because Plasmodium falciparum has the ability to stably maintain replicating episomes, 
a first round of PCR amplification was performed in order to discard plasmid, and the strategy 
will be described in the following chapter. Briefly, the first PCR amplifying from outside the 
homology regions was performed using the proofreading DNA polymerase KAPA Hot Start 
Ready Mix 2x from Kapa Biosystems. The conditions were optimized to work for Plasmodium 
falciparum: 30 cycles of 95°C for 3 minutes (initial denaturation), 98°C for 20 seconds 
(denaturation), 57°C for 20 seconds (annealing), 62C for 2 minutes (extension), and a final 
extension at 68°C for 2 minutes. All the PCR products were verified on a 1% agarose gel for size 
confirmation, and purified using the protocol described earlier, with their concentration 
accurately measured using nanodrop. 
PCR products from outside the homology region that were purified were used as a 
template for a nested PCR, with a total of 100ng loaded. Two PCRs were performed using a 
strategy of adaptor ligation as described in the overview of Illumina Sequencing in the previous 
chapter. First PCR was performed in duplicate for analysis purposes, using primers 91 and 97 
listed in appendix, the later amplified the region of interest containing the barcode, with PCR 
settings as described previously in Gomes et al. 2015 (Gomes et al. 2015). These primers bind 
the annealing sites annotated as arg444/arg445 in Figure 1.16 of introductory chapter, flanking 
each barcode used in most of the experiments in this project, unless specified otherwise. This 
generated an amplicon of 167bp which was later used in a second PCR reaction. The later one 
was performed in order to anneal the Illumina adapters on the 5’ end, together with a unique 
index tag to be able to identify each sample in a BarSeq pool. Throughout the length of the 
project, multiplexing never exceeded 96 different samples in a single lane of MiSeq. This final 
library was amplified using the universal primer PE1.0 and any of the 96 synthesized unique 
oligonucleotides. All of the primers are listed in appendix. All the PCR reactions performed in 
the process of getting the library ready for NGS were ran on a 1% agarose gel for size validation, 
then PCR purification was performed as described earlier. The concentration of the samples 
was measured using a dsDNA Qubit HS Kit from Thermo Fisher and pooled together in 
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equimolar amounts, for a final dilution of 4nM that was used for Illumina MiSeq sequencer 
service at the Sanger Institute. 
The diluted libraries were loaded at 50% PhiX concentration and at a low cluster density 
(<400k cluster density; 4x10^5 cluster/mm2) given their low complexity. The reads were paired-
end with a length of 150bp. Illumina MiSeq v300 kits were provided for each run for the 
Illumina Walk-Up Sequencing service available at the Wellcome Trust Sanger Institute, or were 
used from the Bespoke team at the Sanger Institute. 
2.5.1.2 Fitness calculation for competition assays  
 Once the reads were obtained from the MiSeq sequencer, a Python script (see 
https://gist.github.com/mgalardini/4bc16dc0101aaacce675d719579cee66) was developed by 
Marco Galardini in order to find individual barcodes in a complex pool. A fasta file containing a 
list of sequences to look for was provided only exact matches were counted. Sequences with 
low quality base calling or non-exact matches were excluded for posterior analysis. The output 
file would be composed of the haplotypes/barcodes, day, condition and the read counts, which 
were later analysed using R.  
A comprehensive R script was developed in order to start from the input file described 
earlier and to work out the relative abundance of each parasite in the pool. Briefly, this was 
measured as the proportion of each barcode over time, and the relative growth rate was 
measured as the log2 of the change in barcode proportion over time. All of the analysis that led 
to all the figures presented throughout this work were performed using R packages ggplot2 and 
tidyverse (https://www.tidyverse.org/), which combines other data managing packages such as 









Chapter 3: Establishing a safe harbour for barcode insertion in 
the Plasmodium falciparum genome and using a pool of 
barcoded plasmids as a readout of transfection efficiency.  
3.1 Summary: 
The aim of this chapter was to provide a proof of principle for barcode sequencing in P. 
falciparum parasites. I first adapted the barcode cassette from the PlasmoGEM linear KO 
vectors (Bushell et al. 2017) to a circular P. falciparum donor plasmid, pCC1 (adapted from 
Maier et al. 2006).  I then established the pseudogene (Pfrh3) as a feasible safe harbour to 
insert barcodes by co-transfecting the barcode donor plasmid with a Cas9 nuclease and a single 
guide RNA targeting Pfrh3. I then combined these two strategies, and performed pooled 
episomal transfections to understand transfection efficiencies of P. falciparum and to address 
the limitations for generating barcoded parasites at a large scale.  
 
3.2 Background: 
3.2.1 Barcode Sequencing for measuring fitness 
Next generation sequencing (NGS) has pushed the scale of our understanding of 
biological systems in a number of different ways beyond simply enabling the production of 
more whole genome sequences. A key example is the application of NGS to quantify the 
relative growth rate of numerous strains in parallel, for example in chemical-genetic 
interactions screens, otherwise known as chemogenomics. Before NGS, competitive 
chemogenomic assays in yeast were performed using barcode microarrays as a readout of 
fitness, with each individual strain having a different barcode. The advantage of NGS 
technologies allowed the group of Corey Nislow to establish Barcode Analysis by Sequencing 
(BarSeq) technology, applying it to a panel of yeast deletion strains (Giaever and Nislow 2014). 
As each strain was individually barcoded, the authors were able to amplify all 20-mer barcodes 
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with conserved primers containing the required sequence for Illumina NGS. The quantities of 
the barcodes could then be recorded using NGS and the fitness of particular mutants measured. 
This approach outperformed their previous method using microarrays, particularly for non-
essential genes (Smith et al. 2009). More recently, the Billker and Rayner groups at the 
Wellcome Sanger Institute formed the Plasmodium Genetic Modification Project (PlasmoGEM), 
and developed a library of uniquely barcoded knockout vectors targeting, at the latest count, 
more than half of the genome of the rodent malaria parasite P. berghei.  
3.2.2 CRISPR-Cas9 based editing in Plasmodium falciparum 
As outlined in Chapter 1, reverse genetics has not yet been implemented at a large scale 
in P. falciparum. This is in large part because there are some clear bottlenecks that make 
transfection efficiency particularly low in this species, as compared to other species like P. 
berghei or P. knowlesi (Bushell et al. 2017; Moon et al. 2013), and even lower when compared 
to other Apicomplexans such as Toxoplasma gondii (Sidik et al. 2016).  However, factors 
affecting the efficiency of both transfection and homologous recombination still remain to be 
fully investigated in P. falciparum and other Plasmodium species.  
      
The success of CRISPR/Cas9-based genome editing in P. falciparum has been a promising 
development as reverse genetics now seems feasible and scalable for tackling different 
biological questions. However, due to the absence of NHEJ, even simple gene disruptions 
require the provision of a donor sequence when transfecting, adding complexity to vector 
design and scale. However, the absence of NHEJ has the side benefit that off-target effects are 
likely to be minimal, as unwanted double-strand breaks would likely lead to cell death by the 
inability of the parasite to repair these lesions (Ghorbal et al. 2014; Wagner et al. 2014).  
 
Another challenge in the application of CRISPR/Cas9 to P. falciparum is design of the 
gRNAs required to target Cas9 to the correct site. The targeting region of gRNAs are 
conventionally 20 nucleotides long, and require a downstream Protospacer Adjacent Motif, or 
PAM, at the target site that is critical for the nuclease to induce cleavage. While multiple 
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variants of Cas9 are now available, in the case of the conventional Streptococcus pyogenes Cas9 
that has been published in multiple studies in P. falciparum (Ghorbal et al. 2014; Wagner et al. 
2014), the PAM requirement is NGG. Given the low GC content of the P. falciparum genome, 
there can be challenges in designing gRNAs near to the target site that meet this requirement. 
Another consideration that is relevant for the design are the “off-target” scores, which refer to 
the “uniqueness” of the target sequence and the likelihood that the nuclease will cleave 
elsewhere in the genome, although as noted above this is most problematic for organisms 
relying on NHEJ for DNA repair. This score, incorporated in platforms like Benchling, was used 
to identify gRNAs that had at least three “mismatches” to other regions of the genome.  The 
proximity of repair to the cut site has also been shown to impact the editing efficiency, with 
efficiency decreasing as the distance to the cut site increases (Sander and Joung 2014). Lastly, 
the “on-target” score, which measures the activity of the nuclease based on predictive models, 
has been developed using mammalian systems and yeast models. Because it is unclear whether 
these predictions are also true for P. falciparum on-target scores were not be taken into 
consideration throughout this project (Doench et al. 2014). 
3.2.3 Using a pseudogene for barcode insertion    
The first step in establishing Barcode Analysis by Sequencing (BarSeq) for P. falciparum 
was to establish a safe harbour in the genome in which barcodes could be inserted without any 
effect on fitness. Pfrh3 (PF3D7_1252400), or reticulocyte binding protein homologue 3, was 
selected as the target locus because it has been characterised as a pseudogene (Duraisingh et 
al. 2002) and can be disrupted without any effects on parasite growth (Taylor et al. 2001). 
Located on chromosome 12, this gene was first identified in a study by Taylor et al. 2001 which 
set out to identify P. falciparum homologues of P. yoelii and P. vivax proteins involved in 
invasion of erythrocytes. Two key invasion proteins had come out of other studies as having 
sequence similarity; PfRh2a and PfRh2b (Rayner et al. 2000). These two proteins are almost 
identical except in their C-terminal amino acid region, and are both non-essential for invasion. 
Pfrh3 was identified as part of the same family based on sequence homology to other species. 
Unlike PfRh2a and 2b however, the 5’ end of the gene contains two reading frame shifts. While 
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the gene is transcribed in the schizont stages, it would not be predicted to produce a functional 
protein, confirmed by using polyclonal antibodies raised against different fragments of Pfrh3 
(Taylor et al. 2001). With this evidence in favour of Pfrh3 being a pseudogene and not essential 
for parasite growth, it was selected for barcode insertion.  
 
3.3 Methods and Results 
3.3.1 Pfrh3 (PF3D7_1252400) as a safe harbour for barcode insertion 
3.3.1.1 Assembly of barcoding vector with homology arms for targeting Pfrh3   
In order to amplify homology arms of approximately 1kb for Pfrh3, genomic DNA of 3D7 
was extracted using the protocol described in section 2.3.1. This region was also sequenced 
from other strains used later in this project to confirm that the gRNA target sequences were 
conserved, so the same designs could be used across multiple strains. Primers designed to 
amplify the homology regions contained sequences of overlap with each other and included 
restriction sites NcoI and NheI for subsequent ligation of barcodes (p204 and p205). They also 
contained a sequence of overlap to the plasmid backbone of pCC1 (Fig. 3.1A), to allow a three-
fragment Gibson assembly to be performed. The first homology arm, HRI (928bp), was 
amplified using primer p203/p204 and HRII (1200bp) was amplified using p205/p206, for the 
final assembly shown in Fig. 3.2A. Because of the high AT content in the genome of P. 
falciparum  (Pollack et al. 1982), a lower extension temperature was used than that predicted 
for the primers. The cycling settings for this reaction for a Phusion High Fidelity DNA 
polymerase were: 95℃ 2m (initial denaturation), followed by 34 cycles of 95℃ 20s 
(denaturation), 52℃ 20s (annealing), 62℃ 1m (extension) and finalising at 62℃ for 5m (final 
extension). Lanes 2 and 3 in Fig 3.1C show amplification of the two homology arms, which were 




Figure 3.1 Amplification of homology arms of Pfrh3 and cloning into pHHT-FCU backbone.  A. Figure of 
pHHT-FCU vector containing an Ampicillin (AMP) cassette. Initially published by Meier et al. 2006.  The first 
selectable marker encodes the hdhfr (human dihydrofolate reductase) gene, driven by the calmodulin 
promoter (Cam 5’), with a histidine-rich protein 2 3’ UTR as a terminator sequence (hrp2 3’). The second 
selectable marker, yFCU, is for negative selection with compound 5-FC (FCU). B. Design of homology arms for 
amplification and cloning into pHHT-FCU (A). All primers used for this reaction are labelled in the second 
panel, and the dashed lines indicate the 20bp nucleotide overlap for Gibson assembly into the linearised 
vector.  C. PCR-amplified fragments used for Gibson assembly into the pCC1 plasmid backbone. Lane 1 shows 
pCC1 plasmid linearised using restriction enzymes EcoRI and AvrII for Gibson assembly of homology regions 
of Pfrh3. Lanes 2 and 3 are the two homology regions amplified from gDNA, with overlapping regions to 
linearised pCC1 plasmid (p203 and p206) and also overlap between the two regions (p204/p205) for a three-
way assembly. M stands for DNA marker (Hyper Ladder). 
 
Assembly of the homology arms with the pCC1 plasmid was performed by Gibson 
assembly as described in section 2.3.2.6, and confirmed by both Sanger sequencing and with 
diagnostic digestion using NheI/SacI (6.5 and 3kb).  Fig. 3.2A shows the two homology regions 
and the NcoI/NheI restriction sites for subsequent insertion of the barcode. The genomic region 
in Pfrh3 in between the homology arms encodes the guide RNA sequences shown with red 







Figure 3.2 Final pCC1 vector with donor sequence for Pfrh3. A. Wild type locus of Pfrh3 (8.8kb) showing the 
homology regions designed for cloning into the pCC1 backbone. The 120bp region between HRI and HRII 
contains the target sequences of the guide RNAs. B. Plasmid containing homology regions assembled using 
Gibson cloning, with restriction sites NcoI and NheI for barcode ligation. C. A confirmation digest using 
restriction enzymes SacII and NheI to verify insertion of the homology region for Rh3 after Gibson assembly 
(two independent clones shown in lanes 1-2). M stands for DNA marker (Hyper Ladder). D. Final construct 
after assembly of homology arms for Rh3 and removing the negative selectable marker. Primers p203/p206 
were used for the Gibson reaction into pCC1 backbone (B). 
 
Fig. 3.2B shows the assembled pCC1 vector similar to the one published by Meier et al. 
for P. falciparum (Maier, Rug et al. 2008), confirmed using restriction enzymes NheI and SacII 
(approximately 6.5 and 3.1kb bands in Fig. 3.2C). pCC1 utilises the 5’UTR sequence of the P. 
falciparum calmodulin gene (CAM) to drive expression of the human dihydrofolate reductase 
gene-selectable marker (hdhfr), with the aim of conferring resistance to the drug WR99210. The 
original pCC1 includes the yeast negative selectable marker cytosine deaminase (FCU), to select 
double crossover recombinants by using compound 5-Flurocytosine (5-FC). Once the homology 
regions were assembled, multiple attempts were performed to ligate the barcodes between 
these regions. However, the plasmid became unstable, and despite screening multiple colonies 
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it was clear that ligating the barcodes was problematic. For this reason, the negative selectable 
marker was removed to decrease plasmid size, using a restriction digestion with NotI and SacII, 
shown in Fig. 3.2B, and free ends were repaired using the Fast DNA End Repair Kit. A finalised 
version of the construct without the negative selectable marker is shown in Fig. 3.2D and it was 
this version that was used for barcode insertion and subsequent transfection.  
3.3.1.2 Design of 30bp DNA barcodes for insertion into pCC1-Rh3 donor backbone 
In order to find unique barcodes not found across the genome of P. falciparum, the first 
approach was to design 30bp barcodes with a high GC content (50%) which would immediately 
increase the chances of producing sequences that do not exist in P. falciparum given its 
strikingly low GC content. In order to generate a large number of 30bp sequences, a website 
designed by the Maduro Lab at the University of California, Riverside 
(http://www.faculty.ucr.edu/~mmaduro/random.htm) was used. Once this strategy was 
established, Frank Schwach at the Sanger Institute wrote a script for generating random 
sequences and then searching for them across the whole genome of the reference strain 3D7 of 
P. falciparum. All sequences produced were assessed for their potential to form internal 
secondary structures using predicting software as described in section 2.3.2.1. Ultimately, two 
independent barcodes as a proof-of-principle were cloned after ordering them as 
oligonucleotides.    
 
Fig 3.3A-B shows the two sequences that were used for the pilot experiment to 
understand whether the Pfrh3 locus could function as a safe harbour for barcode insertion, and 
how they were annealed into a digested pCC1 backbone. Oligonucleotides p171/p172 were 
used for Barcode 1 and p173/p174 for Barcode 2 (Fig. 3.3B). Annealed primers were ligated in 
between the homology regions for Pfrh3 using restriction sites NcoI and NheI, generated with 
primers p205 and p206, marked in blue and red, respectively in Fig. 3.1A. Fig. 3.3C shows 




Figure 3.3 Insertion of a 30bp DNA barcode into Pfrh3. A. 30bp sequences for two barcodes designed 
containing at least 50% GC content, flanked by NcoI/NheI restriction sites marked in blue and red, 
respectively. B. Ligation of barcode into pCC1-Rh3 donor (hDHFR) by standard T4 ligation. C. Confirmation of 
barcode insertion into pCC1 backbone by Sanger sequencing, using sequencing primers p191/p196. 
 
3.3.1.3 Design of gRNAs targeting Rh3 and assembly into pDC2-Cas9 expressing vector 
gRNA expression vectors for targeting Pfrh3 were generated as a modified version of the 
pDC2 vector developed in the lab of David Fidock (Fidock et al. 2000). This vector contains the 
sequence for expressing a nuclease Cas9 together with a sgRNA under the control of a U6 
promoter as in (Ghorbal et al. 2014). After transfection, the plasmid can be selected for with 
DSM-1, which targets dihydroorotate dehydrogenase (DHODH), and for which the yeast 
enzyme provides resistance (Ganesan et al. 2011). The gRNAs were ordered as standard 
oligonucleotides, and after annealing were ligated into the pDC2 backbone, previously digested 
using restriction enzyme BsbI, shown in Fig. 3.4.  
 
Taking into consideration the criteria for selection of gRNAs described in section 3.2.2, two 
independent guide sequences were identified (Fig. 3.4A), taking into account the total number 
of mismatches and their position relative to the PAM (Hsu et al. 2013). The positive sign on the 
left refers to the strand orientation, in the case of the two guide RNAs selected (in green), they 
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were both on the positive strand (+). Fig. 3.4B shows the oligos used to generate the two 
selected guide RNAs. A map for the BbsI-digested vector is shown in Fig. 3.4C, in which the 
desired guide sequences were ligated. Confirmation of successful ligation was obtained by PCR 
and direct Sanger sequencing (Fig. 3.4D and E).  
 
Figure 3.4 gRNA design strategy for targeting Pfrh3. A-B. Guide RNAs designed using software Benchling. 
Sequences in green were selected for cloning into pDC2-CAM-Cas9-U6-yDHODH (A) and the oligonucleotides 
ordered for annealing and ligation (B). C. Sequence flanked by BbsI sites that is replaced by gRNAs shown in 
Fig. 3A-B. D. Confirmation of gRNA1 and gRNA2 after ligation using the gRNA sequence as a reverse primer 
(p215 and p217), and p36 as forward primer resulting in a 262bp PCR product. E. Sanger sequencing 
confirming the insertion of the gRNA1 in between BbsI sites by using primer p36. In blue and red (B, C, D) are 
the sites for annealing into the pDC2 backbone previously digested with BbsI. 
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3.3.2 Pfrh3 can be used as a safe harbour to insert DNA barcodes   
Once the correct insertion of the barcode sequences into pCC1 were confirmed (Fig. 
3.3C-D), parasites were transfected. These first attempts were for optimization and in order to 
improve the overall low efficiency of transfection of P. falciparum (Hasenkamp et al. 2012), and 
to validate whether Pfrh3 could be used as a harbour to drop in the 30 nucleotide fragment 
encoding a single barcode as a proof-of-principle.     
Both the Cas9-gRNA and donor-barcode vectors were co-transfected into the standard 
laboratory reference strain, 3D7. In this case, transfections were performed by electroporation 
of 50 µg of DNA per plasmid. An AMAXA 4D electroporator system was used, and the parasite 
stage selected based on previous studies were rings (Wu et al. 1996). 
Parasites were obtained within three weeks after electroporation, with continuous drug 
selection using compound WR99210.  A set of genotyping reactions were designed to validate 
integration of the 30bp barcode sequence into the non-essential gene Pfrh3 by differentiating 
between the WT and edited locus (Fig. 3.5A-B). In both cases, the forward primer p191 anneals 
outside the Pfrh3 homology arms, so a positive PCR product could not be generated from non-
integrated episomes remaining in the transfected parasites (Crabb et al. 1997). Reverse primers 
recognised either the WT genomic sequence (p215) or edited barcode sequence (p174), as 
shown in Fig. 3.5A-B. The presence and size of PCR products was evaluated by gel 
electrophoresis, as shown in Fig. 3.5C. The first three lanes correspond to the wild type 3D7, 
which was used as a control, and as expected only yielded a band for the unedited locus (lane 
3). In contrast, the transfected line was positive for the barcode insertion (lane 5), but no 
unedited wild type product was visible (lane 6), indicating the efficiency for the editing reaction  






Figure 3.5 Strategy for genotyping of Pfrh3 mutants.  A-B. Genotyping strategy for determining WT and 
edited locus within the transfected population of parasites to measure the efficiency of integration. The WT 
locus was amplified by using p191 and p215 (A). The edited locus also uses p191 outside the homology region 
and p174 within the barcode as a reverse primer (B). C. Gel electrophoresis showing the genotyping reactions 
for both wild type and edited 3D7. Lanes 1,4 show the amplification of a 3kb PCR product (faintly visible in 
lane 4) that was used for confirmation using Sanger sequencing. Lanes 2,5 report from the edited population 
and lanes 3,6 amplify the WT locus. 
 
While the editing reaction seemed very efficient, dilution cloning was carried out in 
order to isolate parasite clones that had no remaining wild type population. Bulk culture was 
diluted such that 0.5-0.8 parasites would be present in each well in a 96-well plate, so that any 
parasites that emerge are likely to be clonal. After 17 days, an aliquot from each well was 
transferred to a Sybr Green I lysis plate to measure DNA concentration and thus identify 
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positive wells, as described in section 2.1.3. Fig. 3.6A shows two of the clones (A8 and C9) that 
were expanded and subsequently genotyped. Integration of barcode 1, flanked by restriction 
sites NcoI and NheI, was confirmed by Sanger sequencing (Fig. 3.6B).  
 
Figure 3.6 Genotyping of Pfrh3 mutant clones. A. Genotyping strategy performed on two independent 
clones isolated after limiting dilution cloning. PCR amplification of the barcoded locus (lanes 1,5) and the wild 
type locus (lanes 2,6) indicate both clones are barcoded. Additional reactions were performed to detect the 
presence of episomes for the pDC2-Cas9 plasmid (lanes 3,7) and the donor pCC1 plasmid (lanes 4,8). B. 
Confirmation of integrated barcode in clone A8 by Sanger sequencing. The sequencing was performed on a 
PCR product that would amplify the genomic Pfrh3 locus but not the episome, using primer combination 
p191/p194 shown in Fig. 3.5A-B. 
 
Overall, the integration efficiency at Pfrh3 was high, as shown from PCR genotyping 
performed on the bulk transfection before cloning, where there was no amplification using the 
primer combination that would identify the presence of the wild type Pfrh3 locus. Two sets of 
reactions were able to determine the presence of the episomes within the transfected 
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population, and confirmed that that pCC1 plasmid remains replicating after drug pressure was 
removed (transfected parasites were selected for only six days with WR99210). By contrast, no 
amplification for pDC2-yDHODH, the plasmid containing Cas9 and the gRNA, could be observed, 
potentially because the parasites were not selected with DSM-1. The persistence of pCC1 was 
not surprising, as it has been proposed that episomes can start aggregating and rather than 
replicate as circular vectors, form concatemers that can persist within the population 
(Williamson et al. 2002). This might explain the presence of a PCR product even after dilution 
cloning, suggesting that extended drug-free culturing does not produce parasites that lack 
episomes.   
3.3.3 Adapting the BarSeq approach to Plasmodium falciparum by generating 
pools of barcoded plasmids 
The work above establishes a CRISPR-based approach for tagging parasite lines at the 
Pfrh3 locus with barcodes, but making individual barcoded mutants one at a time is laborious. 
In P. berghei, dozens of different barcoded parasite mutants can be generated with a single 
transfection, and this has allowed fitness measurements in the blood stages at a large scale 
(Bushell et al. 2017; Gomes et al. 2015). I therefore decided to test whether pooled transfection 
approaches could be applied to P. falciparum, by generating pools of barcoded vectors that 
could be transfected either in the absence of the Cas9 cleavage event such that they are 
maintained as episomes, or in the presence of Pfrh3 cleavage to insert the barcodes into the 
genome. Initial experiments using episomal barcodes were performed in order to understand: 
1. transfection efficiency and 2. the number of unique plasmids taken up by a single parasite, 
for the purpose of having an estimate of the potential limitations in performing large-scale 
genetic screens in this species.  
In order to generate pools of barcodes, the backbone vector from the P. berghei 
PlasmoGEM resource, pGEM, (Gomes et al. 2015) was used as template to amplify barcode 
cassettes. The linear knockout vector design is shown in Fig. 3.7A, which contains constant 
primer binding sites for Illumina sequencing (in green), flanked by a negative/positive selectable 
marker (hDHFR/yFCU), and generic homology regions targeting a gene of interest in P. berghei. 
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The availability of over 2000 barcode vectors coming from this useful resource was more than 
sufficient for the experiments performed in this study. A plate of 96 different P. berghei gene-
targeting vectors was obtained as bacterial glycerol stocks (plate ID PbSTM_21). All 96 different 
bacteria carrying the unique pGEM vectors were cultured individually (to avoid competition) in 
deep 96-well plates overnight at 30℃, in TB medium with 30ug/mL of kanamycin. After each 
individual bacteria grew to an appropriate optical density (OD), and assuming similar growth 
rates across wells, they were pooled and a single library containing all 96 vectors was extracted 












































Figure 3.7 Adapting the PlasmoGEM approach to P. falciparum. A. Amplicon from PlasmoGEM vectors 
containing a unique barcode, which is 10-11bp long and not found in the genome of P. falciparum. Primers 
used to amplify the barcode with the annealing site for NGS are shown in green (Arg444/Arg445). Flanking 
the amplicon are the positive/negative selectable markers and the homology region targeting any gene of the 
P. berghei genome. B. Amplicon shown in 3.7B is amplified with p212/p219 which contain 20nt overlap 
(orange) to pCC1 for Gibson assembly.  
 
Barcode cassettes from this pool of 96 different vectors were amplified using primers designed 
to amplify the 100 bp amplicon used for generation of P. berghei BarSeq sequencing libraries, 
but with the addition of sequences of overlap to the P. falciparum vector pCC1 described above 
(Fig. 3.2D) to permit Gibson assembly. As before, the Rh3 donor plasmid had been linearised 
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with NheII and NcoI, as marked in Fig. 3.3B. The one-step cloning reaction is shown in Fig. 3.7B, 
in which amplification of pooled barcodes from Fig. 3.7A was performed using primers 
containing a 20bp nucleotide overlap to pCC1 for Gibson assembly. The final assembled vector 
which was used for parasite transfection was transformed into One-Shot TOP10 competent E. 
coli cells. Several hundred colonies were obtained after the transformation, which were pooled 
together and plasmids extracted in a large midi-prep to obtain enough material for 
transfection. Multiple glycerol stocks were made from this prep, which were routinely used 
throughout the project.     
 
The complexity of the plasmid prep was confirmed by Sanger sequencing. Fig. 3.8 shows 
the chromatogram of the plasmid pool, using sequencing primers p195 and p196. As expected 
there is a high-complexity region corresponding to the barcode region (brown highlight), 
indicating that multiple different pCC1 vectors, each containing a unique barcode, were present 
within the midiprep. 
 
Figure 3.8 Genotyping of pool of barcoded vectors used for transfection. Sanger sequencing of barcode 
region ligated in between homology arms for Pfrh3 in plasmid backbone pCC1. The high complexity of the 
pool is highlighted (light brown). Primer combination used was p196/p195.  
 
To assess the relative abundance of different barcodes within the pCC1 pool, a direct 
amplification strategy was used, which consists of two PCR steps and a single round of 
purification of PCR products, to prepare libraries for Next Generation Sequencing  (Cruaud et al. 
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2017).  With the purified products, a nested PCR reaction was performed as shown in Fig. 3.9. 
The first set of primers, Arg444 and Arg445, are long oligonucleotides that amplify directly from 
the constant binding site and thus will amplify any barcode within those flanking regions. This 
product (PCR1 in Fig. 3.9) is approximately 100 bp long and contains binding sites for the 
second PCR that introduces the Illumina adapters, labelled in red. The latter was performed by 
using plasmid DNA from the pool, with PCR settings modified from (Gomes et al. 2015), as per 
requirements for HiFi KAPA polymerase: 95℃ for 2min, followed by 35 cycles of 98℃ for 20 
seconds, 58℃ for 20 seconds and 72℃ for 30 seconds, and a final extension at 72℃ was 
performed for 1 minute.  The number of cycles had been previously optimised to work from 
infected blood of P. berghei (Gomes et al. 2015), and appears to be sufficient to reach barcode 
saturation, and thus was selected for this approach.   
 
 
Figure 3.9 Library preparation for BarSeq. Method for generation of libraries compatible with Illumina 
platform MiSeq. A nested PCR approach uses primers Arg444/Arg445 to amplify from the constant binding 
sites (green). These primers have overhangs compatible with Illumina index tags PE1.0 and index 1-96 which 
anneal the Illumina adapters that bind to the flow cell (Gomes et al. 2015).  
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Because of the low complexity of the samples, due to the flanking regions of the 
barcode being the same for every vector, the order in which each base is read will essentially be 
the same for every cluster formed in the flow cell until the barcode is reached. This can produce 
errors during Illumina sequencing, so it is important to increase the diversity in the clusters as 
much as possible to avoid introducing errors in base calling during the imaging process. To 
overcome this issue, genomic DNA from the bacteriophage PhiX is added to the sequencing 
libraries, known as a spike-in. Increasing the concentration of PhiX in the sample mix increases 
the diversity of the clusters. This had been previously optimised for the P. berghei work, and 
the settings were left constant throughout this dissertation. A normal sequencing run for 
MiSeq, specifically for whole genome sequencing, will have up to 5% PhiX, but given the low 
complexity of the BarSeq samples 40-50% PhiX was routinely spiked into each sample. Another 
method for dealing with the low complexity was to use a low cluster density. Normally, for 
whole genome sequencing, a cluster density of approximately 8x105 clusters/mm2 is used, 
however for the barcode sequencing runs, the final cluster density for these amplicons was 
4x105 clusters/mm2.  
 
The raw fastq reads for two input pools that were sequenced were obtained directly 
from the sequencer and analysed. Both pools originated from the same midi prep but were 
sequenced on different days and using different multiplexing strategies, thus providing total 
read count libraries of different length. Fig. 3.10A shows the distribution of the raw counts after 
being counted from the fastq files. The green arrow shows that most barcodes for both pools 
are above one thousand reads, however the second input shows overall lower abundance for 
all the barcodes. In order to understand how the abundance would affect the overall 
complexity of barcodes, the proportion of each barcode in the experiment is shown in Fig. 
3.10B for both pools, showing that even though the abundance of input pool 2 is lower in terms 
of absolute counts, the two proportions are consistent within sequencing replicates, with an R2 
of 0.98. Because all subsequent analysis is performed by assessing changes in the relative 
proportion of different barcodes in different experiments, variation in the overall read counts 
are not problematic. Given the sensitivity of the approach even barcodes at very low 
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abundance (10% of the most abundant barcode in the pool) have been shown to be detected 



























Figure 3.10 Plasmid pool sequencing and comparison. A. Raw counts for two pools sequenced as part of 
different multiplexed runs but originally from the same plasmid preparation. The y-axis are the barcode 
sequences present in the pools and x-axis indicates the raw counts. B. Linear correlation of the proportions 
between the two barcode (BC) input pools, showing an R2 of 0.98. 
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3.3.4 A limited number of plasmids are taken up by P. falciparum when 
transfected with a complex vector pool 
The efficiency of transfection in P. falciparum has been previously assessed using a 
luciferase-based approach, where a plasmid expressing a luciferase reporter was 
electroporated into infected erythrocytes. By performing a time course of luciferase activity, 
efficiency of transfection was assessed in a more sensitive manner than other methods, such as 
the time it takes parasites to become visible by microscopy after transfection, or to reach a 
certain parasitaemia (Skinner-Adams et al. 2003). Using the luciferase approach in combination 
with the best transfection protocol, the efficiency can reach up to 1.08x10-5, a measurement 
equivalent to the ratio of parasites expressing luciferase at different time points post 
transfection until parasiteamia reaches 1%, to the input of parasites that got electroporated 
initially (Hasenkamp et al.  2012). However, these studies have the limitation that they do not 
provide any information about how plasmids get distributed throughout the parasite 
population - a few parasites could be taking up many plasmids, or each parasite could be only 
taking up one, and the luciferase activity would be unchanged.  
I therefore used my pool of barcoded vectors, coupled with a high throughput 
sequencing approach, to gain a better understanding of the dynamics of DNA uptake in P. 
falciparum, and assess the “multiplicity of transfection”, i.e. the number of unique plasmids 
taken up by each parasite. Barcode vectors were used to examine both the proportion of these 
vectors taken up by parasites, and how these uptake events were distributed over the parasite 
population. 
Transfections were performed in the laboratory strains 3D7 (Transfections 1 and 2) and 
Dd2 (Transfections 3-5). 50ug of the precipitated plasmid donor pool described earlier were 
loaded into each transfection, which were performed using the same conditions used as in 
section 2.2.1.1. Once resistant parasites were detectable by microscopy after continuous 
selection with WR99210, cultures were expanded to 10mL. In order to get an accurate 
representation of the parasite population, the parasitaemia and haematocrit were kept at 3% 
and >5%, respectively. Genomic DNA was isolated, and the barcodes were amplified by the 
nested PCR reaction described (Fig. 3.9). The workflow for all barcoding experiments is shown 
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in Fig. 3.11, and consists of 3 steps: 1. transfection of plasmid pools, 2. recovery of transfected 
parasites, and 3. library amplification for high throughput sequencing.  
 
Figure 3.11 Graphical representation of a BarSeq approach for measuring transfection efficiency using pools 
of amplicons containing 96 unique barcodes. The three steps in the process are in between the gray arrows 
and are 1. transfection of pools of 96 barcoded vectors, 2. recovery of transfected parasites with continuous 
selection, and 3. library amplification for high throughput sequencing. 
 
The first approximation for understanding the barcode complexity was to design a 
genotyping PCR amplifying genomic DNA extracted after parasites were visible by microscopy. 
These PCR products were then examined by Sanger sequencing, as shown in Fig. 3.12 which 
shows the chromatogram across the barcode region of the recovered episomes. A region of 
high complexity was observed in the barcode region, consistent with the recovery of multiple 







Figure 3.12 Genotyping of two independent transfections (Tx1 and Tx2). Chromatogram for the two 
transfections showing the barcode region inside the light brown box as being the only region with high 
complexity. Forward (p196) and reverse (p195) primers used for Sanger sequencing from episomes, and the 
yellow region reflects poor sequence quality at the start of the p195-primed reactions.  
 
To more accurately measure the distribution of vectors maintained episomally, library 
preparation of PCR amplicons was generated as in Fig. 3.9. Analysis of the raw fastq reads was 
performed to measure the relative proportion of each barcode in each transfection. Figure 
3.13A shows the barcode proportions in the five independent transfections, with the y-axis 
representing the proportion of the total counts for each barcode, sorted on the x-axis by their 
abundance in the input pool.  
From this figure, it cannot be determined whether the most abundant barcodes in the 
input were the ones that got into the parasites most effectively to be stably maintained, as no 
clear correlation can be determined between the input abundance and recovery. Rather, these 
pilot studies were aimed at understanding the dynamics of transfection in P. falciparum. Fig. 
3.13B-C shows the distribution of barcodes across the different transfections, which indicates 
the level of stochasticity between transfections. Fig. 3.13B shows the distribution of the log 
ratio of barcodes recovered in the different transfections, and the distribution of barcodes in 
the input pool (gray). To further investigate the high degree of stochasticity observed in the 
distributions, the difference between the log ratio in the input pool and the output (different 
transfections) was measured (Fig. 3.13C). From the results in Fig. 3.13C, the distribution of the 
difference between input and output suggests that the source of the stochasticity may result 
from the specific complement of plasmids taken up by the parasites from each independent 
transfection, not necessarily being the most highly abundant barcodes in the input the ones 
that get taken up. Alternatively, stochasticity may be introduced by different growth rates that 
individual parasite clones might have, and that competition might have occurred in the time 
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taken for the culture to reach a parasitaemia high enough for genomic DNA to be extracted. 
However, this latter possibility seems less likely given that all barcodes should have equal 
fitness. Regardless of the explanation, it can be concluded that transfections 3, 4 and 5 seem to 
have a distribution in which only a few barcodes comprise most of the DNA pool and are on the 
more positive side of the distribution, and that there is a higher amount of noise observed from 









Figure 3.13 Barcode abundance and distribution measured with NGS. Transfections 1 and 2 were performed 
in 3D7 and 3-5 in Dd2. A. Transfection of a pool of 96 uniquely barcoded vectors. A. The data is sorted by the 
most abundant barcodes present in the input pool (first panel, gray). The y axis represents the proportion of 
each barcode in the total pool, as measured with Next Generation Sequencing. B. Distribution of the log2 of 
the barcode proportion across 5 transfections and input (gray) C. Density plot showing the difference 
between the log2 ratio of the input and the output (transfections 1-5). Transfections 1 and 2 were performed 






To understand the relationship between abundance of barcodes in the input and the 
output across transfections, each of their proportion values were plotted against the 
proportion of the barcodes in the input. Fig. 3.14A shows the linear correlation of the different 
transfections to the input. From this analysis, generally the lower counts for the output are 
widely distributed across the x-axis (input), and this would suggest that the most abundant 
vectors were not necessarily those that were present at the endpoint of the transfection. The 
highest linear correlation between abundance in the input and the output was observed in 
transfection 2, (R2=0.214), but this is a relatively weak positive correlation, and in some cases, 
there was essentially random uptake of barcodes, with R2=0.0034 and R2=0.017 for 
transfections 4 and 5, respectively.  
 
To define how well barcode abundance correlated across transfections and input, a 
Pearson correlation matrix was built and its values are plotted in Fig. 3.14B. Transfection 2, as 
predicted, had the highest correlation to the input (0.47), as opposed to the lower ones from 
transfections 3 to 5 with correlation values between 0.02 and 0.016). Lastly, with the different 
replicates available, it is possible to infer that replicates of 3D7 have an overall lower 
stochasticity in plasmid uptake than Dd2, having a correlation to the input pool of over three 













Figure 3.14 Correlation of barcode proportion across transfections and input. A. Scatter plot showing the 
independent variable (input), and the dependant variable (output) for each of the five transfections. B. Plot 
of values of correlation matrix of all transfections to the input pool and to each other. 
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Assuming the distributions of the DNA plasmids follow a bimodal distribution, Theo 
Sanderson designed an analysis in which these distributions are represented as a superposition 
of two normal distributions: the more positive distribution representing barcodes successfully 
taken up by the parasites and the more negative representing barcodes that did not make it in 
the transfection. For each transfection, a mixture of the two distributions was used to calculate 
the number of unique barcodes that were present in each transfection, and are shown for each 
transfection in Table 3.1. Additionally, a random sampling of barcodes was simulated taking the 
relative proportions in the input, and the numbers of DNA molecules that this translates to, 











Figure 3.15 Simulation of uptake of DNA molecules. Simulation performed by Theo Sanderson from the 
Rayner group. Taking random sampling of 96 barcodes, assuming the bimodal distribution represented as 
two normal distributions that indicate whether the barcodes were successfully maintained in the transfection 
(the more positive distribution) or barcodes that never made it to the transfection (more negative values of 
the distributions).  
Table 3. 1 Results of the simulation from barcode distribution Table shows molecules that the number of 
barcodes correspond to, considering the molecular mass of a standard plasmid. 
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3.3.5 Co-transfection results in high multiplicity of transfection for those 
parasites successfully transfected 
 The fact that large numbers of unique plasmids, albeit many at relatively low 
abundance could be recovered from each transfection might suggest a potential for 
multiplexed screening. However, in P. falciparum, it is known that a single parasite is capable of 
taking up at least two plasmids when co-transfected, as has been shown for GFP/RFP 
colocalisation studies (M. C. S. Lee et al. 2008; Struck et al. 2008), or more recently two-plasmid 
CRISPR/Cas9 approaches (Ghorbal et al. 2014; Wagner et al. 2014). To establish whether the 
majority of parasites were taking up multiple plasmids, limiting dilution cloning was performed 
from the bulk parasites recovered in transfection 5 to examine the distribution of plasmids in 
individual parasites. This transfection was selected because it was the least complex in terms of 
barcode numbers. Barcode sequencing of cloned parasites (Fig. 3.16) showed that each clone 
contained multiple barcodes. In every one of the eight clones sequenced, 4 to 8 barcodes were 
detected, suggesting that all parasites had in fact taken up multiple plasmids. In fact, only two 
different combinations of barcodes were observed among the clones (clones 1 and 5 represent 
the two types), with most of the clones having the same barcode content as the sequenced 
bulk population.  Even though the transfection efficiency is very low, there is clearly a non-
random distribution of plasmid uptake, and a strong preference for individual parasites to take 
up multiple plasmids. This suggests that alternate approaches will be required for scaling 
reverse genetics in P. falciparum using a pooled vector strategy, as the pooled vectors will not 
be distributed randomly across the parasite population, and individual parasites will receive 

























Figure 3.16 Distribution of barcodes across individual clones. Measurement of the complexity of episomes in 
individual parasite clones obtained with limiting dilution, showing two clone-types, clone 5 representing one 
clone type and the rest another type. The y axis is the proportion of each barcode in the total read counts. 
 
3.4 Discussion 
A key element of the planned approach to monitor parasite fitness in competitive 
growth assays is the ability to tag individual parasites with a unique barcode. Here, I established 
and targeted a non-essential locus (Pfrh3) as a safe harbour in which to insert a single 30bp 
 106 
DNA barcode using CRISPR/Cas9 expressing vectors (Fig. 3.6A-B). This strategy was effective, 
and was extended in order to have a better understanding of transfection efficiency, as well as 
testing whether the barcoding strategy can be made scalable by simultaneous transfection of 
multiple barcodes, and then subsequently cloning out single barcoded parasites by limiting 
dilution. The results show that the complexity of stably maintained episomes can be used as a 
readout of transfection efficiency, by Sanger sequencing and by a high throughput sequencing 
strategy (Figs. 3.12, 3.13A). Remarkably, from the results, P. falciparum, as P. berghei, is able to 
take up multiple vectors (potentially a few dozen) when transfected in a ring-stage culture. 
However, the results and analyses also raise questions on whether it is possible to perform 
reverse gene targeting at the whole-genome scale, such as in other species. The results of using 
multiple transfections in two different laboratory strains (Dd2 and 3D7) and measuring the 
complexity after transfection by analysing next generation sequencing reads, indicate that 
individual parasites routinely take up multiple plasmids. These results have implications for 
future CRISPR-based approaches that rely on the introduction of libraries of gRNA plasmids, 
such as employed by Sidik et al. 2016 in T. gondii (Sidik et al. 2016), and indicate that further 
work will be required to understand transfection parameters in P. falciparum.  
 
Even though there has been more than a decade after the first transfections were 
performed in P. falciparum, many factors related to the limitations in the efficiency at which 
DNA gets delivered to the parasite remain unknown. From this data, from the complex pool of 
barcoded vectors, an estimation could be made that for each transfection (one cuvette), 
approximately 60 million parasites were electroporated, and between them they took up only 
9-120 molecules of DNA, as shown by the simulations given the distributions shown in Fig. 
3.13B. Given this result, I was also able to show that independence in the uptake events is not 
possible. If plasmid uptake was completely independent, it would be expected that each of 
these molecules would be found in a different parasite, which translates to a transfection 
efficiency of approximately  ̴1 x 10-6, , consistent with previous observations (Hasenkamp, et al. 
2012; Skinner-Adams et al. 2003). With these results on efficiency, the chances of a single 
parasite taking up 2 molecules would then be approximately 1 x 10-36, and given the limited 
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number of parasites that were electroporated in the cuvette (60 million), that would be too low 
for any transfected parasites to be observed. Multiple plasmid uptake must therefore be the 
norm, and in fact, two-plasmid transfection approaches that rely on dual-selection markers are 
routinely used for co-localization experiments or delivery of Cas9 and donor plasmids (Ghorbal 
et al. 2014; Wagner et al. 2014). The clonal dilution performed show that parasites are 
routinely transfected with up to 5 molecules, suggesting that plasmid-uptake events are far 
from statistically independent. 
 
There are a number of possible hypothetical bottlenecks in Plasmodium transfection. 
The data presented suggests that availability of DNA is not likely to be a crucial limitation, and it 
is possible that lower concentrations of DNA might even achieve superior results. It is also 
seems likely that the use of "two plasmid" systems, for instance for supplying a donor and a 
Cas9 vector, are unlikely to lead to significantly lower efficiencies than one plasmid systems 
with current transfection conditions. Further understanding these dynamics will be particularly 
important for the development of multiplexed CRISPR-screens, where low multiplicities of 
transfection will be crucial. This knowledge will be fundamental to the exploration of the 
parasite’s genome and the unravelling of gene function as well as host-parasite interactions.  
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Chapter 4: Using a panel of genetically diverse barcoded 
parasites to assess fitness and antimalarial resistance: a proof 
of principle of BarSeq in Plasmodium falciparum. 
4.1 Summary 
The aim of this chapter was to establish a proof of principle of the application BarSeq to 
assess P. falciparum fitness and response to antimalarial drugs. First, I generated a panel of 
barcoded parasites using a scalable approach with the plasmid pools described in chapter 3. 
Second, I used this panel of barcoded parasites, which included strains from different parts of 
the world and with different sensitivities to antimalarial compounds, in pooled growth 
competition assays with and without drug pressure. Changes in the relative proportion of each 
barcode over time were quantitated using BarSeq high throughput sequencing, and relative 
changes in parasite growth within the panel in the presence or absence of antimalarial 
compounds was assessed. 
4.2 Background: 
4.2.1 Barcode sequencing for measuring growth at a high resolution 
In the previous chapter, a method was developed for generating barcoded parasites. 
We showed that Pfrh3 can be used as a safe harbour to insert these barcodes, and that plasmid 
pools can be transfected and recovered episomally. Once this was optimised, a first attempt to 
do competitive assays and measure fitness (as parasite growth rate in vitro) using pools was 
developed and will be expanded in this chapter.  
Tracking growth rates using Barcode Sequencing is relatively new to apicomplexan 
parasites. The PlasmoGEM team at the Sanger Institute used this approach for high throughput 
growth phenotyping in P. berghei, in one of the first attempts in any Plasmodium species to use 
systematic reverse genetic approaches to generate knockout mutants and insert barcodes for 
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tracking their fitness (Bushell et al. 2017). In a related study undertaken by Sidik et al. 2016, a 
CRISPR/Cas9 based genome editing approach was used to target all genes across the genome of 
Toxoplasma gondii.  In their study, which took advantage of the presence of the NHEJ pathway 
in Toxoplasma, a Cas9 nuclease was constitutively expressed from a plasmid, and a library of 10 
sgRNAs per predicted protein-coding gene was provided in order to establish gene essentiality 
at the whole genome scale (Sidik et al. 2016). The sgRNAs themselves acted as the barcodes, 
with the absence of particular sgRNAs from the bulk culture indicative of gene essentiality. 
These two studies, therefore, used versions of Barcode Sequencing to track parasite growth, 
but with the purpose to understand gene essentiality, not parasite fitness or drug response.  
By contrast in other systems, particularly the yeast model Saccharomyces cerevisiae, 
barcode sequencing has been used to track with high resolution the evolution of clonal lineages 
in order to quantify the process of adaptive evolution. Recently, Levy et al. 2015 use this 
approach to track the adaptive mutations that were acquired through asexual evolution, which 
were essential in determining or shifting the overall fitness landscapes of the population. By 
using a highly efficient barcode insertion strategy to generate thousands of barcoded lines, the 
appearance and expansion of subpopulations that have a fitness advantage could be tracked.  
The authors developed a system in which they could insert barcodes into a neutral region of the 
yeast genome using the Cre-loxP recombination system, which the authors referred to as a 
“landing-pad”. Once the libraries of barcoded yeast coming from a clonal lineage were 
generated, they were pooled together and tracked over 168 generations. By this approach, the 
acquisition of beneficial mutations over time due to adaptive evolution was measured, 
providing an overview of the concept that independent beneficial mutations that appear in an 
asexually evolving population can act collectively after an accumulation of stochastically 
acquired independent mutations, and have a very strong impact in driving the dynamics of the 
population. This study also provided evidence of the power of approaches to perform high 
throughput phenotyping in asexually replicating populations  (Levy et al. 2015).  
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4.2.2 Measuring fitness in Plasmodium falciparum 
Parasite fitness is an oft discussed concept, particularly in the context of drug resistance 
mutations, but has proven difficult to quantitate. Due to the limitations in transfection 
efficiency for P. falciparum, a general feature of most assays that are aimed at measuring 
parasite fitness is that they rely on head-to-head competition comparing at most two lines. One 
approach to measuring parasite fitness in this way was to use a GFP-competitor line co-cultured 
with a non-fluorescent query line, which allowed a readout using flow cytometry. In one 
example, a drug-resistant mutant in elongation factor 2 was mixed in a 1:1 ratio with a GFP-
expressing wild-type Dd2 strain. By performing co-culturing experiments, the authors were able 
to validate that evolved resistant mutants had a cost to parasite fitness (Baragaña et al. 2015). 
Another study assessing parasite fitness used a real time PCR approach to track different 
epidemiologically relevant pfmdr1 alleles, and measure their contribution to parasite fitness 
and to modulating drug response to antimalarials such as chloroquine and mefloquine. In this 
approach, competition assays between isogenic lines with the various pfmdr1 alleles introduced 
by gene-editing approaches were set up, and growth of each line quantified by designing 
primers which would detect the specific polymorphisms in the different strains. The 
concentration of each allele was then used as a measure of relative growth in competition  
(Hayward et al. 2005).  
More recently, the group of David Fidock used pyrosequencing to determine the 
contribution of different Pfkelch13 alleles to fitness in isogenic lines with epidemiologically 
relevant polymorphisms generated using zinc-finger nuclease mediated gene editing, described 
in section 1.5.2.3 (Straimer et al. 2017). This method requires four different enzymes which all 
work to convert inorganic pyrophosphate released after nucleotide incorporation performed by 
a DNA polymerase (enzyme 1), to ATP by an ATP-sulfurylase (enzyme 2), releasing necessary 
energy for a third enzyme, a luciferase to emit light with the oxidation of a luciferin molecule 
after incorporation of a specific nucleotide provided. A fourth enzyme (apyrase) is required to 
degrade the nucleotides that do not get incorporated, and thus allow for the order of 
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nucleotides to be determined by the light emission of a given nucleotide  (Ahmadian et al. 
2006). 
Overall, these methods have highlighted the importance of measuring fitness as part of 
the overall understanding of the complexity of drug resistance in P. falciparum parasites. 
However, all these approaches have only allowed for phenotyping two lines in parallel, which 
makes scaling up difficult. Therefore, I undertook to develop an approach to combine barcode 
insertion by CRISPR editing with Barcode Sequencing to measure in vitro parasite growth of 
multiple parasite lines in parallel.  
4.2.3 Drug sensitivity assay in Plasmodium falciparum 
Reliable drug sensitivity assays are essential to monitor any infectious disease. The 
effectiveness of a compound with known or unknown mode of action can be typically measured 
with ex vivo or in vitro sensitivity assays. These have been particularly relevant in regions with 
high prevalence of drug-resistant P. falciparum parasites, like Southeast Asia, where a 
continuous surveillance of changes in drug susceptibility remains crucial. Because of the 
emergence and spread of parasites with an increased tolerance to the current frontline 
antimalarial artemisinin, the following are crucial for surveillance of resistance to both 
artemisinin and partner drugs: 1. monitoring molecular markers of resistance (if known), and 2. 
phenotypic validation using drug-sensitivity assays like pulse-based ring-stage assay (RSA(0-3h)) 
or standard 48-72h inhibitory concentration assays to pinpoint any change in the tolerance 
levels of parasites to particular compounds  over time (Lim et al. 2013).  The RSA(0-3h), 
developed by Witkowski et al. 2010 and described in section 1.4.5.2, allowed for 
characterisation of parasites originating from Cambodia and showing a higher survival to 
artemisinin treatment, highlighting the resistance mechanisms present in these parasites, at the 
early ring stages (Witkowski et al. 2010). An alternative assay was developed by the group of 
Colin Sutherland, and showed equivalent results to the standard RSA(0-3h). By pulsing with DHA 
for 6 hours with the different concentrations used in a standard 48-hour inhibitory 
concentration assay, a shift in survival was shown to be associated with carrying a mutant allele 
of pfap2-mu, another candidate of artemisinin resistance in Africa. This assay also provided the 
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advantage of not requiring a tight synchronization as the RSA(0-3h) does (Henriques et al. 2015). 
Ex vivo drug sensitivity assays rely on the short-term maturation of ring stages extracted from a 
patient infected with malaria and have been essential for determining the status of resistance 
in the field. However, throughout this dissertation, in vitro assays were performed by using 
both flow cytometry and microscopy from Giemsa stains, as described in section 2.4, which rely 
on culture-adapted parasite strains that are maintained  (Russell et al. 2013).  
In this chapter, approaches to integrate both fitness and drug response measures, using 
pools of barcoded parasites, were performed and the phenotypes were validated with standard 
72-hour inhibitory concentration assays for measuring tolerance to partner drugs, or by RSA(0-3h) 
for artemisinin. 
4.3 Methods and Results 
4.3.1 Generating barcoded parasite clones from different genetic backgrounds 
I used the barcoding approaches developed in the previous chapter as the starting point 
for generating parasite strains carrying a barcode into the Pfrh3 locus, by transfecting the 
plasmid pools described. The issue of multiplicity of transfection, with multiple barcode 
plasmids being delivered to a single cell, will not impact our strategy as only one barcode can 
be inserted at the target site in a given line. To tag parasite lines, the plasmid shown in Fig. 3.4 
expressing Cas9 and a guide RNA, and the plasmid pool shown in Fig. 3.7B bearing diverse 
barcodes, were co-transfected into different genetic backgrounds.  
 
The rationale for transfecting multiple barcodes was to facilitate to scale up of library 
generation. Depending on the efficiency of integration, from a single transfection multiple 
clones bearing different barcodes could be isolated via dilution cloning, resulting in individually 
barcoded parasites. A total of 50ug of the mixed plasmid pool and the plasmid for Cas9 
expression were transfected using the protocol in section 2.2.1.1. Parasites were selected for 
with WR99210 (donor plasmid) for six days, and on average it took 3-5 weeks for parasites to 
become visible by microscopy. At this point they were expanded and cloned by limiting dilution. 
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The time from the point of electroporation until parasites were visible was highly variable. Fig. 
4.1 summarises 9 different successful transfections in the 3D7 background, showing the 
number of days until parasites were visible by microscopy on the y-axis. From these results, it is 
evident that transfection outcomes, at least with this transfection method, are remarkably 











Figure 4.1 Length of transfections for editing of Pfrh3. Independent transfections were performed on a 
standard laboratory strain (3D7), with the number of days until parasites were visible by microscopy shown 
on the y-axis. 
 
 A set of genotyping reactions were designed to confirm the integration of the barcodes 
after transfection, including an additional reaction to ensure that the nested PCR would not 
produce any remaining episomes. To confirm their presence, and estimate the efficiency of 
barcode integration, the PCR reactions shown in Fig. 4.2A were performed. Fig. 4.2B shows an 
example of a bulk culture post-transfection, with barcode integration detected by amplifying 
from within the amplicon (p239) and a primer outside the homology region contained within 
the plasmid (p191). Little to no wild-type locus was typically observed (lane 2). Lanes 3 and 4 
show reactions to detect the two plasmids that were co-transfected, pCC1 and pDC2 containing 
the donor region for homologous recombination and the Cas9 and gRNA, respectively. In order 
to confirm the integration efficiency and the complexity of barcodes, a first PCR was performed 
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using p191/p194 (marked with the blue arrows), represented with the dashed square in Fig. 
4.2B. This 3kb product flanks the homology regions and thus does not capture episomal donors 
on pCC1. Fig. 4.2C shows the chromatogram of two independent transfections with the barcode 
pools integrated into the native locus, Pfrh3. From this figure, not only a high complexity can be 
predicted from the variable barcode region but it also shows high recombination efficiency. 
Both transfections shown were performed in a 3D7 background, and once parasites were 
visible, dilution cloning was performed in order to isolate individually barcoded parasite clones 
which could then be used in competition assays. Besides this reference strain, additional strains 










Figure 4.2 Genotyping strategy and integration efficiency of barcode pool. A-B. Genotyping strategy for 
integrated barcodes into Pfrh3. A long PCR (1) was performed by using primer combination p191/p194 (3kb) 
and used for Sanger sequencing shown in C. Forward primer p191 was used in combination with either p215 
(WT locus) or p239 (edited barcode) for genotyping by PCR (1.5kb product). An example of a parasite line 
with near 100% editing is shown in (B). Additional PCR reactions were performed to detect the presence of 
the pDC2-Cas9 plasmid (p163/p195) or the pCC1 donor plasmid (p189/p190).  C. Chromatogram showing a 
high complexity region indicating multiple barcodes are present in the bulk culture. This product is flanked by 
constant primer binding sites for nested PCR reactions described earlier to allow amplicon sequencing by 
NGS. 
 
The next step was to generate the library for Illumina Sequencing using the nested PCR 
reaction described in Chapter 3 (Fig. 3.9). The reaction was performed by using as template the 
3kb PCR product from outside the homology region for Pfrh3, as shown in 4.2A, again to ensure 
that only integrated barcodes were amplified and quantitated. After completion of the nested 
PCR, purification and dilution to 4µM were performed for Next Generation Sequencing. Fastq 
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files were analysed as before and the square root of the barcode proportions of the input pool 
and the two independent transfections are shown in Fig. 4.3. From these results, a range of 5 to 
7 uniquely barcoded parasites were recovered, and in order to isolate them, the bulk 
population was cloned by limiting dilution (section 2.1.3), and clones containing unique 


















Figure 4.3 Integrated barcodes measured by NGS. Transfection of a pool of 96 uniquely barcoded vectors 
together with the pDC2 plasmid expressing Cas9. The data is sorted by the most abundant barcodes present 
in the input pool (first panel, gray). The y axis represents the square root of the proportion of each barcode in 
the total pool, per individual transfection as obtained with Next Generation Sequencing. 
 
The same strategy was used to barcode other strains listed in Table 4.1. Overall, unique 
barcodes were introduced into three clones of 3D7 and two clones for V1/S. Unfortunately, the 
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efficiency of integration for the Cambodian parasite (CAM) was lower and even after screening 
multiple clones, only one barcoded line could be obtained. 
 
Table 4.1 Barcoded parasite strains. A barcode ID was assigned based on the order of barcodes on the 
original PlasmoGEM PbSTM_21 plate from which they were amplified, and that was correctly matched with 
the integrated barcode from the pool.  
4.3.2 A pilot study of BarSeq in P. falciparum  
To establish the parameters for BarSeq, two experimental set-ups were tested. To 
examine the ability of BarSeq to detect inherent growth differences between strains, a long-
term co-culture experiment was performed over 30 days (4.3.2.1). A shorter duration set of 
experiments were performed to test the impact of drug pressure on barcode abundance 
(4.3.2.2). The barcoded parasite clones listed in Table 4.1 were mixed together in equal 
proportions. In order to adjust their parasitaemia, flow-cytometry was used to obtain an 
accurate measurement of live parasites by co-staining with both Mitotracker Deep Red and 
Sybr Green I. The parasitaemia was adjusted so that each of the six clones would be initially 
present at 0.5% parasitemia out of the total 3% of the mix, which was then used as the initial 
time point after confirmation of total parasitemia by microscopy. All competition assays were 
performed in triplicate unless otherwise specified, and maintained for varying durations, 
ranging from hours to several weeks depending on experimental design. Figure 4.4 summarises 




Figure 4.4 General experimental design for Barcode Sequencing experiments. Different parasite clones of 
genetically diverse strains with different drug sensitivity profiles were pooled together in triplicate. A 
competition assay was performed for varying lengths of time depending on the experiment. Genomic DNA 
was extracted at each timepoint and the nested PCR reactions described above were performed prior to 
loading onto a MiSeq sequencer. The CAM strain is the only Pfkelch13 mutant, carrying the C580Y mutation 
and having an increased survival to artemisinin (Ariey et al. 2014). 
 
4.3.2.1 A 30-day competition assay shows inherent fitness differences across strains 
In order to understand whether there were inherent differences in the in vitro fitness 
across strains, a competition assay was performed over a one-month period. The assay 
revealed that the non-3D7 strains, V1/S and CAM, were almost completely outcompeted by 
3D7 after 29 days of co-culture (Fig. 4.5). By comparing the barcode proportion of the total 
counts, a significant change in proportion between 3D7 and non-3D7 strains was observed. By 
contrast, the growth rates across three independently barcoded clones of 3D7, presented as 
3D7A-C, were similar across the one-month assay. As it was a first pilot for BarSeq, only PCR 
duplicates were measured, therefore all further assays included biological duplicates or 
triplicates. The last time point of the assay was on day 31, however for the analysis, data was 
only considered until day 25. This is based on previously optimised parameters for P. berghei in 
which any measurement with counts accounting for less than 10% of the most abundant 





















Figure 4.5 Competition assay in absence of drug over 31 days. Pilot of competition assay of three 
independent strains, with internal replicates for 3D7 as three uniquely barcoded clones in order to establish 
whether the internal replicates had similar growth rates. Second panel is the change in proportion from day 0 
until day 25 and below the adjusted p-value after comparison of means from an analysis of variance (ANOVA) 
and TukeyHSD test. Technical duplicates were performed for this assay.  
 
4.3.2.2 Change in barcode proportions reveal drug resistance phenotypes 
To determine if BarSeq could be used in short-term assays to identify drug-sensitivities, 
triplicate cultures were initiated containing the barcoded clones described above, synchronised 
at early ring stages. The pooled cultures were grown in the presence or absence of different 
concentrations of chloroquine for 18 consecutive days, with samples isolated and extracted 
every four days. The assays were performed in 6-well plates at 3% hct, and at each timepoint 
4mL at 5-8% parasitaemia was collected, lysed with 0.15% saponin, and used for DNA extraction 
and BarSeq. The remaining culture was monitored and adjusted such that the parasitaemia 
would be in the 1-5% range. BarSeq samples were prepared as in Fig. 4.4 and were multiplexed 
onto one MiSeq lane.  To determine the appropriate chloroquine concentration, standard 72h 
drug-sensitivity assays were performed (described in section 2.4.1) and were compared with 
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previously published IC50 values, if available. Fig. 4.6 shows a standard inhibitory curve for the 
three strains used. 
Based on the IC50 obtained from this analysis, and confirmation with the published data 
(Ref IC50 in Fig. 4.6), two concentrations were used for the BarSeq approach based on the IC50 of 
the chloroquine-sensitive strain, 3D7. For the strain from Cambodia (CAM), a reference IC50 was 
not available, however because this strain was used in further experiments, the IC50 value was 










Figure 4.6 Chloroquine standard dose-response curve. Dose response curve for strains used in competition 
assays measured by using a dose response model (drc) (Ritz et al. 2015).  Second panel showing the 
experimental values obtained and the published values (Ref. IC50), both of which were considered for design 
of BarSeq experiments. Technical duplicates were performed for the assay, with three biological replicates 
showing the similar IC50 curves. 
Figure 4.7 shows BarSeq analysis of relative growth of each barcoded line in the 
presence of 1 and 3 IC50 concentrations of chloroquine for the 3D7 strain. The upper panel 
shows the growth curves, with the y-axis representing the log of the proportion of each 
barcode in the total counts per replicate, per day. Overall, the internal replicates of 3D7 and 
V1/S, represented by unique barcode sequence per clone, showed no difference in growth as 
expected, whereas some differences were observed when comparing 3D7 to the resistant 
strains V1/S and CAM (p-value 0.02 and 0.03, respectively).  The bottom panel in Fig. 4.7A 
shows the change in proportion over time, and an analysis of variance (ANOVA) coupled with a 
Tukey HSD test to compare the means across groups between days until day 13, with the 
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significance values listed in Fig. 4.7B. The final sample on day 18 was not taken into account as 
the counts for all 3D7 barcoded clones were below the threshold in the high chloroquine 
treated samples. As expected, the phenotypes observed by BarSeq were consistent with the 
differences in drug IC50, showing a significant difference in the means between the chloroquine 
resistant (V1/S and CAM) and sensitive (3D7) strains at sub-lethal concentrations, with p-values 
< 0.01. This provides evidence that pressuring the mixed parasite pool at a relatively low 
chloroquine concentration, 3-fold over IC50 of the sensitive strain, was sufficient for clear 
































Figure 4.7 A. BarSeq of the pool of five clones, in the absence of drug and with increased chloroquine 
concentration.  
The x-axis corresponds to time (in days), and the y-axis represents the log2 of the proportion of each barcode 
in the total read counts obtained. Left panel is the untreated control and middle and right panels show the 
increasing concentration of chloroquine based on the values obtained in Fig 4.6, for 1 and 3 the IC50 for 
3D7. B. Change in proportion of each barcode over 18 days of competition. C. Analysis of variance across 
groups and mean comparison using a TukeyHSD for all timepoints except day 18, with significance values 
shown as the adjusted p-value.  Technical triplicates were perfomed for this assay, and two biological 
replicates confirmed the same results.  
In order to understand whether the method would be consistent in discriminating 
changes in response to higher dosages over shorter time frames, a linear regression was 
performed for each growth curve, and the slope of that regression at each concentration is 
shown in Fig. 4.8B. As expected, the slope of the sensitive strain, 3D7 decreases as the 
concentration increases, indicating the approach can also be used to determine the effect of 
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increasing concentrations on survival. The three concentrations used were equivalent to 2 to 
10 the IC50 for 3D7. To estimate whether there was a difference in the rate at which the less 
tolerant strain would become outcompeted at different drug concentrations, a linear regression 
model using R was performed for each parasite clone, and the log value of the slope is shown in 
Fig. 4.8B. On the y-axis of Fig. 4.8B, the log of the value of the slope for all the time points is 
measured by a linear regression for the different curves. Because it is shown in log base 2, the 
positive curves corresponding to the chloroquine-tolerant strains have a slope greater than 1, in 
contrast with less than 1 for the sensitive clones. As expected, the difference in the slope 
between 2 and higher concentrations was significant, whereas between 5 and 10 IC50, no 



























Figure 4.8  Response to increasing concentrations of chloroquine measure by BarSeq. A. Growth curves at 
different concentrations of chloroquine ranging from 2-10 the IC50 for the sensitive strain, 3D7 over a course 
of 6 days (x-axis) B. Average slope from triplicates at the three concentrations used, taken from performing a 
linear regression on the growth curves shown in (A). The y-axis represents the log2 of the average slope 
across all timepoints for each strain, and the x-axis represents the increasing concentration in nM. Technical 
triplicates were performed for this assay.  
4.3.2.3 Change in barcode counts reflect mefloquine sensitivity, but not DHA or piperaquine 
Given the efficacy of the protocol in revealing the expected phenotype for well-
characterised drug sensitivities of the strain panel, other clinically relevant antimalarial 
compounds (particularly those which are used in combination with the frontline antimalarial, 
artemisinin) were applied to the experimental setup. Mefloquine has been used in combination 
with artesunate since rising resistance in Thailand and Cambodia rendered it ineffective as a 
monotherapy (Vijaykadga et al. 2006; Denis et al. 2006). Resistance to mefloquine has been 
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associated with a copy number amplification in the multidrug resistance gene Pfmdr1 (Price et 
al. 2004). Recently malaria programs in Southeast Asia have been encouraged to use triple 
combinations of dihydroartemisinin-piperaquine-mefloquine, informed in part by genomic 
surveillance studies showing a rise in a molecular marker of piperaquine resistance 
(amplification in plasmepsin 2 and 3), and a deamplification in Pfmdr1 (Amato et al. 2018). To 
establish the concentration conditions for these drugs for use in BarSeq experiments, the drug-
response curves for mefloquine, piperaquine and DHA were obtained experimentally (Fig. 4.9A) 
and compared to those available in the literature (Duraisingh et al. 2000).   
 
Figure 4.9 Dose-response curves for mefloquine, piperaquine and DHA.  A-C Dose response curves for 
strains used in competition assays measured by using a dose response model (drc) (Ritz et al. 2015), for 
mefloquine (A), piperaquine (B), and dihydroartemisinin (DHA) (C).  Panels under the growth curves 
represent the respective experimental values obtained and the published values (Ref. IC50), both of which 
were taken into account for the design of BarSeq experiments.  The x-axis corresponds to the concentrations 
of the compound, on a log scale, and the y-axis to the percentage inhibition. Technical duplicates were 
performed for the assay. 
Figure 4.10A-B shows a BarSeq experiment using the 3D7 IC50 of either mefloquine or 
piperaquine as the selection pressure. As expected, for the case of mefloquine, even though 
the difference in IC50 fold-change in concentration across strains is small (2 or 3-fold), by using 
the concentration of the wild-type strain 3D7, a sensitivity phenotype for V1/S and CAM was 
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validated at this low concentration. Interestingly, V1/S shows a hypersensitive phenotype when 
exposed to mefloquine, based on this approach. An analysis of variance and mean comparison 
were performed as with chloroquine and the statistical significance is shown (p-adj of 6.6x10-
5). Mefloquine hypersensitivity in chloroquine resistant strains has been previously shown by 
Durasingh et al. (2000), and it has important implications for implementing policies for drug 
combinations, as the genetic architecture of hypersensitivity has not been dissected (Duraisingh 
et al. 2000).  An additional assay used a dilution of mefloquine as with chloroquine, confirming 
a dose-dependent effect, with no significant fluctuations at the lower concentrations (between 
2 and 5 IC50). At 500nM mefloquine, all strains maintain the same proportion of the total 
reads, as the read counts drop over time, suggesting that in this short period of time during the 
competition assay, there is still DNA from dead parasites that is amplified; however, it does not 
represent changes in growth (Fig. 4.11). Giemsa smears were made at every time point and 
confirmed the absence of live parasites by microscopy at 500nM. 
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Figure 4.10 BarSeq of barcoded clones in presence of mefloquine and piperaquine.  A. Competition assays 
of the barcoded pool in the presence of different antimalarial compounds. The y-axis represents the log2 of 
the proportion of each barcode in the total read counts obtained over time. B. Change in proportion until day 
13 for mefloquine and until day 18 for piperaquine, panel below shows significance between the means of 
the different groups measured for both compounds by performing an analysis of variance (ANOVA) and 
TukeyHSD test for mean comparison. Technical triplicates were performed for this assay. 
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Piperaquine exposure at 1IC50 revealed significant differences between 3D7 and V1/S 
(Fig. 4.10A-B), however, the magnitude of the change in proportion over time at this drug 
concentration is comparable to the result obtained for the untreated control (Fig. 4.7A), 
reflecting differences in the inherent fitness of the strains. To show that the standard assay at a 
sublethal concentration of piperaquine was ineffective for this specific panel of strains, a 
replicate experiment was performed (at the IC50), together with an untreated control, and the 
change in proportion was measured. Fig. 4.12 shows no significant difference across 
experiments, evidence that the drug has no effect at this concentration on the strains used. 
Note that for this analysis, the proportion of the total reads corresponding the V1/S-B clone at 
the lowest concentration was too low for analysis, as the fluctuations would not be accurately 
representative of a change in the slope of a linear regression, or the rate at which the 
proportion decreases over time. In addition, the Cambodian strain has not been associated with 






























Figure 4.11 Response to increasing concentrations of mefloquine and piperaquine measured by BarSeq 
Growth curves at different concentrations of mefloquine (A) and piperaquine (B), ranging from 2-10 the IC50 
for the strain used as the wild-type (3D7), over a course of 6 days (x-axis), y-axis representing the log2 of the 















Figure 4.12 Unchanged barcode proportion with piperaquine exposure at low dose. Analysis of the change 
in barcode proportion over time for the pool of barcoded parasites over a course of 18 days. Two 
independent biological triplicates using piperaquine are shown together with the data from the untreated 
control from Fig. 4.7A. Each panel represent a different clone and an analysis of variance was performed and 











It has been shown by the group of Didier Ménard that an alternative assay to the 
standard 72-hour inhibition assay correlates better with treatment outcomes. A piperaquine 
survival assay (PSA) was developed, in which ring-stage parasites are pulsed with 200nM of 
piperaquine for 24 hours, then a washing step is performed and parasitaemia is measured at 72 
hours from start of treatment. As with the RSA(0-3h) for artemisinin, a survival rate greater than 
10% is considered resistance  (Duru et al. 2015). A similar drug treatment regime to the PSA 
may thus be necessary in order to use the BarSeq approach to measure piperaquine sensitivity. 
We anticipated that a modified BarSeq approach might also be necessary for artemisinin, given 
the short half-life of the drug in vivo (2-4 hours) (Titulaer et al. 1991). Figure 4.13 shows a 
BarSeq experiment performed by using dihydroartemisinin (DHA). Two approaches were used 
as an attempt to detect the expected phenotype for the parasite background harboring the 
C580Y mutation in Pfkelch13. In the event that a standard competition assay at a sub-lethal 
dose would not reveal the phenotype, a parallel experiment was performed in which the pool 
of barcoded parasites was pressured at the IC50 of 3D7 every 24 hours, starting at ring stages. 
Surprisingly, both experimental approaches revealed that the drug was not having any effect at 
this concentration and amount of time (Fig. 4.13 A-B). A significant difference was observed 
between V1/S and both 3D7 and CAM in the pulsed experimental set up (Fig. 4.13 B), however 
when the average change in proportion was compared (Fig. 4.13 C), no significant differences 
could be detected between these two experimental designs, suggesting that  shorter pulses at a 
more precise parasite stage, akin to the RSA(0-3h) would be necessary to distinguish the K13-



























Figure 4.13 Response to constant pressure or pulsed DHA on panel of barcoded clones by BarSeq. 
Competition assay with the panel of six clones in the presence of the main active metabolite of artemisinin 
(DHA). To mimic the short half-life of the compound, two strategies were tested, constant pressure at 1IC50 
(constant) and by pulsing for 6 hours every 24 hours at the same concentration (pulsed). A. Growth curves 
for both approaches, constant pressure and by pulsing at the IC50 for 3D7. B. Change in proportion over 18 
days of competition for constant and pulsed DHA, and significance between the means of the different 
groups for the two conditions.  C. Mean comparison of both approaches (constant and pulsed). The y-axis 
represents the log-2 of the change in proportion over the different timepoints. 
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4.3.2.4 Change in barcode counts after an artemisinin pulse similar to an RSA(0-3h) reflects 
higher tolerance in a Pfkelch13 C580Y background 
The success of an ACT depends ultimately on how effective its partner drug is, and given 
the short half-life of artemisinin, the partner should have a longer half-life to assure killing of 
remaining parasites after artemisinin levels have declined. Results from previous studies that 
were described in section 1.4.4, such as Noedl et al. 2008, showed that only a small fraction of 
the treatment failures with artemisinin as a monotherapy were due to resistance, combining a 
higher IC50 and a delayed parasite clearance in the circulating blood (Noedl et al. 2008). This 
standard inhibitory assay (IC50), however, does not show a shift high enough to define a 
resistance phenotype, and is not always well correlated with slow-clearance from patients, 
partly because of the short half-life of the drug and the frequency of treatment failure 
(Dondorp et al. 2010). Other studies have shown that these standard in vitro assays might not 
reveal less sensitive strains because P. falciparum parasites get arrested during the first 24 
hours of development (Tucker et al. 2012), however, these delayed rings have not been fully 
characterised. Artemisinin resistance therefore would be determined solely as the reduction in 
the clearance rate of parasites in peripheral blood (> 5 hours), until new in vitro assays were 
developed. An RSA(0-3h) relies on the treatment of early rings which were shown to be the stage 
most resilient to treatment, thus recapitulating the brief exposure to the concentration of 
artemisinin in circulating blood (700nM), as described in section 2.4.2. This assay was optimised 
by Witkowski et al. 2013, aimed at targeting 0-3-hour post-invasion rings, showing for the first 
time a clear shift in susceptibility of early rings in parasites isolated from Cambodia (Witkowski 
et al. 2013).  
As shown by the DHA inhibitory concentration assay (Fig. 4.9C), no significant shift could 
be detected for DHA between strains despite a small increase in tolerance observed for the 
Cambodian strain, consistent with the observations made by Noedl et al. 2008 (Noedl et al. 
2008). However, this minor difference was not sufficient to be detectable by BarSeq, as shown 
in Fig. 4.13A-B.  
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To develop a better method for using BarSeq to detect a phenotype for the Cambodian 
strain (CAM), containing the C580Y mutation in Pfkelch13, a different BarSeq experiment was 
developed which would recapitulate the conditions established for the RSA(0-3h). Fig. 4.14A 
shows survival rates for strains used in previous work by Ghorbal et al. 2014 and Straimer et al. 
2015. A Cambodian isolate (Cam3.II), harbouring the C580Y mutation was published as having a 
24% survival, whereas V1/S and NF54, both carrying the reference allele for Pfkelch13, had a 
0.3% and 0.7% survival rate, respectively.  
In order to optimize conditions to perform a BarSeq experiment by using a pulsing 
strategy similar to an RSA, we first attempted to perform a standard RSA(0-3h) to determine if 
lowering the concentration of the active metabolite dihydroartemisinin would increase the 
survival of the sensitive strains and avoid amplification bias from DNA coming from dead 
parasites. A concentration of 250 nM was used for pulsing the pool of barcoded parasites (t = 0 
hours) for 6 hours, followed by drug washout, and recovery for 72 hours (t = 72 hours). Using 
these conditions, Fig. 4.14B shows a survival rate of 7.3% for 3D7 (a clone of NF54, table 2.1), 
and 33% for CAM, as measured by microscopy in triplicate after counting 10,000 cells (as in 
section 2.4.2.1). A t-test was performed showing no significant difference between the two 
strains, however the number of data points is low to perform any statistics, coming from 






Figure 4.14 Theoretical and experimental RSA(0-3h) values.  A. Reference survival rates for strains equivalent 
to the strains used for BarSeq. V1/S and CAM3.II have survival rates previously reported in Straimer et al. 
2015. Survival of NF54 (parent line of 3D7) as reported by Ghorbal et al. 2014 or Straimer et al. 2015. The 
values for NF54 V1/S and CAM3.II are 0.7, 0.3 and 24.1%, respectively.  B. RSA(0-3h) performed by using 250 
nM DHA. Measured by standard light microscopy of 10,000 red blood cells for 3D7 and for CAM wild type. 
 
The next step was to mix the panel of barcoded parasites and perform a BarSeq 
experiment using a three-hour exposure of 250nM of DHA, with gDNA collected at 0, 3, and 72 
hours. To achieve the tightly synchronised early-ring culture required, the different barcoded 
strains were synchronised independently by performing multiple rounds of sorbitol treatment 
as in section 2.1.1.2, and mixed together at late trophozoite stages prior to a schizont 
purification using Percoll. Upon reinvasion, the pool of early rings was pulsed with 250 nM as 
described above. Fig. 4.15A-B shows the different strains that were included in the competition: 
two uniquely barcoded clones of 3D7 (blue) as internal replicates, CAM (orange), and one clone 
for V1/S (green). The growth curves for the four clones, measured by the barcode proportion 
over time (0-72 hours on the x-axis), show that at 72 hours the sensitive strains 3D7 and V1/S 
are outcompeted by CAM (Fig. 4.15A), demonstrating that tailoring the conditions for the 
BarSeq experiment to the drug profile can yield the expected phenotypes. This data also 
provides further evidence that there is indeed a loss in sensitivity to DHA by harbouring the 
K13-Y580 mutation in this Cambodian strain background, and also confirming the need to 
perform in vitro assays by pulsing for a short amount of time and with a high concentration, 
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similar to how the drug acts in vivo. Additionally, our results show that it is not necessary to go 
to the highest reported concentrations in order to observe a significant difference between 
tolerant and sensitive strains (p-value=0.042).  
Fig. 4.15B shows two additional measurements that are typically used for RSA(0-3h) which 
are the growth rate and survival. The growth rate is taken by measuring the ratio of the 
untreated pool (non-exposed or NE) and the initial counts (INI), showing that the rates for both 
CAM and 3D7 are above one, indicating that over 72 hours they grew, whereas V1/S decreased 
in terms of the proportion of counts in the total reads and in absolute raw counts. Given the 
high synchronicity of the cultures, the results can be explained by these parasites making less 
progeny or by some internal competition for nutrients that might lead to this strain being 
outcompeted very rapidly, thus having a lower parasitaemia at the end of the competition than 
at the beginning. This had been observed by previous competition assays in this chapter (Fig. 
4.7). For the drug-treated condition, the survival rate is the ratio of the proportion of counts of 
the total reads in the treated over the untreated, showing a fold change of >3 for the tolerant 























Figure 4.15 RSA-like assay using BarSeq. A. Competition assay with four barcoded clones (two clones for 
3D7, one for V1/S and one for CAM). An RSA(0-3h)-like experiment was performed and proportion measured 
by BarSeq from reads in the total mix by high throughput sequencing (y-axis, top panel), over 72 hours at 
three independent time points (x-axis). The lower panel represents the change in the proportion for the four 
clones and significance between CAM and V1/S. B. Measurement of growth rates as the ratio between the 
untreated (NE), and the initial counts (INI) both measured by the proportion of read counts from the total, 
and right panel showing the fold change in survival as the ratio between the treated (DHA) and the untreated 
(NE). Technical triplicates were performed for this assay. 
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4.4 Discussion and future work 
Understanding the mechanisms of action of antimalarial drugs is essential in order to 
validate present and future drug combinations. By increasing the knowledge on the biology of 
drug resistance, or the molecular target of specific compounds, the feasibility of combinations 
can provide information regarding which compounds might be synergistic or antagonistic.  
Today, many phenotypic assays can be done in the lab as a result of the successful  
adaptation of P. falciparum into continuous culture (Trager and Jensen 1976), and advances in 
genome sequencing and genetic techniques have made studies aimed at identifying 
associations between phenotype and genotype possible. Regarding drug resistance, there are 
various examples that use these technologies to establish an association between population 
genetics and drug resistant parasites, for example as reported by Miotto et al. 2013 or Ariey et 
al. 2014 linking the Pfkelch13 molecular marker of artemisinin resistance and the various 
polymorphisms present in the field with the clinical outcome of treatment failure (Miotto et al. 
2013; Ariey et al. 2014). In addition to this, genome editing of malaria parasites has also shed 
light into some of the mechanisms of resistance to antimalarial compounds. This has been 
widely used to study molecular markers of artemisinin (Pfkelch13) and chloroquine (Pfcrt) 
resistance,  amongst others, and the impact of mutations in these genes on resistance has been 
measured by different phenotypic assays (Ghorbal et al. 2014; Straimer, Lee et al. 2012). 
An understanding of the fitness effects of drug resistance mutations is also essential to 
understand the epidemiology of resistance, but this has been much more sparsely studied. The 
different assays described in section 4.2.2 have been useful at determining the contribution of 
some particular alleles to fitness in different genetic backgrounds, but all only allow for 
phenotyping of two lines at the same time (Baragaña et al. 2015; Hayward, Saliba, and Kirk 
2005; Nair et al. 2018).  
To overcome this limitation and to pilot the way for large-scale phenotyping of parasites 
to measure both fitness and drug response, I developed a method by which we could generate 
libraries of parasites of diverse genetic backgrounds carrying a unique barcode inserted in a 
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constant region (Pfrh3). I had shown previously that large pools of plasmids can be maintained 
in a single transfection as stably replicating episomes. I then combined this approach with 
CRISPR/Cas9 editing to generate libraries of barcoded parasites that can be cloned by limiting 
dilution. Even though the efficiency of transfection varied, as shown in Fig. 4.1, parasites would 
reliably come back with barcodes inserted, indicating that the gRNA is efficient in initiating the 
homology directed repair pathway. Given the results from the observations from the previous 
chapter (section 3.3.4), which showed that DNA uptake events are far from statistically 
independent, I was able to show that when co-transfecting with Cas9 a pool of up to 96 
uniquely barcoded plasmids, I obtained 5-9 successful integration events per transfection in the 
bulk culture, with individual parasites harbouring a single integrated barcode (Fig. 4.3). 
 Having successfully barcoded strains covering sufficient genetic diversity and drug 
response phenotypes, I also show the first attempts to apply BarSeq in P. falciparum by using 
these strains in a pool. These results highlight the potential power of this technology to 
measure inherent fitness of different strains and their drug response to known antimalarial 
compounds.  
The BarSeq results show relatively subtle phenotypes, such as the fact that V1/S is 
hypersensitive to mefloquine, as had previously been shown by Duraisingh et al. 2000. Given 
that chloroquine and pyrimethamine resistance have spread worldwide, the finding that an 
epidemiologically relevant gene can be involved in modulating resistance to both chloroquine 
and mefloquine (Pfmdr1), as the phenotype observed from V1/S is fundamental. Previously this 
had been shown by standard inhibitory concentration assays only (Duraisingh et al. 2000). The 
results presented here highlight that the efficacy of mefloquine at concentrations that are sub-
lethal to 3D7 can have dramatic effects on V1/S. Additionally, BarSeq shows that a recently 
adapted artemisinin-resistant strain originating from Cambodia (CAM) shows an intermediate 
phenotype to mefloquine (Fig. 4.10A), a result that brings some concern given the fact that 
mefloquine is being used as a combination drug with artemisinin derivatives to combat 
multidrug resistant parasites in Southeast Asia, where the CAM strain originated. I also used 
BarSeq to investigate the interaction of the strain panel with other compounds from the 
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quinoline class of antimalarials such as piperaquine (Fig. 4.10B), which is also used widely as a 
partner drug with dihydroartemisinin. The results showed no difference between strains, 
suggesting that it should be repeated including piperaquine resistant lines such as those which 
have emerged in Western Cambodia as part of the recent outbreak of multidrug resistant 
parasites (Amato et al. 2018). To that end, future work will aim to barcode additional parasites 
with diverse clinical phenotypes that will supplement and be studied in perspective with the 
pool generated in this chapter, by applying an alternative assay to measure piperaquine 
response as in Duru et al. 2015 (Duru et al. 2015). 
The results shown also highlighted the use that this method has in unravelling the 
phenotype of increased tolerance to the frontline antimalarial artemisinin, by performing an 
RSA-like drug exposure for the pooled parasites in which early rings are pulsed with high 
concentrations of its main metabolite, dihydroartemisinin (Fig. 4.15). The results with BarSeq 
correlate well with standard RSA assays that are quantified by using light microscopy of Giemsa-
stained slides (Fig. 4.14), and demonstrate that different exposure regimens can be employed 
with the BarSeq approach depending on the phenotype being examined. 
In addition, my BarSeq results show striking evidence that some strains have an 
enhanced fitness when grown in vitro in the absence of any selective pressure. Measuring 
growth rates across strains has been done in the past using a variety of approaches. In a recent 
study by Murray et al. 2017, the multiplication rates of different strains were measured by 
growing them independently, and at different time points the number of genomes in 
subsequent generations was measured with qPCR. From the analysis, the authors concluded 
that Dd2 had higher exponential multiplication rates than other strains such as 3D7, D10 or 
HB3, over 48 hours (Murray et al. 2017). With the method I have developed growth rates are 
measured in competition rather than independently, and it was particularly striking to see that 
when I compared 3D7 to both V1/S and CAM in the absence of the drug (Fig. 4.7A), there was a 
clear fitness advantage of 3D7 over the other two strains.  
A clear remaining question is what is the underlying biological basis of differences in 
fitness. Some ways by which I will explore fitness differences in the future will be to understand 
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whether there is a decrease in the number of merozoites (progeny) in the segmenting schizonts 
across strains, or if there is a difference in the length of the life cycle. Finally, I will assess 
whether there is an invasion phenotype that might explain the rapid decrease in the V1/S 
population when mixed with the other strains. Interestingly, across all the competition assays 
performed, V1/S exhibited lower fitness than a more recently adapted, multidrug resistant 
strain from Cambodia (CAM), consistent with the  possibility that relatively robust fitness might 
play some part in the spread of this CAM parasite lineage among artemisinin-tolerant parasites 
in Southeast Asia (Amato et al. 2018). Because of the striking differences in inherent fitness 
across strains, which are non-attributable to any specific genetic differences, I am currently 
considering which strains to mix by carefully measuring their relative growth rates before 
pooling, in order to have equivalent growth rates over the course of the competition to prevent 
rapid loss of specific lines. This had been addressed in the P. berghei knock-out study by Bushell 
et al. 2017, from similar observations in which slow-growing but non-essential mutant 
phenotypes were rapidly outcompeted by other fast-growing mutants of redundant genes, 
precluding careful measurement of differences among slow growth phenotypes (Bushell et al. 
2017).  
This current work, and what I foresee will be an important use of this technology in the 
future is to be able to perform high throughput phenotyping of pools of potentially hundreds of 
barcoded parasites with isogenic backgrounds, carrying different alleles that might have an 
impact on resistance or fitness. In the absence of any drug pressure, I predict that some clones 
will have an enhanced fitness and will take over the population after a certain time. By contrast, 
in the presence of a selective pressure (e.g. drugs or any environmental stressor), the ratio of 
clones will change either in predictable ways based on what is known regarding markers of 
resistance, or in unexpected ways if there are no anticipated interactions between specific 
alleles and their outcome when exposed to a known or unknown antimalarial compound 
(Figure 4.16). The results so far show that a suitably diverse panel of strains will be sufficient to 
elucidate resistance and hypersensitivity phenotypes to different compounds, as seen with 
chloroquine and mefloquine (Fig. 4.7 and 4.10A, respectively). Current and future efforts 
include using this strategy to insert unique barcodes into different strains that have been 
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selected for resistance to many potential antimalarial compounds from the Malaria Box (Van 
Voorhis et al. 2016). The Malaria Drug Accelerator (MalDA) consortium, as an example, has 
been putting a large effort into drug target discovery by selecting for resistance to these 
candidate antimalarial compounds followed by whole genome sequencing, generating a large 
collection of resistant lines in the process. Working with the consortium, we are now in the 
process of implementing an approach to accurately measure fitness of all these mutants in a 
high-throughput manner by using this barcoding approach, as it fits within the scope of  the 
vision of the consortium of using evolution and chemogenomics to accelerate drug discovery 
(Cowell et al. 2018).  
Figure 4.16 Schematic representation of the barcoding approach and its future applications.  The scheme 
shows the strategy for performing multiplexed parallel phenotyping of libraries of barcoded P. falciparum 
clones. The top arrow refers to the use of this approach to measure the inherent fitness of strains in the 
absence of any drug pressure or environmental stress. The bottom arrow indicates that the technology can 
also be used to evaluate the contribution of specific alleles to resistance, and the potential use of it to 








Chapter 5: Contribution of Pfkelch13 alleles to parasite fitness 
and artemisinin resistance in different genetic backgrounds. 
5.1 Summary 
The aim of this chapter is to study the impact on fitness of mutations in Pfkelch13 in a 
KEL1 lineage, originally from Western Cambodia (Pursat). By combining CRISPR/Cas9 genome 
editing and high throughput sequencing I was able to provide evidence that parasites 
harbouring this genetic background are not only more permissive to resistance-associated 
mutations, but also have an enhanced fitness when compared to other strains from within SEA 
or from other continents (listed in table 2.1). 
5.2 Background 
5.2.1 Drug resistance and fitness: an evolutionary arms race 
The efficacy of antimalarial compounds has historically been limited by resistance: 
independent origins of resistant parasites have occurred in Southeast Asia and South America, 
and they have spread to highly endemic regions in Sub-Saharan Africa. Both chloroquine and 
pyrimethamine have followed this path (Schwartz et al. 1983; Roper et al. 2004). With the 
current threat of the emergence of resistance to the frontline antimalarial artemisinin, and to 
some of the partner drugs used in artemisinin combination therapies (Leang et al. 2015), 
identification and validation of alleles that might be modulating a decrease in sensitivity or 
might be compensating for fitness losses associated with resistance (Kublin et al. 2003) will be 
essential to improve surveillance, and thus avoid the consequences of the loss of a frontline 
therapy similar to the spread chloroquine resistance (Trape 2001). 
Fitness, or the ability of an organism to survive and reproduce in a given environment, 
can be negatively impacted by drug resistance, which has been a widely studied topic in the 
context of pathogenic microorganisms such as bacteria, yeast and protozoa. Generally, 
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pathogenic organisms have evolved mechanisms which allow them to optimize biochemical 
processes in order to cope with selective pressures such as drugs, which might incur an 
associated fitness cost (Andersson and Hughes 2010). Mutations acquired can impair the 
normal function of a protein in order to allow it to take on a new role. An example of this in the 
human immunodeficiency virus (HIV) is the acquisition of several mutations in the reverse 
transcriptase, which confer resistance to antiviral therapies but at the same time reduce fitness 
(Collins et al. 2004). Other evidence has shown fitness costs associated with drug resistance in 
P. falciparum. An example is mutations in cytochrome b that decreased susceptibility to the 
antimalarial atovaquone but negatively impacted fitness (Peters et al. 2002), or copy number 
amplifications in the multidrug resistance gene pfmdr1 leading to increased survival upon 
exposure to the antimalarial drug mefloquine but reduced fitness (Preechapornkul et al. 2009). 
Another line of evidence that can be extrapolated from the field is the reversal of resistance to 
chloroquine in Malawi after the drug was removed from use, supporting the idea that 
mutations in the chloroquine resistance gene pfcrt had a fitness cost in these African parasites 
(Kublin et al. 2003). 
The overall premise is that in absence of any drug pressure, the acquired drug-
resistance associated polymorphisms will negatively impact fitness, which in fast-evolving 
organisms can eventually lead to a reversal of resistance (Hastings and Donnelly 2005). An 
alternative scenario, particularly under strong selective pressure, is the acquisition of 
compensatory mutations that will alleviate the fitness costs associated with the drug pressure, 
as described by Rosenthal (Rosenthal 2013).  These compensatory mutations can restore the 
function of the mutated protein to alleviate any negative impact. The longer the selection 
pressure, given the effective population size, the more likely it is that there is a stepwise 
process of acquisition of compensatory mutations, eventually leading to some clones having an 
enhanced fitness almost to the point that they follow equivalent growth rates to the wild type 
clones, as shown by Marcusson et al. 2009 with E. coli (Marcusson et al. 2009). 
 In the historical context of antimalarial drug resistance, various examples support this 
idea: 1. The discovery that acquisition of multiple within-gene mutations in pfcrt was required 
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to reach the full chloroquine resistance phenotype (Gabryszewski et al. 2016); 2. A stepwise 
acquisition of mutations in dhfr is required to both increase tolerance to sulfadoxine-
pirymethamine and compensate for reduced fitness (Lozovsky et al. 2009); and 3. A potential 
intergenic effect of a genetic background compensating for fitness in artemisinin resistant 
parasites (Miotto et al. 2015). 
Candidate molecular markers of increased tolerance, such as mutations in the propeller 
domain of Pfkelch13, are present at high frequencies in Southeast Asia, and to some extent in 
Africa and South America (Amato et al. 2016). Different studies have shown that resistance to 
artemisinin has independent origins and there are different mutations that contribute to a loss 
of sensitivity (Straimer et al. 2017; Straimer et al. 2015; Ghorbal et al. 2014), evidencing a soft 
selective sweep. However, in particular, a lineage carrying mutation C580Y that emerged in 
Western Cambodia seven years ago, named KEL1 by Amato et al., has been supplanting other 
artemisinin-resistant populations with other non-synonymous mutations in Pfkelch13  (Amato 
et al. 2018). Additional evidence presented in the work by Amato et al. 2018 indicates that 
resistance to the partner drug piperaquine had the same origin. Tracing the evolution of this 
new lineage (KEL1/PLA1) reveals it is spreading from Western to Eastern Cambodia, and is also 
taking over other local parasite populations with resistance-associated mutations. 
5.2.2 Epistatic interactions and their role in drug resistance 
         Some of the scenarios in which compensatory mechanisms can alleviate fitness 
costs associated with drug resistance can be explained by intergenic or intragenic epistatic 
interactions (Weinreich and Chao 2005; Keightley and Kacser 1987). This has been widely 
studied in the context of antibiotic resistance, and it was shown that a form of epistasis can 
come from the acquisition of compensatory mutations that alleviate costly mutations that 
might impair cellular function, which is often easier than reverting a mutation that has a high 
fitness cost (Maisnier-Patin et al. 2002). This scenario can often also explain the evolution of 
multidrug resistance in bacteria (Trindade et al. 2009). In addition to this, epistatic interactions 
can have a different outcome depending on the genetic background. Epistasis involving 
multiple genes acting together (magnitude epistasis), having a different outcome on phenotype 
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depending on the genetic background, can be defined as positive or negative epistasis. There 
are two scenarios for positive epistasis: the additive effect of two deleterious mutations 
alleviates the fitness costs associated with the negative effects of each independent mutation, 
or alternatively if the mutations are beneficial it can lead to an improvement in function greater 
than would be expected by the function of the independent mutations; both cases describing a 
positive epistasis (He et al. 2010). Negative epistasis, on the other hand, refers to the same 
additive effect but with a negative outcome on phenotype, which can also be a consequence of 
addition of either beneficial or deleterious mutations (Khan et al. 2011). Overall, both types of 
epistasis have been widely studied with the aim of shedding light on how the effect of variants 
can be impacted by the genetic background, and how this determines the fitness landscape by 
shaping the adaptive evolution of organisms. How the epistatic interactions affect fitness 
would, in theory, depend on the population itself: the effective population size (Ne), the extent 
to which populations recombine, mutation rates and interspecific competition, are all factors 
determining the directions organisms can take to either increase or decrease fitness. In the 
context of P. falciparum, given the emergence and spread of drug-resistance parasites from a 
very confined geographical location in Southeast Asia with a small Ne, it is important to 
understand the fitness landscapes of these parasites, which we hypothesize will be shaped by 
positive epistatic interactions of drug-resistance associated genes in these successful lineages. 
There have been some approaches undertaken to address these questions, considering the 
limitations in performing experimental genetics at scale for validation of gene function. 
Generally, studies have focused on the impact of single mutations on the outcome of drug 
susceptibility. However, how individual resistance mutations can impact the overall fitness can 
be different than the expected outcome if each mutation and its impact on fitness would be 
considered independently. An example was shown with the different pathways leading to 
resistance to the antifolate pyrimethamine in P. falciparum, by using a yeast model to introduce 
the different combinations of mutations seen in the field and studying their effect on fitness 
(Lozovsky et al. 2009). 
Overall, resistance emerging in particular regions of the world can be a result of the 
local transmission intensity, or competition with other parasites, as recently shown by Bushman 
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et al. (Bushman et al. 2018), however it can also be linked to genetic backgrounds better 
tolerating resistance-associated polymorphisms: the latter is likely to play a key role in driving 
the epidemiology of drug resistance. One explanation is that epistatic interactions in the 
different parasite populations might have a different outcome: different genetic backgrounds 
might have an impact on the resistance phenotypes observed, and multidrug resistant strains in 
Southeast Asia, such as the  KEL1/PLA1 lineage described by Amato et al. 2018, might be more 
likely to become resistant to other drugs, because of positive epistasis resulting from 
compensatory mechanisms emerging as a result of the local epidemiology, interventions, and 
evolutionary bottlenecks.  
 5.3 Methods and Results 
5.3.1 Targeting vectors for CRISPR/Cas9-based editing of Pfkelch13 
To evaluate the effect of different Pfkelch13 alleles on parasite fitness in different 
backgrounds, multiple strategies were designed for generating constructs for mutating 
parasites from different strains. 
5.3.1.1 Design of donor templates for CRISPR/Cas9 editing of Pfkelch13 
Donor templates for CRISPR/Cas9 can be used in multiple different strategies to modify 
the genome. As described in chapters 3 and 4, a donor template can be used in order to disrupt 
a gene, in that particular case Pfrh3 by insertion of a barcode. However, more elaborate donors 
can also be used to insert selectable markers, for example inserting a fluorescent tag in order to 
perform localisation experiments (Bushell et al. 2017; Sidik et al. 2016), or site specific changes 
to introduce specific synonymous or nonsynonymous substitutions as seen in Ghorbal et al. 
2014. These approaches rely on a donor sequence either being provided as a separate plasmid 
from that expressing Cas9, or together as a single plasmid. The size of the donor region can 
vary, and it has been shown that a region of 0.5 to 1kb of homology is sufficient for initiation of 
the repair pathway present in this species (Knuepfer et al. 2017), however concrete evidence 
on the optimum length that leads to the highest efficiency does not exist for P. falciparum. In P. 
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berghei, as in several model eukaryotes, the general rule is that longer homology leads to 
higher efficiency in recombination (Pfander et al. 2011), although this data was generated in 
the absence of CRISPR cleavage. 
Because the interest of this chapter is to introduce point mutations into Pfkelch13, 
several considerations were taken in order to design the donor sequences. First, in order to 
prevent further cleavage by the Cas9 nuclease, donor regions were designed to contain 
polymorphisms that protect the endogenous sequence, also referred to as “silent” or “shield” 
mutations.  In chapters 3 and 4 this problem was addressed by deletion of the cleavage sites by 
the 100 bp sequence containing the barcode, thus protecting the edited parasites from further 
cleavage. For performing single nucleotide edits, however, since the intention of this chapter is 
to modify a gene predicted to be essential (Birnbaum et al. 2017; Schwach et al. 2015), the 
function of the protein needs to be maintained. Therefore, synonymous mutations were 
introduced at the cleavage site, closer to the PAM to better protect the endogenous gene. 
Because the efficiency of repairing a double-strand break can vary between 
transfections, a simple PCR-based genotyping strategy is desirable, however designing selective 
primers to differentiate the wild type and edited locus when there are only a few differences 
might be challenging. To overcome this difficulty, a region within the donor template can be 
“recodonised”, which introduces silent mutations in between the two homology regions. This 
strategy would also be helpful as by disrupting the homology between the cut site and desired 
mutation, the repair machinery needs to extend beyond the mutation of interest in order to 
find the region of homology. Additionally, it increases flexibility in terms of gRNA design, as 
multiple gRNAs can be covered within this recodonised region, thus increasing the overall 
editing efficiency. 
In order to generate parasite lines harbouring different epidemiologically relevant 
polymorphisms in Pfkelch13, the two donor-design strategies were used for homology-directed 
repair, by using a two-plasmid approach as in chapters 3-4, or a single-plasmid approach. For 
the first donor strategy, following a similar approach from section 3.3.1.1, two homology arms 
were amplified from genomic DNA from the laboratory strain 3D7, using p265/p318 (homology 
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arm 1, 503 bp) and p267/p317 (homology arm 2, 450bp). Primers p267 and p265 had sequence 
overlap with each other and p318/p317 to previously digested vector pCC1 using restriction 
enzymes EcoRI and AvrII. The overlap between p267 and p265, as shown in Fig. 5.1A would 
contain the mutations to be introduced, which included the mutation C580 to Y, or to reverse 
the Y in a Cambodian background back to the reference allele (C). In addition to this 
polymorphism, two silent mutations were designed in the donor to prevent further cleavage by 
Cas9, at the PAM site (Fig. 5.3A). The two homology fragments and the digested pCC1 were gel-
purified and assembled by Gibson cloning (section 2.3.2.7). 
For the recodonised approach, the donor region was synthesised as a gBlock by 
Integrated DNA Technologies (IDT). The sequence of the recodonised region was informed by a 
Perl script, developed by Adam Reid at the Sanger Institute, that would consider the codon 
usage genome-wide and provide the most common alternative codon for a given sequence of 
any length (usually 100-150bp), for that amino acid in P. falciparum. Fig. 5.1B shows the general 
design of this approach. Two homology arms flank a 120bp recodonised region (in gray), with 
the entire donor flanked by 20bp overlap on each end (red) to the free plasmid ends for Gibson 
assembly. The plasmid used here had the pDC2 backbone shown in Fig. 5.1D, digested with 
EcoRI and AatII. Fig. 5.2 shows a chromatogram of the region around position 580. The top 
panel shows the sequence obtained by using the first approach, highlighting the two silent 
mutations at the PAM site, and codon TGT for cysteine. The bottom panel shows a section of 
the silent mutations across the recodonised region. 
Fig. 5.1 C and D show the two versions of plasmids used for transfection. The first 
approach was to clone the donor region into pCC1 following the same protocol as in section 
3.3.1.1 (C), whereas the second approach was performed on the pDC2-CAM-CoCas9-U6-hDHFR 
plasmid, which contains a codon-optimised Cas9 driven by the calmodulin promoter from P. 
falciparum, and a U6 cassette for the expression of a single gRNA as before. In the same 
plasmid, the donor sequence can be cloned by digesting the plasmid with EcoRI and AatII, and 
performing a direct Gibson reaction from either the two-arm homology version or by ordering 
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the synthetic genes containing 700 bp of homology and approximately 20bp at each side for 















































































Figure 5. 1 Cloning of donor sequence using two strategies for editing of Pfkelch13 
A. Figure illustrating the first donor design.  A 750 bp donor sequence with homology to Pfkelch13 was amplified 
with primers containing sequence overlap for Gibson assembly into the pDC2 backbone using primers (p265/p318 
for HR1 and p267/317 for HR2). The HR1 -HR2 overlap encompassed mutations marked as silent 1 silent 2 and 
C580Y. B.  Strategy for generating a donor sequence containing 100 bp of recodonised sequence as described, by 
ordering a synthetic sequence as a gBlock from IDT C.  First editing strategy by utilising the pCC1 donor plasmid 
and the pDC2 Cas9-containing plasmid. The cloning strategy was as described earlier for pfrh3 in section 2.3.2.6. 
pCC1 contains the region of homology and both negative and positive selection cassettes. pDC2 contains Cas9 for 
expression under the control of the calmodulin promoter (Cam 5ґ), and expression of the gRNA from a U6 
promoter. D. Single plasmid for expression of a codon optimised Cas9, a hDHFR selectable marker, the gRNA from 
a U6 promoter, and the K13 donor sequence for homologous recombination.  
 
 
Fig. 5.2 shows a chromatogram of the region around position 580. The top panel shows the 
sequence obtained by using the first approach, highlighting the two silent mutations at the 
PAM site, and codon TGT for cysteine. The bottom panel shows a section of the silent 











Figure 5. 2 Genotyping of plasmids with different donor sequences. 
Sanger sequencing showing the two donor-design strategies, with two alternate C580 codons highlighted with the 
gray box. The top panel shows the standard strategy used in Ghorbal et al. 2014, by designing two silent mutation 
(red squares) at the gRNA binding site (Ghorbal et al. 2014).  The bottom panel shows the strategy by which the 
100 bp of the donor sequence are recodonised to 1). facilitate genotyping by PCR, 2). increase the opportunity to 
use multiple gRNAs targeting the same locus, and 3).  drive recombination from the cut site past the mutation of 
interest. 
.  
5.3.1.2 Design of gRNAs targeting K13 and cloning into pDC2-Cas9 vector  
Design of gRNA was performed in the same way as in section 3.3.1.2. Three 
independent gRNA sequences predicted by Benchling were selected based on distance to the 
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mutations of interest. The three red arrows on Fig. 5.3A indicate the gRNA sequences, next to 
the PAM sites, on the negative strand indicated by the orientation of the arrow. The strategy 
for gRNA cloning was the same as described in section 2.3.2.6, by standard T4 ligation with 
annealed oligonucleotides into a pDC2 backbone digested with BbsI (Fig. 5.3B). Three gRNAs 
were designed and cloned to target Pfkelch13, by using annealed primers p237/p238 (gRNA1), 
p614/p615 (gRNA2), and p616/p617 (gRNA3). They were all confirmed by Sanger sequencing by 






Figure 5. 3 Design and cloning of gRNAs for targeting Pfkelch13.  
 A. Wild type locus showing the two positions that were used as silent mutations for the donor design (silent), and 
position 580. Red arrows are the gRNAs used, with their respective PAM (B), identified by using Benchling. B. 
Primer ID and gRNA sequence, with restriction site BbsI (red and blue), and the cloning site flanked by the U6 
promoter and the U6 terminator sequence. C. Sanger sequencing of three gRNAs using primer p36, with BbsI site 




5.3.2 Mutations in Pfkelch13 and their impact on resistance and fitness 
5.3.2.1 CRISPR/Cas9-based editing of Pfkelch13  
 
Once the correct insertion of the donor sequences into either the two or one plasmid 
approach described in Fig. 5.3 was performed, parasites were transfected using the different 
methods described (section 2.2). Overall ring transfections worked well for standard laboratory 
strain; however for recently adapted isolates (e.g. CAM), a preloading approach in which 
parasites were added to electroporated RBCs resulted in more efficient recovery. Nonetheless, 
as with other approaches, for the majority of transfections no parasites were recovered even 
after waiting for more than 50 days. More than 20 independent transfections were performed 
for each of the different strains used, and 10% of those had parasites become visible by 
microscopy 30 days or more post-transfection, all of which were subsequently confirmed to be 
successfully edited. Overall, the single plasmid approach (Fig. 5.1D) resulted in higher 
transfection efficiency than the two-plasmid system, however, given the low number of positive 
transfections we cannot assign causation to this targeting approach. The length of selection was 
the same as with the Pfrh3 editing transfections described in Chapter 4: constant drug pressure 
for six days and then culture maintenance after transfection followed the protocol described in 
section 2.2.  
 
The genotyping strategy for the first donor described was to amplify the relevant region 
in the endogenous Pfkelch13, using primers flanking the donor sequence to avoid amplifying 
DNA from any remaining episomes. Fig. 5.4 shows chromatograms of the bulk population prior 
to cloning of the different edited lines that were generated. The reference strain 3D7, used as a 
wild type strain for the previous experiments using BarSeq, was selected for introducing the C5 
80Y mutation in Pfkelch13. To better understand how mutations in this gene can impact fitness 
differentially across genetic backgrounds, and in particular in a KEL1 lineage, this latter strain 
was transfected with a version of the editing plasmid to revert the mutation Y580 back to the 
reference allele C580. In addition, another epidemiologically relevant SNP was introduced. The 
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nearby mutation A578S is not linked with any resistance phenotypes, but was reported in 
various studies as being at high frequency in Africa (Amato et al. 2016; Maiga-Ascofare and May 
2016). The chromatogram indicates a high efficiency of editing using gRNA1 (Fig. 5.3C), which 
had been published before (Ghorbal et al. 2014). The two additional gRNAs designed (Fig. 5.3A-
B) did not yield parasites after transfection. This may mean that they are inefficient in targeting 
Cas9 to the cut site, although it should be noted that the combination of low efficiency for 
targeting an essential gene with stochasticity in the transfections, means that the absence of 
editing with these gRNAs is not necessarily attributable to either plasmid design or the gRNAs 
themselves. Once editing at the bulk population level was confirmed, dilution cloning plates 
were made to isolate clonal lines, which were expanded for confirmation, phenotype validation 









































Figure 5. 4 Genotyping of edited locus from bulk culture.  
Reverse complement sequence of Pfkelch13 using sequencing primer p327 and showing the endogenous gene 
with some of the mutations of interested introduced using the first donor sequence strategy. These sequences are 
from the bulk population which was then cloned as in section 2.1.3. This reaction was performed by using KAPA 
Hot-Start Master Mix (section 2.3.2.2), with primer combinations p325/p328. PCR products were confirmed and 
purified as in section 2.3.2.5. 
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5.3.2.2 NGS analysis of CRISPR/Cas9-edited lines  
Two clones per edited line (CAMRev and 3D7C580Y were selected for whole genome 
sequencing. Genomic DNA was extracted as in section 2.3.1, and 1µg was provided to the 
Bespoke Team at the Sanger Institute for processing, library preparation and sequencing on an 
Illumina MiSeq platform. Once the fastq files were generated, I adapted scripts that allowed for 
mapping of the reads to the latest reference of 3D7 from PlasmoDB, using a Burrow-Wheeler 
Algorithm, as described in 1.2.1. Once BAM files were generated, they were indexed for both 
visualisation of reads and to perform SNP calling of the CRISPR-edited lines, using the pipeline 
from Snippy, which uses variant calling software Freebayes (https://github.com/tsee 
mann/snippy). To visualise reads, the BAM files were directly loaded onto the genome viewer 
software IGV 2.4.8, from the Broad Institute.  
Fig. 5.5A-B show an alignment of two independent clones for each strain that were sent 
for whole genome sequencing (C4, A5 for 3D7 and A5, B5 for CAM), together with the parent 
strains that were used for genetic modification. From the reads shown, the region shows good 
coverage and indicates a clonal population for all the transfected parasites, and highlighted are 
both the mutation of interest (amino acid position 580), and the two silent mutations designed 
as part of the donor sequence. The two sequences on the top are the two wild type strains used 
(parent strains), which do not show the silent mutations, and harbour the reference allele for 
Pfkelch13 C580 for 3D7, or the Y580 allele in CAM that confers higher tolerance to artemisinin 







































Figure 5. 5 Alignment of sequencing reads to the reference 3D7 using IGV  
Reverse complement of whole genome sequencing reads of two independent clones for each CRISPR-edited line, 
using genome visualization software IGV from the Broad Institute 
(https://software.broadinstitute.org/software/igv/).  A. Clones A5 and C4 for 3D7_C580Y MUT show successful 
editing of TGT to TAT (Cys to Tyr), and clones A5 and B5 show the TAT codon from CAM reverted back to the 
reference allele (codon TGT for Cys). Because all four clones are edited, the silent mutations are seen, marked with 
the red box. B. Zoom-in of edited region showing the mutated position 580, and the two silent mutations for a 
representative clone of each genetic background (clone C4 for 3D7 and clone A5 for CAM). 
 
The results of the variant calling pipeline provide further evidence of the parent strain 
used for editing by aligning to the reference sequence of 3D7 (table 5.1). It also provided 
reassurance that the clones selected were actually clonal, by the absence of any wild-type reads 
aligning to the reference at this particular locus.  The top row indicates the observed sequence 
in both lines for the introduced silent mutations (TGGC), and the second row the allele at codon 
580. The last two columns show two representative clones and whether they contain the 
reference allele or an alternative, showing a C at position 580 for CAMRev, and a T in 3D7C580Y, 










Table 5. 1 Reference sequence for the position 580 and for the AA position 573.  
Here the silent mutations were designed in the donor sequence. Variant calling software Snippy (http 




From these results using whole genome sequencing analysis we were able to confirm 
editing using the CRISPR/Cas9 based strategy and the homogenous sequence reads allowed us 
to confirm the use of clonal populations for the subsequent experiments.  
 
5.3.2.3 Amplicon sequencing strategy 
 
In the previous chapters, I showed the first evidence that Barcode Sequencing could be 
adapted to P. falciparum, and that it was a useful technology to scale up drug resistance and 
parasite fitness phenotyping. I therefore aimed to perform a two-transfection approach to 
insert DNA barcodes into a non-essential gene (Pfrh3) within edited lines, but because of the 
limited number of selectable markers available for this species (Mamoun et al. 1999), and given 
the genetic bottlenecks that accompany each P. falciparum transfection (Hasenkamp, Russell, 
and Horrocks 2012), I developed an alternative approach for accomplishing a goal of measuring 
in vitro fitness of a limited number of competing parasites in a pool. Fig. 5.6 shows the strategy 
developed for this new approach, which entails amplicon sequencing of the Pfkelch13 locus. 
The same principle applies as with the previous strategy but provides less overall flexibility in 
terms of the number of loci that can be monitored, as the amplification and counting is 
performed from the locus of interest rather than an independent and more complex barcode. 
With this approach, the mutations introduced into Pfkelch13 were in effect used as a barcode 
to track the growth and appearance of different alleles over time. Fig. 5.6A shows the region 
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which is used as amplicon and the different combinations of mutations introduced into the 
genome of the two strains, 3D7 and CAM. The primers shown amplifying from the 5’ and 3’ 
region (in green and red, respectively), were designed as oligonucleotides p1492/p1493, and 
contain binding sequences for Illumina adapters shown as PCR2 in Fig. 5.6B. The box in Fig. 5.6B 
indicates the sequences that are used as barcodes for this approach, by employing the counting 
script described in section 2.5.1.2.   
After confirmation of edited clones by standard genotyping methods and by next 
generation sequencing, they were mixed together at equal proportions and competition assays 






































Figure 5. 6 Amplicon sequencing strategy for Illumina.  
Overview of the method for generation of libraries compatible with Illumina platform MiSeq. A. Template for the 
nested PCR approach uses primers p1492 and p1493 containing constant binding sites for Illumina adapters 
(sequence in green). Gray box highlights the mutations introduced in different combinations for this donor-design 
strategy. B.  Nested PCR reaction performed with the two sets of primers. Purple box highlighting the sequences 
used as єrcodes” for amplicon sequencing, from raw fastq reads (section 2.5.1.2). 
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5.3.2.4 A complex pool of CAM and 3D7 does not reveal any impact in growth by harbouring 
Pfkelch13 mutations 
 
From the previous chapter, I had shown that there are differences in inherent fitness 
amon g the strains used: V1/S for example, in the absence of drug pressure, is rapidly 
outcompeted by “fitter” strains such as 3D7, and even the more recently adapted strain CAM 
(Fig. 4.5 and 4.7A). In this section, the aim was to determine the contribution of Pfkelch13 
mutations to modulating fitness across the different strains, using the five different lines shown 
in Fig. 5.4. In the initial experiments, I mixed CRISPR edited lines from different strain 
backgrounds in order to assess whether this approach was sensitive enough to determine 
subtle differences coming from editing single mutations, or if the inherent fitness advantage of 
3D7 would rapidly outcompete any CAM clone. Fig. 5.7 shows a competition assay lasting 35 
days for the mixture of edited 3D7 and CAM lines. Similar to results from chapter 4, this assay 
shows an overall higher fitness for 3D7, compared to CAM, regardless of Pfkelch13 haplotype 
(Fig. 5.7A). After day 7, the counts for CAM start to drop rapidly, an indication of it being 
outcompeted by 3D7, and at the later time points (from day 15), all CAM haplotypes are less 
than 10% of the total counts in the competition. Fig. 5.7A shows the proportion of each 
haplotype over time (left panel), and as a measure of fitness the mean proportion change over 
the entire time course is plotted on a log2 base scale (right panel). Below is a table showing the 
significance values obtained by comparing the mean across groups, showing significant 
differences between both 3D7 clones, and the three clones from C A M (p-value < 0.05). 
However, no significant differences were observed between isogenic clones for either of the 
strains. To understand the rate at which the different isogenic clones grew, the ratio of all the 
mutated alleles to its wild type was measured   until day 24 (Fig. 5.7B). The later measurements 
beyond day 20 were discarded from this analysis because the counts were below the threshold 
described earlier. The ratios for both mutated alleles of CAM relative to wild type declined, as 
measured by using a linear regression, and the mean slope of that regression show both have 
negative values, with CAMRev+A578S having a lower average slope (adjusted p-value 6x10-4), 
indicating it is decreasing more rapidly than the other clones. Contrary to the CAM lines, the 
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slope for the mutated 3D7 parasite remained close to 0, showing that it is not changing when 
compared to the wild type allele, suggesting no appreciable loss of fitness by having the 














Figure 5. 7 Amplicon sequencing to measure the relative proportion of CRISPR-edited lines mixed in a pool. 
A. Competition assay of five independent clones (3 for CAM and 2 for 3D7), carrying different Pfkelch13 alleles, 
their growth over time (left), and change in relative proportion of total read counts in a log2 scale (right). Below 
the results of an ANOVA between groups and a TukeyHSD test to perform pairwise comparison of all means. B. 
Second approach to measure difference in growth across strains by performing a linear regression on the ratio of 






5.3.2.5 Change in frequency of amplicons in pool reveal drug sensitivity profiles to known 
antimalarials 
 
To understand whether this pool could reveal phenotypes of the different strains 
generated, and whether having the mutated allele would impact sensitivity to antimalarials, a 
panel of four known compounds were used, and short competition assays were performed in 
order to measure drug sensitivity. Fig. 5.8 shows the results of the competition assay lasting 
eight days: the y-axis representing the change in allele proportion measured in a log2 base. As 
expected, and consistent with the results from chapter 4, sensitivity of the panel of barcoded 
strains to chloroquine revealed resistance of CAM and inversely, sensitivity of 3D7 to this 
compound, as also shown in Fig. 4.7. Given the relevance of studying the impact of different 
Pfkelch13 alleles in modulating drug response, three additional antimalarials were selected 
based on their clinical relevance in the context of multidrug-resistant parasites. Fig. 5.9 shows 
the allele proportions over time for atovaquone, lumefantrine, and halofantrine, tested at a 
concentration of 3XIC50, based on the values reported by Delves et al. 2012 for NF54 (parental 
line of clone 3D7).  From the growth curves in the presence of these compounds, and from 
measuring the change of allele proportion across the eight days, atovaquone and halofantrine 
show no influence on the growth of specific lines, as their mean in log2 is 0. Strikingly, the wild 
type CAM Y580 line showed an increased survival when exposed to halofantrine in comparison 
to the CAM-Y580C mutant, indicating that the Pfkelch13 allele may also modulate response to 
halofantrine. This compound is a candidate antimalarial with a similar structure to 
lumefantrine, however concerns have been raised regarding potential toxicity (Bouchaud et al. 
2009). Based on these results, future work will entail repeating these assays as well as 
conventional dose-response experiments, with the aim of confirming the phenotype and to 
study potential interactions of this Pfkelch13 allele with halofantrine, and whether this 
compound can synergise the effect of an artemisinin derivative in wild type Pfkelch13 parasites. 
Given the importance of the C580Y mutation in modulating the response to the frontline 
antimalarial artemisinin, it will be important to continue studying the phenotype of novel 
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compounds in the context of drug-resistant parasites, and to evaluate their efficiency when 

















Figure 5. 8 Amplicon sequencing of CRISPR-edited lines in the presence of different antimalarials.  
Growth curves of competition assays of four clones (top panel), with the y axis showing time, and the x-axis the 
proportion of each of the four alleles as a log - base - 2.  Panel below shows the change in allele proportion over 
time, and is represented as the log - base - 2 on the x-axis. IC50 values were 0.6nM, 2.8nM, and 0.9 nM for 
atovaquone, lumefantrine and halofantrine, respectively (Delves et al. 2012), and 3 that value was used for the 
competition assay. Technical triplicates were performed for all conditions. 
 
5.3.2.6 Competition between isogenic parasite clones carrying different Pfkelch13 alleles 
reveal a strain-dependent fitness cost 
 
As discussed above in Fig. 5.7, when the two edited strains CAM and 3D7 are mixed 
together, the effect of the fittest strain (3D7) overshadows any minor difference that might be 
related to the contribution of specific Pfkelch13 haplotypes to fitness. To overcome this and to 
shed light into their effect, only isogenic lines were pooled following the same strategy used in 
section 5.3.2.4. Two competition assays were performed with durations of 54 (Fig. 5.9A) and 35 
(Fig. 5.9B) days, with genomic DNA samples collected every 3-4 days. Fig. 5.9A shows the 
growth curves of the 3D7 clones carrying the two different Pfkelch13 alleles: WT (dark blue) and 
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C580Y (light blue). For 3D7, the competition experiment shows that the WT, or reference allele, 
grows better than the C580Y mutated allele. In a study undertaken by Straimer et al. 2017, a 
pyrosequencing approach was used to measure the contribution to parasite fitness of different 
Pfkelch13 mutations that had been previously edited into different genetic backgrounds. By 
performing head-to-head competition assays with the wild type and mutant parasites of 
isogenic backgrounds, Straimer et al. also observed that the C580Y allele had a fitness cost in 
some genetic backgrounds, however for the two artemisinin-resistant Cambodian parasites 
there was no effect on fitness by having this mutation, when compared with the artemisinin-
sensitive reference allele generated using nuclease-based genome editing. This would support 
the importance of certain genetic backgrounds in shaping the epidemiology of artemisinin 
resistance. In addition to this finding, the group of Tim Anderson recently showed that C580Y 
had a higher fitness cost than a less widespread mutation such as R561H, when introduced into 
a wild type Southeast Asian isolate, and thus supports the evidence provided by Straimer et al. 
2017 (Nair et al. 2018; Straimer et al. 2017). These findings collectively are consistent with our 
hypothesis that mutation of Pfkelch13 in a 3D7 background would result in impaired fitness, 
given that 3D7 is originally an African strain that has been adapted to culture for over 40 years, 
and has a wild type phenotype to all antimalarial compounds.  
The observation of fitness differences was only apparent after more than 20 days of 
continuous co-culturing. Before day 20 for both experiments there was a considerable amount 
of noise that could originate from different sources. One potential source of initial variability 
may be phasing of the lifecycle stage of the two lines, with alternating replication and rupture 
cycles contributing to fluctuations, and future work could repeat the competition assay using 
more tightly synchronised parasite clones. Additionally, for these two experiments, the initial 
parasitaemia or hematocrit was not perfectly matched between clones, with the wild type 
clone being almost three times higher than the mutant clone. For the second experiment 
(Fig.5.9B), a similar fluctuation was observed as with the previous assay, however the striking 
peaks may be a result of a less frequent sampling of genomic DNA (only 4 time points until day 
20). For these reasons, calculation of the average change in proportion was taken from day 20 
until the last day of the competition. By doing this analysis, the second panel of both figures 
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shows an increase in the average change in proportion for the wild type allele. From both 
experimental set-ups, it is clear that the effect of the mutated allele in a 3D7 background is 
modest, and the way the assay conditions are established (e.g. length of time of competition) 
will strongly impact the ability to draw statistical significance. When performing a t-test for the 
first competition assay, no significant difference between the two clones on the selected time 
range (p-value = 0.07) was observed, explained by the fact that the proportion of read counts 
for the mutant line on the last days of competition remain at less than 10% of the total counts 
of the competition, effectively implying that at that point the mutant cl one is completely 
outcompeted. The difference for the two clones on the second competition assay, however, 
was significant (t-test, p-value=0.004), however given the time range selected, only three time 
points were considered, three replicates for each.  
For the CAM strain belonging to the KEL1 lineage described by Amato et al. 2018, I 
hypothesised that reverting the artemisinin-resistant C580Y mutation back to the sensitive 
reference allele may not provide an enhanced fitness as it would in other genetic backgrounds, 
potentially related to differential epistatic interactions unique to these successful lineages 
(Amato et al. 2018). Competition assays between isogenic clones for CAM were performed by 
taking the same approach as with 3D7. The first experiment lasted 54 days, and the change in 
allele proportion is shown Fig. 5.10A. Unexpectedly, competing a CAM strain, harbouring the 
C580Y allele, to the reverted (CAMRev) resulted in a loss of fitness, indicating the drug-resistance 
allele was preferred. Unfortunately, for the first experiment, a 3D7 contamination became 
evident above the sequencing noise threshold after day 32 (dashed line), and similar to the 
observation from section 5.3.2.5, 3D7 rapidly outgrew both clones of CAM resulting in 
termination of the experiment. The second experiment shown in Fig. 5.10B shows a consistent 
and striking difference in the growth of the two clones, as the Y580C revertant is outcompeted 
by the wild type CAM.  A t-test on the average change in proportion of the two clones in this 
experiment showed the difference to be statistically significant (p-value = 1.26x10-9).  
  
The results from performing competition assays on variants generated in isogenic 
backgrounds show: 1. The artemisinin-resistance variant C580Y in a KEL1 lineage provides 
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enhanced fitness relative to the sensitive allele, whereas in a standard laboratory strain 3D7 the 
opposite effect on fitness is observed indicating that there might be an epistatic interaction 
that differs across strains, impacting differentially on fitness. 2. The importance of having 
isogenic control clones competing together when performing these assays is highlighted, as 
minor differences will only be evident in this context. When mixing highly diversified strains, 
such as 3D7 and CAM the resolution of the contribution of particular alleles to fitness is easily 
lost. In order to investigate the rate at which each clone decreased in proportion over time, a 
linear regression was used following the same approach as in section 5.3.2.5. Figures 5.9C and 
5.10C show the ratio of the mutant to the wild type allele for 3D7 and CAM, respectively. For 
both cases, a linear regression of the ratio resulted in a negative slope, indicating a reduced 
growth for the mutated allele, for both experiments. 
    
   
      
       
 
      
     
    







Figure 5. 9 Amplicon sequencing strategy used to measure the relative proportion of isogenic lines of 3D7, with 
Pfkelch13 alleles generated using CRISPR/Cas9-based editing.  
A-B. Two independent experiments showing competition assays of two clones lasting 54 days (A), or 35 days (B) 
(time shown on x-axis), with technical triplicates. The relative allele proportion is shown on the y-axis, and for both 
A and B, on the right the change in relative proportion from day 20 until the end of the assay are shown in a log - 
base - 2 scale. An unpaired two-sample t-test was performed for both experiments, and significance levels are 
shown. C. A second approach to measure the difference in growth across strains by performing a linear regression 
on the ratio of mutated to wild-type alleles for the two experiments. 
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Figure 5. 10 Amplicon sequencing strategy used to measure the relative proportion of isogenic lines of CAM, 
with Pfkelch13 alleles generated using CRISPR/Cas9-based editing.  
A-B. Two independent experiments showing competition assays of two clones lasting 54 days (A), or 35 days (B) 
(time shown on x-axis), with technical triplicates. The dashed line on experiment 1 is explained in detail in section 
5.3.2.6, and refers to a 3D7 contamination taking over the culture from this day. The relative allele proportion is 
shown on the y-axis, and for both A and B, on the right the change in relative proportion from day 20 until the end 
of the assay are shown in a log2 scale. An unpaired two-sample t-test was performed for both experiments, and 
significance levels are shown. C. A second approach to measure the difference in growth across strains by 
performing a linear regression on the ratio of mutated to wild-type alleles for the two experiments. 
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5.3.3 Why “Y”? – The role of genetic background in tolerating resistance- 
associated mutations. 
5.3.3.1 CRISPR/Cas9-based editing and high throughput sequencing reveal the impact of 
genetic background in tolerating mutations in pfkelch13  
From the results of the competition assays, it became clear that the Y580 allele in 
Pfkelch13 differentially impacts fitness for two different backgrounds studied: 3D7 and CAM. 
There is a background-specific effect that allows for growth to be enhanced while sustaining 
the artemisinin-resistant allele, which could be a result of positive epistasis, as described earlier 
(He et al. 2010). In order to validate the phenotypes observed, and to bring some molecular 
evidence to support the striking epidemiology of the KEL1 lineage in Southeast Asia (Amato et 
al. 2018), a novel strategy was developed that combines CRISPR/Cas9-based editing and high 
throughput sequencing in order to generate mutant lines for Pfkelch13 that have the potential 
to encode any codon at position 580, in effect mimicking spontaneous mutation at this 
important residue. But using different genetic backgrounds and an amplicon sequencing 
strategy to measure the complexity of mutants obtained post-transfection, the aim was to test 
whether differences in genetic background would result in different outcomes. The strategy is 
shown in Fig. 5.11. This donor template for this approach was synthesised so that it would 
contain a homology sequence of 750bp, containing 100bp recodonised as described in section 
5.3.1.1, and at position 580 contain a random codon to repair to. To accomplish this, a gBlock 
(IDT) was synthesized (section 2.3.2.1), providing as template NNN in the described position, 
meaning that within the pool of donors, all possible codons should be represented. The donor 
sequence was assembled in triplicate reactions following the same protocol as shown in Fig. 
5.1B using Gibson assembly, and then transformed into competent cells as in section 2.3.2.7 
and recovered in a large culture volume to proceed directly to midiprep in order to maintain 
library complexity. To verify the complexity of the plasmid pool, a fraction of the 
transformation was plated and 12 minipreps were performed from colonies generated, for 
Sanger sequencing as shown in Fig. 5.12A. By sequencing 12 clones, an estimate of the 
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complexity of the pool could be assessed, showing 10 different codons, including stop codon 
TAG.  
To fully assess that the plasmid mixture was a highly complex pool representing all 
possible amino acids, as was suggested from Sanger sequencing of a small number of individual 
clones, an amplicon sequencing strategy was developed as shown in Fig. 5.11A-B. The 
proportion of each of the 64 codons   with the donor pool is shown as a log10 scale on the y-
axis, and the codon on the x-axis. Leucine had three codons that were not well represented in 
the pool (CTN for Leu), however alternate codons TTA and TTG were well represented. From 
this result we were able to confirm a good representation of all possible amino acids (shown in 





































Figure 5. 11 Overview of method for generation of libraries compatible with Illumina platform MiSeq.  
A. Design of donor sequence with 100bp of recodonised region, and flanking regions totaling 750bp. The fragment 
was synthesized as a gBlock to assemble using Gibson into a pDC2 backbone previously digested with EcoRI and 
AatII. B. Template for nested PCR approach uses primers p1572 and p1493 containing constant binding sites for 
Illumina adapters (sequence in green). Gray box highlights the recodonised region and position 580, which can 
encode any codon. Red box shows sequences used as “barcodes” for amplicon sequencing, from raw fastq reads 




























Figure 5. 12 Genotyping of plasmid pool of pDC2 backbone with recodonised donor sequence for homology-
directed repair of Pfkelch13, with NNN representing any codon to replace position 580.   
A. Sanger sequencing of bacterial clones after transformation with plasmid codon pool”, showing 12 independent 
clones and 10 unique codons, including stop codon TAG. B. Codon complexity of transfection-ready plasmid pool 
measured by Next Generation Sequencing, the y-axis showing the proportion of each codon on a log10 scale. 
Leucine codons CTN were underrepresented, however codons TTA and TTG are present for this amino acid. C. Pie 
chart showing the proportion of amino acids by taking the average of the different codons shown in (B). 
 
Parasites were transfected with the pooled donors using the protocol described (2.2.1.2 
and 2.2.1.3). Once parasites became visible by microscopy they were expanded and genotyped 
to confirm editing (as in 2.3.1), prior to amplicon sequence of the 580 position. Overall, more 
than 60 transfections were performed into different genetic backgrounds listed in table 2.1.  
The time it took the different strains to come up post-transfection varied across strains: 
transfections in a CAM background took over 35 days, whereas non-Cambodian backgrounds 
took between 20-30. Additionally, the integration efficiency was assessed by using primers that 
would amplify outside the region of homology, and a primer that would only amplify either the 
mutated, or wild type locus. Only transfections which showed a high editing efficiency as 
measured by PCR and Sanger sequencing were submitted for Next Generation Sequencing. Fig. 
5.13 shows the proportion of each amino acid in the total read counts for each transfection for 
which a library was prepared using amplicon sequencing. It was shown previously in section 
5.3.2.6 that for the CAM strain from the KEL1 parasite lineage, there was a fitness advantage by 
harbouring the Y580 allele in Pfkelch13. Notably, through this new approach that provides all 
possible codons for incorporation, when the codon complexity of the transfected parasites was 
analysed, the only strain that had incorporated tyrosine at the 580 position was CAM. This 
result provides strong support for the hypothesis that there is positive epistasis in this genetic 
background which may be facilitating the spread of resistant parasites due to enhanced fitness 
coupled with drug resistance. It should be noted that any native tyrosine would not be counted 
because only mutated parasites could be amplified using the recodonised region that was 
designed for the donor sequence, as shown in Fig. 5.11B.  
Neither of the codons encoding for tyrosine were obtained in any of the other genetic 
backgrounds used for this study.  In addition to cysteine, however, there were multiple codons 
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that were obtained by using this approach. From epidemiological studies, mutations in 
Pfkelch13 which have been linked to clinical artemisinin resistance in Southeast Asia have 
mostly been mapped to the propeller domain of Pfkelch13, which has been associated in other 
organisms as being involved in protein homodimerization for nuclear translocation (Zipper and 
Mulcahy 2002). Because of the essential function of this domain, understanding how mutations 
conferring artemisinin resistance affect the structure of the protein is essential. In 2016, Singh 
et al. published a study in which these mutations were mapped to the six-blade structure of this 
protein. Their analysis was based on the crystal structure of Kelch13 of P. falciparum deposited 
in the Protein Database (PDB 4yy8 or 4zgc). Fig. 5.14 shows the structural mapping of these 
resistance mutations in the propeller domain performed by the authors, with residue 580 
located at the central channel. The structural model shows residues falling into three clusters: 
main clusters 1 and 2 containing most residues (red and yellow, respectively), and residues 
C580 and Y493 falling in between the two clusters, labelled in green. Analysis of clinical parasite 
samples containing mutations in Pfkelch13 revealed that mutations in the second cluster were 
less common than cluster 1, and these residues are not surface exposed, therefore mutations 
would likely affect the structure of the protein. C580, the most prevalent residue mutated in 
Southeast Asia, was expected to form a disulfide bond with C532 (PDB 4zgc), and a hydrogen-
bond with G533 (PDB 4yy8) (Singh et al. 2016).  
My data indicates there are four major amino acids that can replace Cys at position 580, 
meaning that they can be structurally accepted, and the impact they might have on the 
different genetic backgrounds will be discussed in section 5.4. For the non-Cambodian, non-
artemisinin tolerant genetic backgrounds, changes to amino acid serine (TCG), isoleucine (ATC) 
methionine (ATG), valine (GTT) and back to cysteine (TGT) were obtained. CAM, on the other 
hand, is the only background tolerating tyrosine (TAT), plus additional codons for cysteine 
(TGT), serine (TGC and AGC), glycine (GGA) and lysine (AAG), and their implications in terms of 
structure will also be discussed. Overall, these results provide evidence that epistasis might be 







Figure 5. 13 Pie charts showing a summary of the different transfections analysed by amplicon sequencing.  
The original Pfkelch13 haplotype is noted on the right, and in brackets the transfection number, with multiple 
transfections performed for Dd2 and CAM. The proportion of alleles only represent mutated parasites and not 





























Figure 5. 14 Modeling of the propeller domain of K13 from Singh et al. 2016.  
Figure shows 19 mutations identified in genome sequencing studies, some with clinical relevance measured as 
delayed parasite clearance or by performing in vitro or in vivo RSA(0-3h). Red and yellow indicate the two clusters 
identified. Green corresponds to the two residues that were not in any of the identified clusters: C580 and D584. 
The numbers indicate the different blades conforming to the propeller domain (Reproduced from Singh et al. 
2016)  (Singh et al. 2016). 
 
To understand whether any of these alternate codons were found in other Plasmodium 
species, we downloaded all the genome assemblies available for this genus from NCBI RefSeq, 
using a script developed by NCBI (https://github.com/kblin/ncbi-genome-download). The 
sequence of the gene of interest for reference strain 3D7 (kelch, with RefSeq ID CAD52567.1) 
was blasted against all the sequences that were downloaded for the other species in order to 
generate a multiple sequence alignment, using the software MAFFT, from the European 
Bioinformatics Institute (https://www.ebi.ac.uk/Tools/msa/mafft/). This alignment was used to 
build a distance matrix for inferring phylogenies using FastTree (M. N. Price, Dehal, and Arkin 
2009), and for visualization the ETE3 toolkit was used (http://etetoolkit.org/). Fig. 5.15 shows a 
phylogenetic tree and a region of 50 amino acids, with C580 highlighted in yellow. The cluster 
of P. falciparum is composed of all the sequences that were available from isolates deposited at 
NCBI, which did not contain any artemisinin resistant strain with the C580Y mutation. From our 
codon editing results, the most frequently obtained alternative codon was serine, with two 
codons observed: TCG and AGC. By building the tree of Kelch sequences shown in Fig. 5.15, we 
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observed that serine was the only amino acid that existed as an alternative to the highly 
conserved cysteine observed across all the Plasmodium species used for the alignment, and was 
found in Plasmodium gallinaceum and Plasmodium relictum, both avian malaria parasites. The 
presence of serine at position 580 in Kelch proteins from other Plasmodium species suggests 


















Figure 5. 15 Phylogenetic tree using a distance matrix generated using FastTree from an alignment of K13 
sequences across all the Plasmodium species.  
Sequences used were available from NCBI. Only a segment containing 50 amino acids is shown, with residue 580 
highlighted in yellow, with only one alternative amino acid present in two of the Plasmodium species used for this 
analysis. 
 
5.4 Discussion and future work 
The interest in this chapter was to characterise the impact of K13 mutations on a 
Cambodian strain belonging to the KEL1 lineage from Southeast Asia(Amato et al. 2018).  I 
started with the hypothesis that spread of this lineage carrying the C580Y mutation in K13 could 
be related to fitness, with certain genetic backgrounds better tolerating these resistance-
associated polymorphisms, and that this may be one of the factors underlying the current 
 absence of K13-mediated artemisinin resistance in Africa (Henriques et al. 2015). Previous 
studies had shown that C580Y impacted fitness differently depending on the genetic 
background (Straimer et al. 2017), either in a negative or neutral manner. In addition, the 
C580Y mutation incurred a higher “cost” compared to the impact of a different, less widespread 
K13 variant seen in the Thai-Myanmar border(Nair et al. 2018). Overall, both studies ultimately 
highlighted two aims that should be considered carefully to improve drug resistance 
surveillance: 1. The importance of understanding the fitness landscapes of P. falciparum 
parasites at a local and global scale, and 2. That genetic background is important and can 
differentially modulate the phenotypic outcome when a selection pressure is applied. The 
starting point for the experiments performed in this chapter was, therefore, to understand why 
even though resistance-associated variants can emerge spontaneously (Amato et al. 2018), only 
certain genetic backgrounds might facilitate spread. 
In this chapter I used a CRISPR/Cas9-based editing approach in two different strategies 
for site-specific genome editing of K13, a gene encoding for a protein shown to be involved in 
mechanisms of resistance to frontline antimalarial artemisinin in Southeast Asia. The first donor 
design strategy for making the targeting constructs contained the single positions to be 
mutated in the gene (e.g. C580Y, Y580C and A578S), and silent mutations at the PAM site to 
protect the locus from further cleavage by Cas9 (Ghorbal et al. 2014). The second strategy 
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introduced a recodonised (“silent”) sequence of 100bp that would facilitate genotyping and 
would potentially improve efficiency of capturing the desired mutation. Both strategies worked 
for mutating K13, and were used to tackle questions regarding the impact of particular genetic 
backgrounds to parasite fitness. 
The extent to which C580Y has a background-specific effect on the different strains 
used, and in particular on CAM, was studied following the first donor strategy described. 
Competition assays and amplicon sequencing for all five clones described (from both 3D7 and 
CAM), confirmed a need for using isogenic clones, rather than combining different strains, for 
long term co-culture. The latter conclusion came from the finding that the growth rate of 3D7 is 
higher than CAM, and that after less than ten cycles, it outcompetes the less fit strain. For this 
reason, minor differences between isogenic clones carrying these epidemiologically relevant 
alleles might be obscured (Fig. 5.7). The outcome of this first experiment led me to a similar 
conclusion as with the competition assays performed with the different strains barcoded in 
Pfrh3: difference in growth across different strains can be a consequence of varying 
multiplication rates, or an effect of an altered invasion phenotype. However, I also show 
evidence that combining the two strains, regardless of the different growth rates, can be used 
as a tool to perform short-term pooled assays (up to eight days) in the presence of antimalarial 
compounds to study the effect of K13 mutations on modulating response to other 
antimalarials, in a similar way as what was shown in section 4.3.2.2.  Interestingly, these results 
showed that K13 Y580 in CAM results in higher tolerance to halofantrine, a result which will be 
validated given the important epidemiological consequences for the field (Fig. 5.8). 
By competing isogenic clones head-to-head, I showed that C580Y displayed a fitness 
cost in the 3D7 background, however this effect only became significant after 20 days of 
continuous co-culturing. Future competition assays will explore the impact of changing the ratio 
of each clone to understand how it impacts the overall fitness of the less fit clone. For example, 
from the first competition assays, the initial parasitaemia of both lines was not the same, and 
the wild type strain started with an initial proportion of the total reads of 75% (Fig. 5.9). Several 
reasons might explain this. First, if there was a difference in stage between the two lines, that 
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might explain the initial fluctuations in total genomes until cultures became more 
asynchronous. However, this was carefully monitored by Giemsa smear, therefore this is 
unlikely to be the reason for the skew in the ratio WT/MUT. Second, if the haematocrit was not 
the same from the start of the experiment, it is possible that a 3-fold difference in the initial 
proportions might be partly due to an excess in red blood cells in the wild type clones. I think 
that this is one plausible explanation and, in the future, I will perform total cell counts using a 
haemocytometer before initiating competition assays.  Overall however, the allele proportion 
remains unchanged over the first 20 days, indicating that perhaps a skew in the initial 
proportion would not impact the outcome of the competition or the study of the effect this 
particular allele (K13) has on fitness. A similar observation was published in two independent 
studies while this work was being performed, showing that Y580 has a fitness cost that differs 
based on genetic background (Judith Straimer et al. 2017), and that when introduced into a 
wild type parasite, it has a higher “cost” than other K13 mutations seen in the field (Nair et al. 
2018). My results are consistent with both of these studies and with many other studies 
showing how resistance-associated mutations can impact fitness negatively in other organisms 
(Andersson and Hughes 2010). 
To understand the extent to which C580Y is acting as a driver in the epidemiology of 
KEL1, I competed the C580 or Y580 alleles in the CAM background, which originally possessed a 
K13 Y580 haplotype. Strikingly, the results of the competition assay on these isogenic clones 
showed a distinct fitness cost when the allele was mutated to C580 (Fig. 5.10). The first 
experiment, however, did not reveal a strong phenotype because of a contamination with 3D7 
that only became detectable after 20 days of competition, resulting in a drop in total counts for 
the CAM lines and potentially suppressing the growth difference, which in this experiment was 
not-significant (p-value ns). As described earlier, 3D7 has a higher growth rate than most strains 
used throughout this work, as seen in chapter 4 with the mixture that contained 3D7, V1/S and 
CAM. The second competition experiment, however, showed a striking difference between the 
two isogenic clones carrying the K13 alleles: after 35 days of competition, CAMrev was 
completely outcompeted, and a t-test between the two clones revealed a significant difference 
in the change in their relative proportion over time (p-value = 1.26x10-9). This result provides 
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the first direct experimental evidence that the establishment of the K13 Y580 allele on the KEL1 
lineage has occurred on a supportive genetic background that is facilitating the outbreak and 
spread of this allele in Southeast Asia. I consider that these results indicate that a positive 
epistasis might be occurring in this genetic background in which multiple potentially deleterious 
or neutral mutations act in combination to enhancing fitness. Future work to understand the 
nature of the growth difference will include other phenotypic measurements such as merozoite 
numbers (Bunditvorapoom et al. 2018), invasion of host RBCs, and fitness assays on different 
clones to evaluate their phenotypes in competition with the wild type clone. We also plan to 
expand the analysis of the whole genome sequences and try to identify whether potential off-
targets of Cas9 might have introduced other variants that might be impacting fitness. Although 
whole genome sequencing was performed, variants were called using the reference genome 
3D7, meaning that it was not possible to detect variants that were different across CAM clones. 
By combining fitness and drug susceptibility assays throughout this dissertation, I have 
been able to characterize the impact of an important allele for artemisinin susceptibility in 
Southeast Asia, by parallel phenotyping and Next Generation Sequencing. In addition to this, in 
the current chapter I have been able to establish the importance of specific genetic 
backgrounds in modulating fitness, and hypothesized that a positive epistasis in a KEL1 lineage 
might be the reason for the spread of this allele in Southeast Asia. To try to strengthen the 
validity of this finding, I designed a novel experimental approach by which parasites from 
different genetic backgrounds were provided with a pool of plasmids containing any possible 
codon for replacement of 580 in K13. These results support the findings from the competition 
assays on isogenic clones, as the only strain for which the Y580 codon was obtained after 
transfection was CAM, implying a possible high fitness cost of this allele in non-KEL1 
backgrounds. In addition, all strains tested showed a combination of codons comprising a small 
number of amino acids, for which the most common alternative was serine. Notably, serine is 
the only other amino acid apart from cysteine and tyrosine at position 580 observed across 
sequenced Plasmodium species (Fig. 5.17).  
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Amongst the next steps towards validating the relevance of the KEL1 genetic 
background for spread of artemisinin-resistant alleles, I have now generated clones for the 
different codons obtained and will perform RSA(0-3h) and fitness assays to test their impact on 
these phenotypes. In addition, I will transfect the pool of all possible codons into multiple 
parasite backgrounds belonging to the recent outbreak of parasites resistant to both DHA and 
piperaquine (a lineage described as KEL1/PLA1 by Amato et al., 2018), as well as recent 
Cambodian non-KEL1/PLA1 lineages in order to validate the findings. Based on the modelling 
data from Singh et al. I will mutate residue C532 of K13, which based on the predicted structure 
of the propeller domain may form a disulfide bridge with C580. This disulfide bond would be 
disrupted by a C580 to Y580 mutation, and would lead to free SH group from the C532 residue, 
which could potentially act as a sensor of artemisinin resistance. If mutation of C532 in a 
artemisinin-sensitive background results in increased tolerance, or if in an artemisinin-resistant 
background C532 mutation reverts the resistant phenotype to sensitive, it would contribute to 
a mechanistic understanding of the impact of the C580Y polymorphism. Regardless of outcome, 
performing fitness assays at a large scale in the strains mentioned will be informative in 
dissecting the relevance of the genetic background for surveillance and control of the spread of 
these artemisinin resistant alleles in Southeast Asia. 
In Southeast Asia, and particularly in Cambodia, the amount of time that some drug-
resistance alleles remain within a population has been shown to be longer than in Africa. An 
example are the mutations in Pfcrt that still remain at high frequencies in Southeast Asia, 
particularly Thailand and Cambodia, where no chloroquine has been used for the treatment of 
P. falciparum malaria since the early 1990s (Lim et al. 2003; Mwai et al. 2009). On the other 
end, the example of chloroquine-resistant alleles in Malawi reverting back to the reference 
sequence, which led to sensitivity to this compound being regained, show local epidemiology 
and population structure can also impact maintenance of alleles with high fitness costs (Kublin 
et al. 2003). These are examples of the complex nature of the maintenance and spread of 
alleles associated with drug resistance. For the case of artemisinin, there is much less evidence 
of a population-specific effect on resistance and fitness, as K13-mediated artemisinin resistance 
has been successfully maintained in some parts in Southeast Asia (Woodrow and White 2016). 
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My results thus far and my ongoing experimental work will provide valuable evidence for the 
field on the importance of identifying genetic backgrounds tolerating resistance-associated 
mutations, and how population structure and genetic diversity might be facilitating spread of 
these alleles. It is also important to highlight that the work presented focuses on a genetic 
background which has dominated as part of the current outbreak of artemisinin resistance in 
Southeast Asia. This understanding is therefore relevant to malaria intervention strategies in 
highly endemic regions, as an active surveillance for other mechanisms of resistance or changes 
in the fitness landscape in African parasites will be important for containing the spread of 
resistance- or fitness-associated alleles. Even though genomics has made an enormous 
contribution to the understanding of drug resistant populations that have been under strong 
selective pressures from antimalarial drugs (Mackinnon and Marsh 2010), there is a need for 
experimental validation of these findings. Understanding pathways leading to an increased 
fitness in drug-resistant parasites or compensatory mutations, as we have seen on a KEL1 
parasite lineage, will be essential, and genome-based editing approaches are reaching a point 
at which large-scale population genetics studies having become affordable and easier to 
validate these findings. Finally, the validity of these studies at this moment only applies to the 
in vitro experimental work presented. It will be important to translate these questions to other 
elements of parasite fitness in the natural environment. For example, understanding whether 
these variants impact transmission or if the fitness effects are restricted only to the blood 
stages. Therefore, expanding these studies to cover more field isolates and to be able to test 
them for fertility and transmission capabilities are all important steps that we hope this work 








Chapter 6: Conclusions and future work 
 
Over the past decade there has been a significant increase in the attention to and 
money spent on global malaria control, with local elimination and country-wide malaria 
eradication targeted in many areas. There is no question that these efforts have had an 
enormous effect on reducing mortality, due to more efficient vector control, improvement in 
diagnostics, and effective chemotherapies (Hemingway et al. 2016). However, each of these 
pillars supporting recent progress are under threat. Some examples are the spread of 
insecticide resistance (Anopheles gambiae 1000 Genomes Consortium et al. 2017) , the failure 
of rapid diagnostic tests coming from deletions in HRP2/3 (H. Gupta et al. 2017), and finally, the 
emergence and spread of antimalarial drug resistance (Amato et al. 2018). Parasite populations 
in Southeast Asia appear to be the epicentre of malaria drug resistance (Blasco et al. 2017) 
across multiple drug classes. Resistance to quinolines has been an ongoing problem, and there 
has been independent emergence of resistance in various places (Payne 1987). The example of 
chloroquine resistance is particularly notable, which reached such high levels that it had to be 
removed as treatment for P. falciparum malaria (Fidock et al. 2000). Other examples from the 
quinoline class where resistance has emerged to monotherapy are still being used in 
combination with the current frontline antimalarial artemisinin. Some of the combinations with 
quinolines which are currently in use include mefloquine-artesunate, lumefantrine-arthemeter, 
and piperaquine-dihydroartemisinin (Alker et al. 2007; Taylor and Juliano 2014), and resistance 
threatens all of these partner drugs. Resistance is now clearly an issue for artemisinin itself. 
Artemisinin is both a fast-acting drug, primarily on early ring-stages circulating in the blood, and 
a short half-life drug (Dondorp et al. 2010). This particular mode of action made it particularly 
important to anticipate resistance emerging from a monotherapy, which was studied by Noedl 
et al., and later confirmed through various studies of populations of parasite isolates (Noedl et 
al. 2008; Miotto et al. 2015). Given this, partner drugs were deliberately chosen to act on more 
mature erythrocytic stages and to have a longer half-life, to act as cover for any parasites that 
remain after the short-lived artemisinin pulse has been eliminated from the body (Eastman and 
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Fidock 2009). Despite these precautions, treatment failure to ACTs have now been defined by 
different assays and are compound-specific: an in vivo prolonged parasite clearance for 
artemisinin treatment failure (Noedl et al. 2008), in vitro phenotype measured by RSA (Benoit 
Witkowski et al. 2013), and evidence of recrudescence upon treatment of parasites with a 
partner drug, piperaquine (Duru et al. 2015). 
Identifying genetic markers associated with these phenotypes has been accelerated 
because access to whole genome sequencing has become more affordable and ultimately more 
ubiquitous, leading to thousands of parasite isolates being sequenced yearly through collective 
efforts. The expansion of P. falciparum genomics since deep sequencing on clinical isolates was 
first reported (Manske et al. 2012) is striking. These approaches have allowed for a careful 
surveillance of the genetics of P. falciparum isolates pre- and post-intervention policies. A study 
by Miotto et al. is an example in which genomics were used to dissect the epidemiology of 
artemisinin resistance. The authors used a Genome-Wide Association Study (GWAS) to help 
identify markers of a correlation of genotype-to-phenotype in populations with high levels of 
resistance, and identified K13 mutations that had reached high levels of fixation. Not only did 
these studies confirm the pioneering work of Ariey et al. identifying K13 as a molecular marker 
of artemisinin resistance, but also identified other markers linked to the resistance phenotype 
(section 1.4.5.3) (Ariey et al. 2014). Mutations in ferredoxin, PfCRT (chloroquine resistance 
transporter), ARPS10 (apicoplast ribosomal protein S10) and MDR2 (multidrug resistance 
protein 2) were all variants linked to a high-resistance phenotype in at least one of the sample 
groups selected. A reasonable explanation as to why these mutations are at high levels of 
fixation (FST) among these drug-resistant populations is that they might be compensating for a 
fitness loss, thus acting as a “genetic background” that can tolerate resistance-associated 
polymorphisms such as mutations in K13 (Miotto et al. 2015). Testing this hypothesis requires 
experimental studies to attribute function to mutations on resistant and sensitive parasite 
lineages from highly endemic countries, as well as understanding the process by which these 
mutations were acquired over time. Such experiments would allow us to tackle questions such 
as 1. did the genetic background have to be there for K13-C580Y to be successfully maintained, 
and 2. are those mutations epistatic? 
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We are currently at a time when experimental genetics can be performed at scale in 
many organisms (Wang et al. 2014). One of the obvious benefits of increasing the throughput 
of experimental approaches to P. falciparum will be to improve surveillance of this deadly 
disease, by functionally testing the impact of genomic variants that emerge in the field. Because 
of the urgent need to develop tools that can keep up with results from genomic studies, the 
first chapter of this dissertation was focused on understand transfection efficiency and 
dynamics by using a barcode sequencing approach in this species for the first time. The idea of 
generating dozens of mutants within a single transfection, as had been performed successfully 
in both P. berghei and T. gondii. (Sidik et al. 2016; Bushell et al. 2017), was the main objective 
of these experiments. Performing transfections with a pool of plasmids containing unique DNA 
barcodes revealed that while multiple different plasmids were successfully maintained 
episomally, by analysing the sequencing reads at the bulk and clonal levels it became clear that 
individual parasites were taking up multiple plasmids. These results are valuable for the field 
because of their implications for performing large-scale reverse genetic screens, for example, to 
target candidate genes involved in drug resistance mechanisms. Also, they could be valuable to 
understand the compensatory mechanisms taking place under certain selective pressures, or to 
validate GWAS hits and study the effects of particular alleles on a phenotype in a combinatorial 
manner, and measure their epistatic interactions and the phenotypic outcome. 
In the same chapter, I was able to establish that the pseudogene Pfrh3 could be used as 
a safe harbour for barcode insertion, which led to the generation of barcoded parasite strains, 
each with different sensitivities to antimalarials. By pooling these barcoded lines I was able to 
test different antimalarial drugs and use barcode sequencing (BarSeq) to measure growth 
phenotypes by analysing sequencing reads. While resistance phenotypes could be generated, 
the results also showed that strains varied in their relative growth rates when put in 
competition even in the absence of any drug, and drug resistant strains were rapidly 
outcompeted. The implications this might have on the epidemiology of drug resistance 
challenge the perceptions on what the best strategies for containment are, and suggest that 
the high fitness costs of K13-mediated artemisinin resistance might prevent these alleles from 
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spreading to geographical regions where transmission is high and competition from genetically 
diverse strains is also high.   
To tackle this question, future work might entail using BarSeq technology systematically 
on parasite clones carrying different combinations of fitness-conferring mutations, or 
compensatory mutations such as those from the Miotto et al. study. Such an approach would 
allow us to understand the fitness landscapes of these highly-resistant parasites from Southeast 
Asia, and compare them with parasite isolates from epidemiologically distant regions. This 
would allow us to identify alleles, or more accurately combinations of alleles, that should be 
under careful monitoring. Overall, this chapter sets the grounds for performing parallel 
phenotyping at scale by using NGS in some of the lines selected to study the effects of 
particular genetic backgrounds on fitness in artemisinin-resistant parasites. These pilot studies 
led to the experimental design to address the main objective for the last results chapter. 
Without a clear understanding of the effect of the “genetic background”, the extent to 
which pathways leading to resistance will be the same in countries where parasite populations 
and local epidemiology vary greatly cannot be easily predicted. In the approach taken by Ariey 
et al., a Tanzanian isolate (F32-ART5) was selected for resistance for over 120 generations with 
artemisinin. Strikingly, in this experimental design, other than K13 none of the genes from the 
Miotto et al. GWAS were acquired during selection (Ariey et al. 2014). How these long-term 
selections such as the one by Ariey et al. can be extrapolated to real-time evolution of parasites 
in the field remains unknown. One implication is that effectively, not all parasites are “made” in 
the same way, and that even though local emergence of resistance is possible in the different 
geographical regions (Alifrangis et al. 2014; Sá et al. 2009; Amato et al. 2016), certain strains 
are more efficient in spreading these variants, likely due to intrinsic differences in fitness. This 
study therefore highlights how the use of genomics at the population level can support other 
experimental approaches like the one used by Ariey et al. This also highlights the fact that more 
focus should be given to finding ways to validate the functional impact of natural variation 
under strong selective pressures, and scaling up experimental genetics is an obvious next step. 
Additional examples in which genomic studies were linked to drug resistance phenotypes came 
from two recent studies by Amato et al. 2017 and Witkowski et al. 2017(Amato et al. 2017; 
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Benoit Witkowski et al. 2017). In both, a surrogate marker of piperaquine resistance was 
identified: amplifications in two genes, plasmepsin 2 and 3 were present in genomic samples 
from recrudescent Cambodian isolates after treatment with DHA-PPQ. In the study by Amato et 
al., two other genes showed an association with recrudescence: mutations in an exonuclease, 
and in an MCP (mitochondrial carrier protein), both of which are being studied in the Lee group 
at the Sanger Institute. The signal that was more strongly linked with the recrudescence 
phenotype, however, was the copy number variation in plasmepsins 2 and 3. Later studies 
showed that the recent outbreak of DHA/PPQ-resistant parasites arose on a K13-C580Y 
background (KEL1/PLA1)(Amato et al. 2018), emphasising that while local emergence of 
resistance in Southeast Asia occurs frequently, only some lineages are able to take over other 
local populations, suggesting special attention should be paid to particular combinations of 
alleles. 
Several recent studies have begun to investigate these markers functionally. To date, 
amplification of plasmepsins 2 and 3 have not shown an appreciable effect on resistance, 
whereas emerging Pfcrt mutations in Cambodian parasites demonstrate a more robust drug 
sensitivity shift and recrudescence phenotype. Notably, Ross et al., suggest that the 
amplification of the plasmepsin genes was instead a compensatory mechanism to alleviate the 
fitness cost in these parasites with novel pfcrt haplotypes (Ross et al. 2018). This example 
shows that genomic studies can help in surveillance efforts, however the extent to which they 
impact the parasite at the molecular level needs to be evaluated carefully with experimental 
approaches such as the ones developed through this dissertation, to inform any implications for 
malaria control. 
Given the evidence that background has played a key role in the spread of the 
KEL1/PLA1 lineage, the aim of the last chapter was to tackle the questions of the impact of 
genetic background on the in vitro fitness of P. falciparum parasites (chapter 5), by using a 
strain belonging to the KEL1 background. Several different approaches could be taken to 
investigate this - some are envisioned as future work, while others were developed 
experimentally in this chapter. These include: 1) identify parasite isolates which contain the 
“genetic background” (KEL1 vs. non-KEL1), and study their fitness in vitro by performing assays 
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as described (section 5.3.2), 2) use CRISPR/Cas9-based editing to introduce combinations of 
these mutations into a standard laboratory strain like Dd2. This approach might be ideal 
because it uses a constant genetic background, but it has the limitation of given it critically 
relying on the ability to eliminate any remaining episomes in order to perform sequential 
transfections. The limited number of selectable markers could also make this appraoch 
challenging (Ganesan et al. 2011). 3) Transfecting multiple genetic backgrounds (section 5.3.3), 
and replacing codon 580 of K13 in all of them would shed light on which genetic backgrounds 
can tolerate this change that can lead to an increased survival to artemisinin, and would help 
prioritise alleles for functional analysis.   
To start addressing these questions, CRISPR/Cas9-based gene editing was used to revert 
the C580Y mutation in K13 in a Cambodian KEL1 parasite strain referred to as CAM. In order to 
have a comparative study of the effect a particular allele has on fitness, the same mutation was 
introduced into the standard, laboratory strain 3D7. Unsurprisingly, and in concordance with 
recent evidence on the fitness costs of C580Y in non-KEL1 backgrounds (Straimer et al. 2017; 
Nair et al. 2018), this change had a moderate fitness cost in a 3D7 background (Fig 5.9).  By 
contrast, by reverting the Y580 back to C580 (reference allele) in CAM, parasites became less fit 
(Fig. 5.10). This evidence supports the hypothesis of a positive epistasis in a KEL1 lineage, which 
resulted in an enhanced fitness that may have allowed these parasites to spread rapidly and 
take over other, less fit populations. Finally, I presented a radically different approach in which 
multiple genetic backgrounds were edited with a plasmid pool containing all possible codons to 
replace position 580 in K13, provided as a recodonised donor sequence. Supporting the finding 
from the competition assays using edited 3D7 and CAM lines, CAM was the only background 
that preferentially tolerated Y580, whereas all other backgrounds either emerged with the 
reference allele (Cys), or to potentially structurally tolerable changes (e.g. serine, Fig 5.14). 
Future work entailing phenotypic assays on all the viable allele changes will include assays to 
evaluate whether disrupting the predicted disulfide bridge between C580 and C532 has a 
background-specific phenotypic outcome by measuring both RSA(0-3h) and fitness via amplicon 
sequencing. In addition to this, Pfkelch13-editing transfections will be performed in other 
Cambodian backgrounds belonging to: 1) The recent KEL1/PLA1 lineage described by Amato et 
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al., to understand the impact of C580Y. Following the recent findings by Ross et al. suggesting 
amplifications in plasmepsins 2 and 3 are compensating for fitness losses from pfcrt mutations 
linked with piperaquine resistance, representative piperaquine-resistant strains will also be 
evaluated. 2) non-KEL1 backgrounds as a proof-of-concept to confirm the current preliminary 
findings in other genetic backgrounds (V1/S, Dd2, 3D7 and 7G8 in Fig. 5.14) that C580Y has a 
fitness cost except on the KEL1 background. The outcome of this work, therefore, will be 
valuable for the field as it will provide a broader picture of the fitness landscapes of K13-
mediated artemisinin resistance in Southeast Asia. 
Some of the aspects of this work that will be expanded in the future are the lack of 
replication for some of the experiments performed. Particularly, some of the competition 
assays do not have enough biological replicates, therefore it is not possible to determine, 
despite a clear general trend, what the relative fitness of the competing strains are whilst 
providing robust statistical power to the differences observed. In general, the analyses 
performed were using the data points available for each experiment, by comparing the means 
of the difference in growth rate over time. However, the limitations described do not allow for 
significance levels to be determined accurately. This particular issue is the major weakness of 
this work and will be at the epicenter for future experimental work in order to conclude it. In 
addition to this, there are multiple factors of the experimental design that require careful 
analysis, for example how to deal with biological noise, as observed in some of the competition 
assays presented. For this reason, novel approaches will be employed in an attempt to resolve 
the noise coming from the first days of competition. Performing a tighter synchronization, 
together with an accurate adjustment of parasitemia and hematocrit will be essential in order 
to resolve biological or technical noise at early days and to have a more accurate proportion of 
1:1 in head-to-head competition assays. Finally, the limited number of parasite strains that 
were used for performing transfections do not allow for establishing what in the genetic 
backgrounds described is compensating for a loss of fitness, therefore replicating these 
experiments in strains belonging to the recently defined KEL1 lineage, and other representative 
examples of a non-artemisinin resistant parasite strain from Cambodia. 
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The idea of identifying hotspots of malaria transmission within geographical locations 
known to be at the epicentre of multidrug resistance is essential as, in theory, targeted mass 
drug administration (MDA) could be performed in order to eliminate the reservoir of parasites, 
thus interrupting transmission. MDA campaigns have been taking place in one form or another 
since 1932, starting in a rubber plantation in Liberia when plasmoquine was implemented (Rice 
1932), to some of the largest MDA campaigns ever, undertaken in China, starting in the 1960s 
and spanning until today, with almost no cases of malaria now reported in this country (Tang 
2000). This concept, however, has been challenged by the idea that MDA can lead to the spread 
of antimalarial drug resistance. Evidence of indirect MDA leading to this terrible outcome were 
followed by the use of pyrimethamine and chloroquine salts, which led to local replacement of 
sensitive alleles with resistant ones in both Southeast Asia and South America (von Seidlein and 
Greenwood 2003). A direct link between MDA and the spread of resistance is hard to prove 
however. It can also be argued that for the case of South America, a discontinuity in the 
treatment for political and socio-economic reasons also played a role in the emergence of 
chloroquine resistance. Similarly, in Southeast Asia, resistance emerged in some Cambodian 
provinces possibly also as a consequence of the political situation and the migration of non-
immune workers to the local mines (von Seidlein and Greenwood 2003).  
The fact that chloroquine resistance emerged independently in Southeast Asia and in 
South America, both showing a high linkage disequilibrium around Pfcrt, provided evidence that 
the emergence of resistance can occur and become established more efficiently in such regions 
before spreading to areas of high transmission such as Sub-Saharan Africa (Mita et al. 2009; 
Wootton et al. 2002). Because these resistance-associated variants have to take over the 
sensitive populations, genetic diversity will ultimately play a key role their ability to spread. In 
Southeast Asia, for example, diversity is lower than in Africa, primarily maintained by low 
transmission rates. This leads to recombination events being less frequent and accompanied by 
lower prevalence of polyclonal infections. Given this, if a resistant parasite arises in a high-
transmission setting, where recombination is high, it is more likely that this parasite will be 
selected against, by being out-competed by “fitter” parasites, especially in a context in which 
acquired immunity is also higher. This is the main argument suggesting that while resistant 
 198 
parasites can occur at low frequencies in Africa, they are less likely to establish. A modelling 
approach taken in a recent study by Bushman et al. supported the differences between low vs 
high transmission settings for the establishment and spread of drug resistance. Interestingly, 
the authors propose that consistent with all the historical evidence on the emergence and 
spread of antimalarial drug resistance (e.g. chloroquine or pyrimethamine), low-transmission 
settings usually promote maintenance of drug-resistant genotypes, however, they found based 
on the modeling performed that high-transmission settings would actually facilitate spread 
 (Bushman et al. 2018). If this is the case, one of the scenarios of the recent outbreak of 
multidrug resistant parasites in Southeast Asia (KEL1/PLA1), with enhanced fitness, could be an 
example of a successfully maintained parasite lineage. 
A key consideration from for the field is how parasite populations in Africa will manifest 
resistance to the frontline antimalarial artemisinin. Even though reasonable attention should be 
paid to the markers that have been identified in the various genomic studies in Southeast Asia, 
such as those discussed here, it will be important to also focus efforts on studying carefully how 
parasite populations are changing in the different low-transmission settings in Africa. Given the 
importance of low transmission for drug resistance, it is possible that there are currently some 
evolutionary bottlenecks in certain populations that we might be unaware of, and the 
emergence of a resistance-associated polymorphism, possibly non-K13 mediated, might expand 
in frequency given the decreased genetic diversity of these areas. The lessons learned from this 
thesis, about how genomic sequencing and experimental genetics can be brought together, 











7.1 List of primers used 
p36: GTTGTGTGGAATTGTGAGCGG 
p171: CATGGACCCACTCCAGACGAACCTACCGACTTCATG  
p172: CTAGCATGAAGTCGGTAGGTTCGTCTGGAGTGGGTC  
p173: CATGGCAAGAACCTCATCCTACGCTATCCCGACCAG  
p174: CTAGCTGGTCGGGATAGCGTAGGATGAGGTTCTTGC 
p191: GGGTAAACTAGAATATGCTATACCGG  
p194: ACCATCACGGGATAAAGTAACTGG  
p195: CACCATTGAAGAAGAATCTCCTAAG 
p196: CACTTGTTCCTTTCTCATTTGAATC 
p203: AGAACATATTTATTAAATCTACAACTTGTAAAAGCAGAAGAAG  
p204: CGCTCATAGCCCATGGCCTCTATAACCTTCTTAGGAG  
p205: TTATAGAGGCCATGGGCTATGAGCGCTAGCGGTATACATCATTAATTGGAAAGG  
p206: CGCATCAGGCGCCAGCTGGTACATGTTTGAATACTAAC  
p212: CAATTAATGATGTATACCGCCTTCAATTTCGATGGGTAC  
p215: ATTGTGGTAATACAGAAATGGATG  
p216: AAACCATTTATTGCTTCCGCATC  
p217: ATTGGATGCGGAAGCAATAAATG  
p218: AAACCATCCATTTCTGTATTACCA  















91_Illumina (Arg445): TCGGCATTCCTGCTGAACCGCTCTTCCGATCTGTAATTCGTGCGCGTCAG 
97_Illumina (Arg444): ACACTCTTTCCCTACACGACGCTCTTCCGATCTCCTTCAATTTCGATGGGTAC 
PE1.0_Illumina: AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC*T  
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